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Metabolism and signaling were classically viewed as unrelated cellular 
processes. Signaling was considered to be a dynamic process that 
involved transcription, translation, and protein-protein interactions, 
whereas metabolism was categorized as more passive processes involved 
in maintaining and sustaining the cell. Now, it is widely accepted that 
signal transduction often involves reprogramming metabolism. For 
example, insulin shifts the metabolism of glucose, glycogen, and 
triglycerides. Emerging evidence suggests that a reciprocal relationship 
between metabolism and signaling exists as well, where metabolites 
themselves mediate signaling. Diverse modifications such as 
glycosylation, succinylation, acetylation, and nitrosylation are all directly 
derived from metabolites. In this body of work, we report that three heme 
metabolites – carbon monoxide (CO), biliverdin, and bilirubin – play 
critical roles at the intersection of metabolism and signaling. First, we 
report that O2-sensing by the carotid body is mediated by CO. O2 is 
sensed by the enzyme heme oxygenase (HO) as a substrate, which 
produces CO as a product of heme oxidation. CO in turn stimulates 
protein kinase G to inhibit cystathionine-γ-lyase (CSE), an enzyme that 
produces the gaseous molecule hydrogen sulfide (H2S). Less O2 is 
available in hypoxia to produce CO, leading to increased CSE activity. 
CSE produces more H2S as a result, which itself stimulates carotid body 
activity and breathing. Secondly, we report that bilirubin is a physiologic 
iii 
antioxidant with distinct redox activity among endogenous small 
molecules. Whereas major antioxidants such as glutathione and cysteine 
exhibit little to no reactivity towards O2•−, bilirubin readily scavenges 
O2•−. We find that bilirubin’s redox activity is particularly important in 
the brain, where it prevents excitotoxicity and neuronal death by 
scavenging O2•− during NMDA neurotransmission. Lastly, we report that 
pathophysiologic levels of bilirubin excite peripheral itch sensory 
neurons and elicit pruritus (itch) through Mrgprs, a family of G-protein 
coupled receptors expressed in primary sensory neurons. Various 
pathologic conditions result in jaundice, a yellowing of the skin due to a 
buildup of bilirubin. Patients with jaundice commonly report 
experiencing an intense non-histaminergic itch. Despite this association, 
the pruritogenic capacity of bilirubin itself has not been explored, and no 
bilirubin receptor has been identified. 
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Reflexes initiated by the carotid body, the principal O2-sensing organ, are critical 
for maintaining cardiorespiratory homeostasis during hypoxia. O2 sensing by the 
carotid body requires carbon monoxide (CO) generation by heme oxygenase-2 
(HO-2) and hydrogen sulfide (H2S) synthesis by cystathionine-γ-lyase (CSE). We 
report that O2 stimulated the generation of CO, but not that of H2S, and required 
two cysteine residues in the heme regulatory motif (Cys265 and Cys282) of HO-2. 
CO stimulated protein kinase G (PKG)–dependent phosphorylation of Ser377 of 
CSE, inhibiting the production of H2S. Hypoxia decreased the inhibition of CSE 
by reducing CO generation resulting in increased H2S, which stimulated carotid 
body neural activity. In carotid bodies from mice lacking HO-2, compensatory 
increased abundance of nNOS (neuronal nitric oxide synthase) mediated 
O2 sensing through PKG-dependent regulation of H2S by nitric oxide. These 
results provide a mechanism for how three gases work in concert in the carotid 





Cellular communication is mediated through diverse signaling molecules, 
including proteins, lipids, amino acids, and gases. Gaseous messengers are 
distinctive among signaling molecules in that they cannot be stored in vesicles. 
This suggests that gaseous messenger signaling depends on tightly regulated in 
situ enzymatic synthesis instead of exocytotic machinery. Despite a growing 
recognition of the widespread importance of gaseous messengers in various 
biological processes (Mustafa et al., 2009), little is known about their regulation 
under physiological conditions. 
The gaseous messenger carbon monoxide (CO) is important for oxygen (O2) 
sensing (Morikawa et al., 2012; Peng et al., 2014; Prabhakar et al., 1995). In the 
carotid body, changes in blood O2 concentrations are transduced into changes 
in CO production. CO signaling during normoxia inhibits the carotid body 
sensory nerve activity, whereas decreased CO generation during hypoxia 
increases the carotid body neural output (Peng et al., 2014; Prabhakar et al., 
1995). CO acts similarly in the brain to alter cerebral blood flow (Morikawa et al., 
2012). High CO concentrations during normoxia elicit vasoconstriction, whereas 
decreased CO signaling during hypoxia results in vasodilation. CO synthesis in 
the carotid body (Peng et al., 2014; Prabhakar et al., 1995) and in the brain 
(Morikawa et al., 2012) is catalyzed by the constitutively expressed enzyme heme 
oxygenase-2 (HO-2) (Maines, 2004). It is unclear how changes in 
O2 concentrations affect CO synthesis by HO-2. 
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Whereas CO generation is sensitive to changes in O2, CO by itself does not 
trigger responses to hypoxia. Instead, CO affects the generation of another 
gaseous messenger, hydrogen sulfide (H2S) (Peng et al., 2014; 2010; Prabhakar 
et al., 1995; Shintani et al., 2009). H2S mediates increased carotid body sensory 
nerve activity (Peng et al., 2010; Prabhakar et al., 1995) and cerebral vasodilation 
(Morikawa et al., 2012) during hypoxia. Emerging evidence suggests that CO 
suppresses H2S signaling by inhibiting the H2S-synthesizing enzymes 
cystathionine-γ-lyase (CSE) (Peng et al., 2010) and cystathionine β-synthase 
(CBS) (Peng et al., 2014; Shintani et al., 2009; Taoka and Banerjee, 2001; Taoka 
et al., 1999). CSE is the predominant source of H2S in peripheral tissues such 
as the carotid body (Makarenko et al., 2012; Peng et al., 2010), whereas CBS is 
responsible for most of the H2S production in the brain (Paul and Snyder, 2014; 
Yang et al., 2008). It is believed that CO directly inhibits CBS by binding to its 
heme moiety (Shintani et al., 2009; Taoka and Banerjee, 2001; Taoka et al., 
1999). Unlike CBS, however, CSE is not a heme-containing protein, indicating 
that CO inhibits CSE by an alternative and unknown mechanism. 
O2 sensing by the carotid body is critical for regulation of vital functions 
including breathing, heart rate, and blood pressure under hypoxic conditions 
(Kumar and Prabhakar, 2011). Given the critical roles of CO and H2S signaling 
for sensory function of the carotid body (Peng et al., 2010; Prabhakar et al., 1995), 
we sought to determine how changes in O2 affect CO and H2S generation by 
carotid body chemoreceptor cells. The limited availability of carotid body tissue 
(wet weight of the mouse carotid body is ~25 µg) necessitated first studying the 
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effects of O2 on CO and H2S generation in human embryonic kidney (HEK) 293 
cells heterologously expressing HO-2 and CSE. The mechanisms identified in 
vitro were then validated in mouse carotid bodies. 
 
Results 
Cys265 and Cys282 are critical for O2-sensitive CO generation by HO-2 
We first examined the effect of changes in the partial pressure of O2 (PO2) 
on CO generation in HEK-293 cells heterologously expressing HO-2. Cells 
expressing HO-2 generated more CO under normoxia (PO2 = 142 ± 3 mmHg) than 
did empty vector–transfected cells. Reducing the PO2 from ~142 to ~90 mmHg 
had no significant effect, whereas further reductions in PO2 resulted in a 
progressive decrease in CO generation in a stimulus-dependent manner as 
compared with normoxia (Fig. 1a). These findings demonstrated that CO 
generation by HO-2 was inherently responsive to changes in PO2. 
We next sought to delineate the mechanism underlying the inherent 
O2 sensitivity of HO-2. HO-2 has three cysteine residues (Cys127, Cys265, and 
Cys282; numbering of amino acid residues corresponds to the human protein 
unless otherwise stated) in the heme regulatory motif (Fig. 1b) (McCoubrey, 
1997). We investigated whether these cysteine residues are required for the 
sensitivity of HO-2 to O2. Substituting alanine for either Cys265 or Cys282 reduced 
the O2 sensitivity of HO-2, whereas mutation of both Cys265 and 
Cys282 eliminated modulation of CO generation by hypoxia (PO2 = 36 ± 4 
5 
mmHg; Fig. 1b). In contrast, substitution of alanine for Cys127 had no effect on 




Figure 1. Effect of O2 on CO and H2S generation in HEK-293 cells expressing HO-2 and CSE 
alone or together.  
a, CO generation as a function of PO2 in the medium in cells transfected with the empty vector 
and HO-2 vector. b, Effect of mutating cysteine residues in HO-2 on CO generation. Top: 
Schematic representation of cysteine residues in the N-terminal and heme regulatory motif of 
HO-2. Bottom: CO production in cells expressing either wild-type (WT) or mutant (C127A, C265A, 
C282A, or C265A/C282A) HO-2 in response to normoxia and hypoxia. c, Rate of CO generation 
as a function of PO2 in WT and mutant HO-2 (C265A/C282A)–expressing cells. 
Apparent Km values are derived by iterative curve fitting. d-f, H2S generation as a function 
of PO2 in cells transfected with the empty vector or CSE vector (D) or vectors encoding CSE and 
HO-2 (e) or CSE and mutant HO-2 (C265A/C282A) (f). The graphs in (a-f) represent means ± 
SEM (n = 3 to 5 independent experiments). *P < 0.05; **P < 0.01; n.s., not significant (P > 0.05). 
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We then investigated whether changes in O2 affinity accounted for the loss 
of O2-sensitive CO generation in cells expressing double mutant (C265A/C282A) 
HO-2. We found that the apparent Michaelis constant (Km) of wild-type HO-2 for 
O2 was 65 ± 5 mmHg (~88 µM), a value close to that reported previously (Migita 
et al., 1998). In contrast, the Km of HO-2C265A/C282A was 25 ± 3 mmHg (~34 
µM; Fig. 1c). These findings suggest that Cys265 and Cys282 confer low O2 affinity 
for HO-2, thereby rendering CO generation sensitive to changes in PO2. 
 
O2-dependent HO-2 activity inhibits H2S generation by CSE 
In contrast to the intrinsic O2 sensitivity of CO generation by HO-2, H2S 
generation in CSE-expressing HEK-293 cells was unaffected by changes 
in PO2 (Fig. 1d). To reconcile the observations that CSE is not directly sensitive 
to O2, but H2S generation from CSE increases during hypoxia in the carotid body 
(Peng et al., 2010), we hypothesized that CSE was regulated by O2-sensitive CO 
generation. Whereas cells expressing only CSE displayed steady H2S generation 
regardless of changes in PO2, cells co-expressing HO-2 and CSE exhibited 
decreased H2S concentrations during normoxia and increased concentrations 
during hypoxia (Fig. 1e), recapitulating the O2-dependent H2S generation in the 
carotid body (Peng et al., 2010). However, H2S concentrations remained 
unchanged during hypoxia when CSE was co-expressed with the O2-insensitive 
mutant HO-2C265A/C282A (Fig. 1f). These results demonstrate that CO is an 
inhibitor of CSE and that O2-dependent CO generation contributes to increased 
H2S generation by CSE in hypoxic cells. 
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CO inhibits CSE through cyclic guanosine monophosphate 
To delineate the mechanism by which CO inhibits CSE, we first considered 
whether CO inhibits calmodulin, a calcium-dependent activator of CSE (Paul and 
Snyder, 2014). CO might inhibit CSE activity by reducing the pool of intracellular 
calcium available to stimulate calmodulin. However, the intracellular 
Ca2+concentrations ([Ca2+]i) were similar in cells that co-expressed HO-2 and 
CSE and in cells that only expressed CSE (Fig. 2-b). The calmodulin inhibitor 
W7 [N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride] did 
not affect H2S generation (Fig. 2c), arguing against a mechanism in which CO 
inhibits H2S by regulating calmodulin activity. 
 
 
Figure 2. Calcium-dependent calmodulin activity is not required for inhibition of CSE by 
CO. 
a-b, Intracellular calcium ([Ca2+]i) abundance in normoxia and hypoxia in HEK-293 cells 
expressing empty vector (CON) as compared to CSE or CSE+HO-2 expressing cells. n = 62-75  
cells. c, Effect of W7, the calmodulin antagonist on H2S generation in HO-2 + CSE-expressing 
cells. n = 3.  Normoxia= PO2 142 ± 3 mmHg and Hypoxia= PO2 36±4 mmHg. Data represent mean 
± SEM.  n.s. = not significant, p >0.05. 
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CO binds to and activates soluble guanylyl cyclase (sGC) (Verma et al., 
1993), which catalyzes the synthesis of the second messenger cyclic guanosine 
monophosphate (cGMP). To determine whether CO regulates H2S generation 
through sGC/cGMP signaling, we challenged CSE-expressing cells with the CO 
donor [Ru(CO)3Cl2]2 [tricarbonyldichlororuthenium (II) dimer] (CORM-2) 
(Motterlini, 2002). CORM-2 increased cGMP concentrations and reduced H2S 
generation (Fig. 3a-b). Transfection of a small interfering RNA (siRNA) targeting 
the α1 subunit of sGC (Fig. 4a) prevented cGMP accumulation and preserved 
H2S generation in CORM-2–treated cells (Fig. 3a-b). 
To confirm that HO-2–derived CO stimulates sGC/cGMP signaling as does 
exogenous CO, we measured cGMP and H2S concentrations in cells coexpressing 
HO-2 and CSE. Cells expressing HO-2 as well as CSE produced more cGMP 
under normoxia than did cells expressing only CSE (Fig. 3c). The increase in 
cGMP was associated with suppressed H2S production (Fig. 3d). siRNA-mediated 
silencing of sGC reduced cGMP concentrations and prevented HO-2 from 
inhibiting H2S generation under normoxia (Fig. 3c-d). Hypoxia, which inhibits 
HO-2 activity, reduced cGMP concentrations and increased H2S generation. 
Hypoxia had no further effect on cGMP or H2S concentrations in cells with sGC 
knockdown (Fig. 4b-c). Together, these results demonstrate that CO, through 





Figure 3. CO inhibits H2S generation through sGC-dependent cGMP production.  
a-d, Effects of siRNA silencing of sGCα1 on the generation of cGMP and H2S in response to either 
the CO donor CORM-2 (a and b) or coexpression of HO-2 (c and d) in HEK-293 cells expressing 
CSE. Scr, scrambled RNA. e-f, Analysis of serine phosphorylation of CSE. Top: representative 
immunoblot; bottom: densitometric analysis. Effects of siRNA silencing of either sGCα1 or cGMP-
dependent PKG II on serine phosphorylation in cells expressing CSE in response to CORM-2 (e) 
or in CSE/HO-2–coexpressing cells under normoxia or hypoxia or hypoxic cells returned to 
normoxia (f). The graphs in (a-f) represent means ± SEM (n = 4 to 5 independent experiments). 




Figure 4. Effect of siRNA targeted to sGCα1 on hypoxia-evoked changes in cGMP and H2S 
generation in HEK-293 cells.  
a, sGCα1 protein expression in HEK-293 cells transfected with either scrambled (Scr) or sGCα1 
siRNA. Representative immunoblots (upper panel) and densitometric analysis (lower panel). n= 
3.  b-c, Effect of hypoxia on cGMP abundance (b) and H2S generation (c) in CSE+HO-2-expressing 
cells transfected with either scrambled (Scr) or sGCα1 siRNA. n =4. d, PKG I and II mRNA 
expressions in mouse carotid bodies was analyzed by reverse transcription and quantitative real-
time PCR. n = 3 (2 carotid bodies/experiment). e, PKG II protein expression in HEK-293 cells 
transfected with either scrambled (Scr) or PKG II siRNA. Representative immunoblots (upper 
panel) and densitometric analysis (lower panel) are shown. n =3. f, Effect of CORM-2, a CO donor 
on H2S generation in HEK-293 cells expressing either wild-type (WT) or S377E phospho-mimetic 
mutant CSE. n= 4. Data presented are mean ± SEM.  * *p < 0.01, n.s. not significant, p>0.05. 
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CO induces protein kinase G–dependent phosphorylation of CSE 
A major biological action of cGMP is the activation of cGMP-dependent 
protein kinase G (PKG) I and II, which phosphorylate serine and threonine 
residues in target proteins (Kennelly and Krebs, 1991). We explored whether 
activation of cGMP signaling by CO stimulates PKG to phosphorylate CSE. CSE 
immunoprecipitates from CSE-expressing HEK-293 cells were immunoblotted 
with antibodies recognizing phosphoserine. Treatment of CSE-expressing cells 
with CORM-2 induced an increase in the serine phosphorylation of CSE (Fig. 
3e). Likewise, cells coexpressing HO-2 and CSE also exhibited a robust increase 
in serine phosphorylation of CSE under normoxia (Fig. 3f). siRNA-mediated 
silencing of either sGC or PKG II, which is more abundant in the mouse carotid 
body than PKG I (Fig. 4d), prevented phosphorylation of CSE evoked by CORM-
2 in CSE/HO-2–coexpressing cells under normoxia (Fig. 3e-f and Fig. 4e). 
Exposure of HO-2/CSE–coexpressing cells to hypoxia markedly reduced 
phosphorylation of CSE, which completely recovered after being returned to 
normoxic conditions (Fig. 3f), demonstrating the reversible nature of O2-
dependent CSE phosphorylation. 
We next sought to identify the serine residue in CSE that is phosphorylated 
by PKG. CSE belongs to a family of pyridoxal-5-phosphate–dependent enzymes 
{H:1982vb}. Sequence alignment of CSE across species revealed that Ser377 is 
located within a highly conserved putative PKG recognition sequence (Fig. 6a) 
(Kennelly and Krebs, 1991). Mutating Ser377 to alanine (S377A) abolished 
CORM-2– or HO-2–induced serine phosphorylation of CSE (Fig. 6b-c). Neither 
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CORM-2 nor HO-2 co-expression inhibited H2S generation from cells expressing 
CSES377A (Fig. 6d-e). Cells expressing CSE with the phosphomimetic 
substitution S377E exhibited a >90% reduction in basal H2S concentrations (Fig. 
4f), suggesting that phosphorylation of Ser377 attenuated H2S synthesis. 
Together, these results point to the reversible phosphorylation of Ser377 by PKG 
as a switch by which CO regulates H2S generation by CSE. 
PKG signaling inhibits H2S generation and sensory nerve activity of the carotid 
body 
We assessed the relevance of PKG regulation of CSE on carotid body 
function. Because carotid bodies produce high amounts of CO during normoxia 
(Peng et al., 2014), we hypothesized that activation of PKG by CO inhibits H2S 
generation from CSE and maintains low sensory activity, whereas inhibiting PKG, 
similar to exposure to hypoxia, should increase H2S concentrations and augment 
carotid body sensory nerve activity. Indeed, application of a PKG inhibitor, (Rp)- 
8-pCPT-cGMPS (8-pCPT), increased H2S generation in a dose-dependent manner 
in wild-type carotid bodies with a concomitant increase in sensory nerve activity 
under normoxia (PO2 = 142 ± 3 mmHg). However, the PKG inhibitor did not affect 







Figure 5. Inhibition of H2S generation by CO requires phosphorylation of CSE at Ser377.  
a, Top: Amino acid residues in CSE required for H2S generation. Bottom: Sequence alignment of 
CSE across species reveals that Ser377 is evolutionarily conserved (red). Conserved residues are 
outlined by a solid box. Conservative substitutions are shown in gray, and nonconservative 
substitutions are outlined by a dashed box. b-c, Comparison of the serine phosphorylation of 
exogenously expressed WT and mutant (S377A) CSE in cells treated with the CO donor CORM-
2 (b) and in cells co-expressing HO-2 (c). Top: representative immunoblots; bottom: densitometric 
analysis. d-e, Effects of CORM-2 (d) and HO-2 expression (e) on H2S generation in cells 
expressing WT or mutant CSE (S377A). The graphs in (b-e) represent means ± SEM (n = 3 to 4 





Figure 6. PKG-dependent cGMP signaling in the carotid body.  
a-d, Effect of the PKG inhibitor 8-pCPT on (a) H2S generation and (b-d) baseline sensory nerve 
activity of WT and CSE−/− mouse carotid bodies. e-j, Effect of CORM-2 on hypoxia-evoked (e) H2S 
generation and (f-j) sensory nerve response of WT and CSE−/− mouse carotid bodies with or 
without 8-pCPT or the sGC inhibitor ODQ. The insets in the tracings of (b), (c), and (f-i) show 
superimposed action potentials of the sensory nerve fiber from which the integrated carotid body 
sensory nerve activity [CB activity; impulses per second (imp/s)] was derived. Black horizontal 
bars marked with “Hx” represent the duration of the hypoxic challenge (n = 3 independent 
experiments for H2S measurements and n = 6 carotid bodies for each genotype and treatment 
for sensory nerve activity measurements). **P < 0.01. 
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To further assess the role of CO-induced PKG signaling, we treated wild-
type carotid bodies with the CO donor CORM-2 or the sGC activator YC-1 [3-(5′-
hydroxymethyl-2′-furyl)-1-benzylindazole] (Friebe et al., 1996). Both CORM-2 
and YC-1 blocked the increase in H2S concentrations in response to hypoxia, 
and pretreating the carotid bodies with a PKG inhibitor or the sGC inhibitor ODQ 
(1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one) prevented CORM-2 or YC-1 from 
inhibiting H2S generation (Fig. 6e and Fig. 7), demonstrating that CO signals 
through the sGC/PKG pathway to inhibit H2S generation. Neither activating nor 
inhibiting the sGC/PKG signaling pathway altered H2S concentrations in CSE-
null carotid bodies (Fig. 6e and Fig. 7), providing further evidence that CSE is 
the target of CO-induced sGC/PKG signaling. Likewise, both CORM-2 and YC-1 
reduced carotid body sensory nerve excitation by hypoxia in wild-type but not in 
CSE-null carotid bodies, and these effects were reversed by either a PKG 
inhibitor or the sGC inhibitor ODQ (Fig. 6f-j and Fig. 7). 
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Figure 7. Inhibitory effects of YC-1, an activator of sGC on H2S generation and the sensory 
nerve response of the carotid body.  
a, Effect of YC-1 on hypoxia-evoked H2S generation in carotid bodies of wild-type (WT) and   CSE-
/- mice without and with 8-pCPT, and ODQ, a PKG and sGC inhibitors, respectively. n= 3 for 
each genotype and treatment (6 carotid bodies/experiment). b-f, Effect of YC-1 on carotid body 
sensory nerve response to hypoxia in wild-type (WT) and CSE-/- mice without and with 8-pCPT 
or ODQ. Examples of the sensory nerve activity b-e, and average data of the hypoxic sensory 
nerve response (Hx response; f) are shown. n = 6 carotid bodies for each genotype.  The duration 
of the hypoxic challenge in (b-e) is denoted by bars (Hx) and the insets represent superimposed 
action potentials of the sensory nerve fiber from which the data was derived. Normoxia (Nx) = 
pO2 142 ± 3 mmHg, Hypoxia (Hx) = pO2 36±4 mmHg.   Data represent mean ± SEM.  **p < 0.01. 
 
HO-2 governs O2 sensing of the carotid body 
The inherent O2 sensitivity of HO-2 and its ability to regulate the 
generation of the effector molecule H2S led us to investigate whether carotid body 
O2 sensing is fundamentally governed by HO-2. In carotid bodies from wild-type 
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mice, HO-2 was present in glomus cells, which are the primary O2-sensing cells 
of the carotid body (Kumar and Prabhakar, 2011), whereas HO-2 was absent in 
carotid bodies from HO-2–null mice (Fig. 8a), which exhibited a >90% reduction 
in CO production compared to wild-type carotid bodies (Fig. 8b). If HO-2–
dependent CO generation is obligatory for carotid body O2sensing, HO-2–null 
mice should exhibit augmented basal sensory nerve activity and H2S 
concentrations in the carotid body. Indeed, H2S generation and baseline sensory 
nerve activity were greater in HO-2–null carotid bodies than in wild-type (Fig. 
8c-e). However, H2S concentrations and sensory nerve activity still increased in 
hypoxia (Fig. 8c-d and Fig. 8f), suggesting the existence of a residual regulatory 
mechanism that does not involve HO-2. HO-2/CSE double-null carotid bodies 
did not exhibit a sensory nerve response to hypoxia, demonstrating that this 
residual O2-sensing mechanism exploited H2S generation by CSE to trigger 





Figure 8. Gaseous messenger generation and sensory nerve activity in HO-2–null carotid 
bodies.  
a, Adjacent carotid body sections immunostained for HO-2 and tyrosine hydroxylase (TH), a 
marker of glomus cells, in WT and HO-2−/− mice. Scale bar, 20 µm. b, CO generation in carotid 
bodies of WT and HO-2−/− mice. c-f, H2S generation (c) and sensory nerve activity (d-f) of the 
carotid bodies of WT, HO-2−/−, and HO-2−/− + CSE−/− mice. In tracings of (d), the insets present 
superimposed action potentials of the sensory nerve fiber from which the integrated carotid body 
sensory nerve activity (CB activity; imp/s) was derived, and black bars marked with “Hx” 
represent the duration of the hypoxic challenge. Images in (a) are representative of three mice 
per genotype. The graphs in (b), (c), (e), and (f) represent means ± SEM (n = 3 independent 
experiments for CO and H2S measurements and n = 6 carotid bodies for each genotype for 
sensory nerve activity measurements). **P < 0.01. 
 
Neuronal nitric oxide synthase abundance is increased in HO-2–null glomus cells 
Immunocytochemistry of HO-2–null carotid bodies revealed neuronal 
nitric oxide synthase (nNOS) staining in glomus cells (Fig. 9a). In contrast, nNOS 
staining was not detectable either in glomus cells or in nerve fibers of wild-type 
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carotid bodies (Fig. 9a). nNOS generates nitric oxide (NO) in an O2-dependent 
manner (Prabhakar et al., 1993), and similar to CO, NO inhibits carotid body 
sensory nerve activity (Prabhakar and Semenza, 2012). Treatment of HO-2–null 
carotid bodies with the nNOS inhibitor 7-nitroindazole (7-NI) (Babbedge et al., 
1993; Moore et al., 1993) increased baseline H2S concentrations and sensory 
nerve activity, suggesting that NO could also be a physiological inhibitor of H2S 
generation. 7-NI also eliminated the O2 sensitivity of HO-2–null carotid bodies 
(Fig. 9b-e). 7-NI did not affect H2S concentrations or sensory nerve activity in 






Figure 9. NO signaling in HO-2–null carotid body.  
a, Adjacent carotid body sections immunostained for nNOS and tyrosine hydroxylase (TH), a 
marker of glomus cells, in WT and HO-2−/− mice. Scale bar, 20 µm. b-e, Effect of the nNOS 
inhibitor 7-NI on H2S generation (b) and sensory nerve activity (c-e) of carotid bodies from HO-
2−/− and HO-2−/− + CSE−/− mice. In tracings in (c), the insets present superimposed action 
potentials of the sensory nerve fiber from which the integrated carotid body sensory nerve activity 
(CB activity; imp/s) was derived, and black bars marked with “Hx” represent the duration of the 
hypoxic challenge. f-g, Effect of the NO donor NOC-18 on H2S generation (f) and CSE serine 
phosphorylation (g) in HEK-293 cells expressing WT or mutant CSE (S377A). Images in (a) are 
representative of three mice per genotype. The graphs in (b) and (d-g) represent means ± SEM 
(n = 3 for each genotype and treatment for H2S measurements, n = 6 to 8 carotid bodies for each 
genotype and treatment for sensory nerve activity measurements, and n = 3 independent 
experiments for H2S measurements and CSE phosphorylation in HEK-293 cells). **P < 0.01. 
 
NO activates sGC (Arnold et al., 1977) and can thus substitute for CO in 
the same sGC/PKG signaling pathway to inhibit H2S generation by CSE. To 
determine whether NO also inhibits H2S generation by inducing the 
phosphorylation of CSE at Ser377, we treated cells expressing CSE with the NO 
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donor NOC-18 [3,3-bis(aminoethyl)-1-hydroxy-2-oxo-1-triazene] (Shibuta et al., 
1996). Similar to the CO donor, the NO donor decreased H2S generation and 
increased serine phosphorylation of CSE in cells expressing wild-type CSE, but 
not in those expressing CSES377A (Fig. 9f-g). These results demonstrate that NO 
and CO regulate H2S generation in a similar manner, through phosphorylation 
of CSE at Ser377. 
 
Discussion 
Emerging evidence suggests that CO and H2S are critical for O2 sensing by 
the carotid body (Makarenko et al., 2012; Peng et al., 2010; 2014); however, the 
molecular mechanisms by which O2 affect the generation of these gaseous 
messengers have been elusive. Our results establish that HO-2 is sensitive to 
changes in O2availability, even in a heterologous system, such that CO 
generation is high under normoxia and low during hypoxia. This unique 
O2 sensitivity requires Cys265 and Cys282, which lower the O2affinity of HO-2 and 
enable the enzyme to transduce changes in O2 into changes in CO generation. 
The carotid body sensory nerve activity begins to increase only when the arterial 
blood PO2 drops to anywhere between 60 and 80 mmHg [see (Kumar and 
Prabhakar, 2011) for references], which coincides with the apparent Km of HO-2 
for O2 of ~65 mmHg. Thus, the low affinity of HO-2 for O2 is physiologically 





Figure 10. O2 sensing in the carotid body.  
Schematic presentation of the signaling pathways associated with the interplay between three 
gases—O2, CO, and H2S—in glomus cells of the carotid body (CB) and their impact on CB neural 
activity and breathing. Cys265 and Cys282 are located in the heme regulatory motif of HO-2. 
Ser377 is the target residue in the putative PKG recognition sequence in CSE. 
In contrast, H2S generation by CSE is not directly sensitive to changes 
in PO2. CO is a physiological inhibitor of H2S generation by CSE (Peng et al., 
2010). Increased H2S generation during hypoxia is due to decreased CO 
generation, resulting in reduced inhibition of CSE. CO inhibits CSE by 
stimulating sGC/PKG signaling, in contrast to the heme-dependent inhibition of 
CBS by CO (Morikawa et al., 2012; Shintani et al., 2009; Taoka and Banerjee, 
2001; Taoka et al., 1999). PKG phosphorylates CSE at Ser377, rendering it 
inactive. CSE phosphorylation is O2-dependent and reversible, further 
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suggesting that this phosphorylation event functions in a signaling capacity. The 
complex interplay between three gases—O2, CO, and H2S—and its impact on 
carotid body sensory nerve activity and breathing is summarized in Fig. 10. The 
tight posttranslational regulation of CSE activity by PKG-dependent 
phosphorylation suggests a possible role for protein phosphatases and/or cGMP-
dependent phosphodiesterases, which remain to be studied. 
Alternative mechanisms for H2S generation during hypoxia have been 
proposed in trout gill chemoreceptors (Olson et al., 2008a), in cyclostome blood 
vessels (Olson et al., 2008b), and in Caenorhabditis elegans neurons (Ma et al., 
2012). Increased H2S concentrations during hypoxia in lower vertebrates have 
been attributed to decreased oxidative degradation of H2S (Olson et al., 2012). 
While such a mechanism may operate in lower vertebrates, our results indicate 
that in the mammalian carotid body, H2S generation by CSE is not directly 
sensitive to changes in O2; instead, it is regulated through O2-dependent CO 
generation by HO-2. 
A role for HO-2 in O2 sensing by the carotid body has been previously 
proposed (Prabhakar et al., 1995; Williams, 2004). Consistent with this 
possibility, genetic knockout of HO-2, like hypoxia, increased the baseline 
sensory nerve activity and H2S generation of the carotid body. However, we did 
find that HO-2–null carotid bodies still responded to hypoxia as previously 
reported (Ortega-Saenz, 2006). Further investigation revealed that loss of HO-2 
in glomus cells prompts an unanticipated compensatory increase of another O2-
sensitive gaseous messenger–generating enzyme, nNOS, which catalyzes the 
24 
generation of NO. Although the mechanisms underlying the compensatory 
increase of nNOS in glomus cells of HO-2–null mice remain to be investigated, 
inhibition of nNOS eliminated sensory nerve excitation and H2S generation in 
response to hypoxia in HO-2–null carotid bodies. The O2 affinity of nNOS is much 
lower (apparent Km = 350 µM or ~250 mmHg) (Prabhakar et al., 1993; Prabhakar 
and Semenza, 2012) than that of HO-2 (apparent Km = 88 µM or ~65 mmHg), 
suggesting that even a modest reduction in PO2 will lead to decreased NO 
production by nNOS. Similar to CO, NO also inhibits carotid body sensory nerve 
activity (Prabhakar et al., 1993; Prabhakar and Semenza, 2012) and inhibits 
CSE by inducing the phosphorylation of Ser377. Collectively, these findings 
suggest that HO-2 governs carotid body O2 sensing by affecting H2S generation 
through PKG-dependent phosphorylation of CSE. In the absence of HO-2 activity, 
nNOS provides an alternative mechanism by which H2S generation can be 
regulated according to O2 availability, thereby providing an important fail-safe 
redundancy for a vital homeostatic process. 
How might regulation of H2S by either CO or NO contribute to O2 sensing 
by the carotid body? The prevailing model of O2 sensing by the carotid body 
suggests that hypoxia increases the sensory nerve activity by inhibiting O2-
sensitive K+ channels in glomus cells, leading to depolarization-induced voltage-
gated Ca2+ influx and release of neurotransmitter(s) to excite sensory nerve 
endings [see (Kumar and Prabhakar, 2011) for references]. Similar to hypoxia, 
H2S increases carotid body sensory nerve activity by inhibiting O2-sensitive 
K+ channels in glomus cells, resulting in voltage-gated Ca2+ influx [see 
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(Prabhakar, 2013) for references]. Furthermore, hypoxia is ineffective in causing 
voltage-gated Ca2+ influx and neurotransmitter secretion in CSE-null glomus 
cells (Makarenko et al., 2012). Together, these findings suggest that H2S 
transduces the hypoxic stimulus to changes in ion channel function and 
neurotransmitter release from glomus cells to elicit sensory nerve excitation. 
Dysregulation of CO and H2S production in the carotid body can give rise 
to an abnormal chemosensory reflex, resulting in pathological consequences 
such as hypertension, pulmonary edema, and poor ventilatory adaptation to 
hypoxia (Dempsey and Forster, 1982; Hackett et al., 1988; Peng et al., 2014; Tan 
et al., 2010; Trzebski, 1992). Solely by correcting abnormal CO or H2S 
concentrations, it has been possible to successfully control hypertension in 
spontaneous hypertensive rats and prevent pulmonary edema in rats exposed to 
hypobaric hypoxia (Peng et al., 2014). Given the explosion of interest in surgically 
transecting carotid bodies as a therapeutic strategy in patients with essential 
hypertension and heart failure (Marcus et al., 2014; Paton et al., 2013), we 
believe that pharmacologically perturbing components of the sGC/PKG signaling 
pathway identified in this study is a more viable and safer approach for treating 
carotid body–related morbidities. Moreover, whereas gaseous messengers are 
important for O2 sensing, their biological functions are by no means confined to 
it. It is becoming increasingly recognized that dysregulated gaseous signaling 
contributes to diverse diseases, including hypertension (Peng et al., 2014; Yang 
et al., 2008) and Parkinson’s disease (Vandiver et al., 2013). Given that HO-2, 
NOS, and CSE are all present in the vasculature as well as in neurons (Kajimura 
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et al., 2010; Paul and Snyder, 2012; Paul et al., 2014), dysregulated crosstalk 
between CO, NO, and H2S may contribute to the pathophysiology of these 
disorders. Accordingly, this newfound understanding of gaseous messenger 
signaling likely has substantial implications in a diverse set of physiological and 
pathophysiological conditions. 
 
Materials and methods 
Experimental Model and Subject Details 
Mice 
Animal care and use 
All experiments were performed in accordance with protocols approved by the 
Animal Care and Use Committee at the University of Chicago and the Johns 
Hopkins University School of Medicine. 
 
HO-2−/−, CSE−/−, and HO-2−/−CSE−/− mice 
Experiments were performed on age-matched, male C57BL/6J, HO-2−/− and 
CSE−/− mice (from S. H. Snyder and R. Wang) unless otherwise noted. Double 
HO-2 and CSE knockout mice were created by crossing HO-2−/− females with 
CSE−/− males. Animals were euthanized by intracardiac injection (0.1 ml) of 
euthanasia solution (Beuthanasia-D Special, Schering-Plough). 
Cell culture  
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Human embryonic kidney 293 (HEK293) cells were cultured in DMEM (Gibco) 
supplemented with 10% FBS, 100 U/mL penicillin and streptomycin, and 2 
mM glutamine at 37°C with 5% CO2. 
Method Details 
Materials and preparation  
Solvents and compounds were obtained as follows:  
CORM-2 (Sigma-Aldrich, #288144), ODQ (Tocris Bioscience, #0880), YC-1 
(Sigma-Aldrich, #Y102), 8-pCPT (Enzo Life Sciences, #BML-CN206-001), 7-NI 
(Tocris Bioscience, #0602), W7 (Tocris Bioscience, #0369), NOC-18 (Sigma-
Aldrich, #A5581), and IBMX (Sigma-Aldrich, #I5879) 
 
Material preparation: 
All drugs were freshly prepared during the experiment. The following 
concentrations of drugs were used: CORM-2, 10 µM; 8-pCPT, 10 µM; ODQ, 15 
µM; YC-1, 30 µM; W7, 100 µM; and NOC-18, 250 µM. In experiments involving 
HEK-293 cells, cells were treated with desired concentration of drugs 30 min 
before the experiment. In the studies with ex vivo carotid bodies, the 
chemoreceptor tissue was continuously superfused with desired concentration 
of drugs added to the reservoirs. In the experiments with 7-NI, mice were 
treated with 7-NI (10 mg/kg intraperitoneally) 1 hour before harvesting carotid 




HO-2 (rat) was cloned into pcDNA3.1 with N-terminal myc tag. Mouse CSE was 
cloned into pCMV-myc. Mutations of HO-2 and CSE were performed using the 
QuikChange II XL mutagenesis kit (Agilent Technologies, #200521) according 
to the manufacturer’s instructions. Mutations were verified by Sanger 
sequencing at the University of Chicago Core sequencing facility. HEK-293 cells 
were cultured in Dulbecco’s modified Eagle’s medium (Life Technologies, 
#11995-065), 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin 
(100 U/ml) in 5% CO2 atmosphere at 37°C. Cells were plated on 60-mm plates 
and transfected with 0.5 µg of plasmid pcDNA encoding either wild-type or 
mutant HO-2 and/or 2 µg of plasmid DNA encoding either wild-type or mutant 
CSE using Lipofectamine (Invitrogen, #18324-012) according to the 
manufacturer’s protocol. 
Immunoblot and immunoprecipitation assays 
Immunoblot assays (HO-2, CSE, sGCα1, PKG II, and phosphoserine) and 
immunoprecipitation of CSE in HEK-293 cell lysates were performed as 
described (Yuan et al., 2013). The following primary antibodies were used: anti–
HO-2 (1:1000; Abcam, #ab90492), anti-CSE (1:1000; Novus Biologicals, 
#NBP1-52849), anti-sGCα1 (1:1000; Abcam, #ab50358), anti-CGK2 (PKG II; 
1:1000; Abcam, #ab110124), anti-phosphoserine (1:1000; Chemicon 
International, #AB1603), and anti–α-tubulin (1:1000; Sigma-Aldrich, #T6199). 
Measurements of H2S and CO 
H2S and CO generation in HEK-293 cells and carotid bodies was determined as 
previously described (Peng et al., 2010). In the experiments involving carotid 
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bodies, six tissues from three mice were pooled in a given experiment. In 
experiments assessing the effect of PO2 on H2S and CO generation, sealed 
tubes containing the reaction medium along with the center well were flushed 
with either 21% O2 or varying proportions of O2-N2 gas mixtures for 15 
min. PO2 in the reaction medium was determined by a blood gas analyzer 
(ABL5, Radiometer). H2S concentrations were calculated from a standard curve 
relating Na2S concentration to absorption at 620-nm light. CO concentrations 
were calculated from a standard curve relating CORM-2 ([Ru(CO)3Cl2]2; 1 mol of 
CORM-2 is equivalent to 0.7 mol of CO) to absorption at 590-nm light. The 
generation of H2S and CO was expressed as nanomoles per hour per milligram 
of protein. 
Measurements of cGMP 
cGMP concentrations were determined by a chemiluminescent enzyme-linked 
immunosorbent assay (Cell Biolabs, # STA-506) according to the 
manufacturer’s instructions. Before the experiment, cells were treated with 1 
mM IBMX (3-isobutyl-1-methylxanthine) to inhibit degradation of cGMP by 
phosphodiesterases. cGMP concentrations were normalized to protein 
concentration as determined by bicinchoninic acid assay. 
Measurements of intracellular calcium concentrations 
Intracellular calcium concentrations ([Ca2+]i) in HEK-293 cells were measured 
using Fura-2AM as previously described (Makarenko et al., 2012). Background 
fluorescence was subtracted from signals. Image intensity at 340 nm was 
divided by 380-nm image intensity to obtain the ratiometric image. Ratios were 
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converted to free [Ca2+]i using calibration curves constructed in vitro by adding 
Fura-2 (50 µM, free acid) to solutions containing known concentrations of 
Ca2+ (0 to 2000 nM). The recording chamber was continually superfused with 
solution from gravity-fed reservoirs. 
Immunocytochemistry 
Carotid bodies were harvested from anesthetized mice and perfused with 
heparinized saline followed by 4% paraformaldehyde for 30 min. Adjacent 
carotid body sections (8 µm thick) were immunostained with either rabbit anti–
tyrosine hydroxylase antibody (1:4000; Pel-Freez, #P40101), rabbit anti–HO-2 
antibody (1:200 dilution; Abcam, #ab90492), or rabbit anti-nNOS antibody 
(1:200; Cell Signaling, #4231) as previously described (Peng et al., 2010; 2014). 
Carotid body sensory nerve activity 
Sensory nerve activity was recorded from ex vivo carotid bodies harvested from 
anesthetized mice as previously described (Peng et al., 2010; 2014). Briefly, the 
carotid sinus nerve was treated with collagenase, and a few nerve bundles were 
isolated. Action potentials from one of the nerve bundles were recorded using a 
suction electrode (~20-µm-diameter tip). In general, two to three action 
potentials of varying size and amplitude were seen in a given nerve bundle. 
Action potentials of similar height, duration, and shape (“single” unit) were 
selected using Spike histogram software (LabChart 7 Pro) for analysis of the 
sensory nerve activity. To obtain a stable baseline sensory nerve activity, 
carotid bodies were first superfused for 1 hour with normoxia-equilibrated 
medium. Subsequently, baseline sensory nerve activity under normoxia was 
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recorded for 5 min. Sensory nerve responses to hypoxia were monitored for 3 
min. The PO2 in the medium was determined by a blood gas analyzer (ABL 5). 
Hypoxic response was measured as the difference between the sensory nerve 
activity under baseline and during hypoxia (Δimp/s). 
Quantitation of PKG isoform mRNA 
The mRNA expression of PKG I and PKG II was analyzed in the carotid bodies 
by quantitative real-time polymerase chain reaction (Bio-Rad), and the data 
were normalized with 18S mRNA as previously described (Nanduri et al., 2012). 
Two carotid bodies were pooled in a given experiment. The primers used for 
PKG I (Prkg1), PKG II (Prkg2), and 18S ribosomal RNA (rRNA) were as follows: 
Prkg1, CCTTGCAGGGGGAGGATGTAA (forward), TTGGCGAAGAAGGCAGCTTC 
(reverse); Prkg2, CTGCGGAGCAAAGTGGCAGA (forward), 
CCTGCAGCTTGTTCAGCTGGAT (reverse); 18S rRNA, 
GTAACCCGTTGAACCCCATT (forward), CCATCCAATCGGTAGTAGCG (reverse). 
Quantification and Statistical Analysis  
All data were reported as means ± SEM derived from three independent 
biological experiments, unless otherwise stated in the figure legends. Statistical 
analysis was performed with either one-way or two-way analysis of variance 
(ANOVA) with repeated measures followed by post hoc Tukey’s test. For the 
analysis of normalized data, the Mann-Whitney test was used. P values <0.05 
were considered significant. 
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Bilirubin is one of the most frequently measured metabolites in medicine, and 
yet its physiologic roles remain unclear. Bilirubin can act as an antioxidant in 
vitro, but whether its redox activity is physiologically-relevant is unclear 
because many other antioxidants are far more abundant in vivo. Here, we 
report that depleting endogenous bilirubin renders mice hypersensitive to 
oxidative stress. We find that mice lacking bilirubin are particularly vulnerable 
to superoxide (O2•−) over other reactive oxidants and electrophiles. Whereas 
major antioxidants such as glutathione and cysteine exhibit little to no 
reactivity towards O2•−, bilirubin readily scavenges O2•−. We find that bilirubin’s 
redox activity is particularly important in the brain, where it prevents 
excitotoxicity and neuronal death by scavenging O2•− during NMDA 
neurotransmission. Bilirubin’s unique redox activity towards O2•− may underlie 
a prominent physiologic role despite being significantly less abundant than 
other endogenous and exogenous antioxidants.  
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Introduction 
Bilirubin is one of the most frequently measured metabolites in clinical 
medicine, used to diagnose conditions such as hepatobiliary disorders (Osborn 
et al., 1959), hemolytic anemia (GIBLETT et al., 1956), and dyserythropoiesis 
(BERENDSOHN et al., 1964). It is the terminal product of mammalian heme 
metabolism, in which heme oxygenase (HO) oxidizes heme to biliverdin, which 
biliverdin reductase (BVR) then reduces to bilirubin (Kutty and Maines, 1981) 
(Fig. 11a). Despite being widely and regularly measured in patients, bilirubin is 
still largely considered a surrogate biomarker with little function, and its 
physiologic roles remain unclear. Bilirubin is also neurotoxic at high micromolar 
concentrations (CLAIREAUX et al., 1953). As bilirubin exhibits toxicity and has 
no obvious function, it has remained puzzling why diverse organisms evolved 
and retained the ability to produce it. However, bilirubin synthesis is dynamic, 
inducible, and tightly regulated, suggesting it may serve important physiologic 
functions. For example, bilirubin synthesis exhibits circadian periodicity (Kaasik 
and Lee, 2004) and is both temporally and spatially controlled during 
development (Falchuk et al., 2002). Bilirubin synthesis also rapidly increases 
during oxidative stress (Applegate et al., 1991), but why heme metabolism 





Figure 11. BVR-/- mice lack bilirubin and accumulate biliverdin.  
a, Schematic diagram of heme catabolism, in which heme is oxidized by heme oxygenase (HO) 
and cytochrome P450 (CPR) to biliverdin. Biliverdin is subsequently reduced to bilirubin by 
biliverdin reductase (BVR). b, The mus musculus Blvra gene. c-d, PCR from somatic DNA for exon 
3 (c) and RNA for full-length Blvra (d) from WT and BVR-/- mice. e, Representative photographs 
of gallbladders of WT and BVR-/- mice. f, Representative 405 nm HPLC chromatogram of 10 µM 
biliverdin, bilirubin, and hemin. g, Representative 405 nm HPLC chromatogram of bile pooled 
from 6 WT and BVR-/- mice. h, Representative 450 nm HPLC chromatogram of plasma from one 
WT and BVR-/- mice. i, Blvra RNA levels in different regions of the brain measured by quantitative 
PCR. Points represent individual mice. Mean ± SEM depicted. ** = P < 0.01 by two-way ANOVA 
followed by a post hoc Tukey test. j, Confocal images of bilirubin immunostaining in cerebellar 
sections from WT and BVR-/- mice. Scale bar = 100 µm. k, Coomassie blue gel of recombinantly 
purified UnaG. l, Ligand specificity for UnaG. Normalized fluorescence intensities of 1 µM 
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apoUnaG incubated with various concentrations of bilirubin, hemin, and biliverdin. Mean ± SEM 
depicted. m-p, Live-cell images of neurons co-expressing UnaG and mCherry (m) or IRFP and 
mCherry (o). (m) left column, mCherry; middle column, UnaG; right column, merged image. (o) left 
column, mCherry; middle column, IRFP; right column, merged image. left row, WT; right row, BVR-
/-. Scale bar = 50 µm. Mean UnaG fluorescence (n) and IRFP fluorescence (p) from WT and BVR-
/- neurons transfected with UnaG (n) or IRFP (p) normalized to mCherry fluorescence as a 
transfection control. Points represent independent data points. Mean ± SEM depicted. n = 9-12 
neurons per genotype per co-transfection. ** = P < 0.01 by two-tailed unpaired Student’s t-test. 
 
Some evidence suggests that bilirubin has antioxidant activity. However, 
whether bilirubin is a physiologic antioxidant is still a point of contention. Earlier 
conclusions were based on in vitro data (Stocker et al., 1987), experiments with 
exogenous bilirubin (Baranano et al., 2002; Doré and Snyder, 1999), and 
correlative findings from hyperbilirubinemic rats (Dennery et al., 1995). 
Moreover, these studies have not identified physiologically meaningful 
differences between bilirubin’s and biliverdin’s antioxidant activities despite 
being evolutionarily and chemically distinct metabolites (Jansen et al., 2010; 
Stocker et al., 1987), leaving bilirubin’s specific biology obscure. Whether 
bilirubin is a physiologically-relevant antioxidant is also unclear because 
bilirubin is dwarfed by many more abundant antioxidants, some present at 
10,000-fold higher concentrations (Maghzal et al., 2009; McDonagh, 2010). 
Despite this, several epidemiological studies suggest that mildly elevated serum 
bilirubin lowers the risk for ischemic stroke and coronary artery disease (Djousse 
et al., 2001; Perlstein et al., 2008; SCHWERTNER et al., 1994). The incidence of 





Figure 12. BVR-/- mice cannot synthesize bilirubin and accumulate biliverdin.  
a, Western blots for BVR and β-actin from brains, spinal cords, trigeminal ganglia, spleens, livers, 
pancreases, hearts, kidneys, and testes of WT and BVR-/- mice. b, photographs of bilirubin 
produced from lysates of various tissues from WT and BVR-/- mice. The green pigment is 
biliverdin, whereas the yellow pigment is bilirubin. c, rates of bilirubin production in different 
tissues from WT and BVR-/- mice. Box and whisker plots depict the median and the 25th–75th 
percentiles with whiskers extending to data at the most extreme ends (i.e., below the 25th 
percentile or above the 75th percentile position). Points represent independent data points. 
 
hyperbilirubinemia, is 5-fold lower than the general population (Vitek et al., 
2002). While these studies hint at a physiologic role for bilirubin, they are 
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correlative and do not concretely identify bilirubin’s physiologic functions. To 
directly evaluate whether bilirubin is a physiologic antioxidant, we generated a 




Depleting endogenous bilirubin renders cells vulnerable to oxidative death 
Early work approached studying bilirubin by deleting the enzyme HO-2 
(HO-2-/-) (Doré et al., 2000; 1999), one of the two HO isoenzymes (Maines et al., 
1986). However, HO-2-/- mice are confounded models for studying the redox 
biology of bilirubin, because they also accumulate heme and free iron (Dennery 
et al., 1998), both oxidants (TAPPEL, 1955). Here, we have generated a genetic 
mouse model that selectively lacks endogenous bilirubin without perturbing 
heme levels. To eliminate bilirubin, we targeted exon 3 of Blvra, thereby deleting 
BVR’s obligate NAD(P)H-binding domain (Kikuchi et al., 2001) and ensuring that 
any splice variant cannot produce bilirubin (Fig. 11b). Compared with WT 
mice, BVR-/- mice appear grossly normal. We confirmed loss of Blvra DNA and 
mRNA by PCR (Fig. 11c-d) and BVR protein by western blot analyses of various 
tissues (Fig. 12a). BVR-/- tissues do not produce bilirubin even when 
supplemented with biliverdin, demonstrating a general inability to generate 
bilirubin (Fig. 12b-c). HPLC analyses of bile from WT and BVR-/- gallbladders 
(Fig. 11e-g) indicate a loss of endogenous bilirubin and an accumulation of 
biliverdin in BVR-/- mice. Similarly, HPLC analyses of plasma (Fig. 11f and 1h 
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and Fig. 13a-c) indicate loss of endogenous bilirubin. Biliverdin levels are below 
the limit of detection in both WT and BVR-/- plasma. Feces from BVR-/- mice are 
still pigmented despite lacking bilirubin, presumably because biliverdin is still 
readily excreted in bile (Gåfvels et al., 2009; Nytofte et al., 2011). Unlike HO-2-/- 
mice, BVR-/- mice exhibit unaltered plasma heme (Fig. 11f and Fig. 13b and 
13d) and HO-2 expression (Fig. 13e-j), establishing BVR-/- mice as useful tools  
 
 
Figure 13. Epistatic heme catabolism is unaltered in BVR-/- mice.  
a, Representative HPLC chromatogram of 10 µM biliverdin, bilirubin, and hemin standards. 
Absorbance was measured at 450 nm. b, Representative HPLC chromatogram of plasma from 
WT and BVR-/- mice. Absorbance was measured at 405 nm. c, Relative quantification of plasma 
bilirubin in WT and BVR-/- mice via HPLC as detected by absorbance at 450 nm. Points represent 
individual mice. N.D. = not detected. Mean ± SEM depicted. ** = P < 0.01 by two-tailed unpaired 
Student’s t-test. d, Relative quantification of plasma heme in WT and BVR-/- mice via HPLC as 
detected by absorbance at 405 nm. Points represent individual mice. Mean ± SEM depicted. ns 
= P > 0.05 by two-tailed unpaired Student’s t-test. e-j, above, western blots for HO-2 and β-actin 
from brains, spinal cords, spleens, pancreases, kidneys, and testes of WT and BVR-/- mice. below, 
relative quantification of HO-2 expression in each tissue. Points represent individual mice. Mean 
± SEM depicted. ns = P > 0.05 by two-tailed unpaired Student’s t-test. 
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to specifically assess the redox biology of bilirubin without confounding effects 
from heme and iron.  
To assess bilirubin function in vivo, we first examined BVR expression in 
WT mice (Fig. 14a-b). BVR protein is variably expressed, with lowest expression 
in the heart and highest expression in the brain, spinal cord, spleen, and kidney. 
Within the brain, BVR mRNA is enriched in the cerebellum, double that of the 
cerebral cortex and almost five times higher than the corpus striatum (Fig. 11i). 
To determine where bilirubin might function in the brain, we assessed its 
localization immunohistochemically. Bilirubin exhibits discrete enrichment in 
neurons, with striking localization to Purkinje and some granule cells in the 
cerebellum (Fig. 11j). We also assessed the neuronal distribution of bilirubin 
with UnaG (Fig. 11k), a protein that fluoresces upon binding bilirubin (Kumagai 
et al., 2013). UnaG is highly specific for bilirubin with an EC50 of 15 ± 1 nM and 
does not fluoresce with heme or biliverdin (Fig. 11l). UnaG fluoresces in isolated 
cultures of WT but not BVR-/- neurons (Fig. 11m-n), suggesting that WT neurons 
autonomously produce bilirubin. In an analogous approach, we also expressed 
a phytochrome-based near-infrared fluorescent protein (IRFP) that fluoresces 
upon binding biliverdin (Filonov et al., 2011). BVR-/- neurons exhibit over 3 times 
greater IRFP fluorescence than WT neurons, consistent with an accumulation of 





Figure 14. BVR expression across tissues.  
a, Representative western blots for BVR and total protein from brains, spinal cords, trigeminal 
ganglia, spleens, livers, hearts. pancreases, kidneys, lungs, and testes of male WT mice. b, BVR 
expression across various tissues by western blot normalized to tissue expressing the least BVR. 
Points represent individual mice. Mean ± SEM depicted. 
 
BVR-/- cells are specifically hypersensitive to O2•− 
To assess whether removing endogenous bilirubin renders cells sensitive 
to oxidative stress, we challenged fibroblasts (MEFs) from WT and BVR-/- 
littermate mice with various oxidants and electrophiles. BVR-/- MEFs are highly 
vulnerable to oxidative death (Fig. 15a) and are particularly sensitive to the 
superoxide (O2•−) donors pyrogallol, paraquat, and menadione. BVR-/- MEFs are 
comparatively mildly sensitive to the oxidant hydrogen peroxide (H2O2) and the 
electrophile 4-hydroxynonenal (4-HNE). BVR-/- MEFs are also unable to clear 
reactive oxygen species (ROS) as efficiently as WT MEFs after exposure to 
menadione, as measured by the fluorescent redox probe dihydroethidium (DHE) 
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(Fig. 15b). Virally reintroducing BLVRA into the genome of BVR-/- MEFs restores 
their vulnerability to pyrogallol (Fig. 16), indicating that BVR-/- cells are prone 
to oxidative death specifically due to loss of BVR. Because BVR-/- cells lack 
bilirubin but also accumulate biliverdin, we treated MEFs with biliverdin to test 
whether excess biliverdin sensitizes cells to oxidative stress. However, biliverdin 
does not alter WT cells’ baseline viability or susceptibility to oxidative stress (Fig. 






Figure 15. BVR-/- cells are hypersensitive to exogenous and endogenous O2•− over other 
ROS and electrophiles.  
a, WT and BVR-/- MEF viability after 8 h exposure to varying concentrations of pyrogallol, 
paraquat ,menadione, H2O2, or 4-hydroxynonenal (4-HNE). Mean ± SEM depicted. n = 2-4 in 
triplicate. b, Live-cell images of dihydroethidium (DHE) fluorescence from WT and BVR-/- MEFs 
after exposure to 25 µM menadione for 1 h. Scale bar = 100 µm. c, Representative HPLC 
chromatograms of DHE alone, DHE + KO2, authentic ethidium (E+), and DHE + KO2 spiked with 
authentic E+. d-f, (d) Representative normalized HPLC chromatograms of organic extracts from 
WT and BVR-/- MEFs loaded with DHE at baseline or after treatment with 25 µM menadione for 
1 h. Cells treated with bilirubin were pre-treated with 500 nM bilirubin for 30 min just prior to 
menadione. (e-f) Relative quantification of E+ and 2-OH-E+ extracted from WT and BVR-/- MEFs. 
Points represent independent data points. Mean ± SEM depicted. * = P < 0.05 and ** = P < 0.01 
by two-way ANOVA followed by a post hoc Tukey test. g-h, Live-cell images (g) and quantification 
(h) of MitoSOX Red fluorescence WT and BVR-/- MEFs after exposure to 25 µM rotenone for 4 h. 
Cells treated with bilirubin were pre-treated with 500 nM bilirubin for 30 min just prior to 
rotenone. Scale bar = 25 µm. Points represent independent data points. Mean ± SEM depicted. * 
= P < 0.05 and ** = P < 0.01 by two-way ANOVA followed by a post hoc Tukey test. 
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BVR is a remarkably pleiotropic protein. Apart from reducing biliverdin to 
bilirubin, BVR functions as an enzyme-linked receptor at the plasma membrane 
(Wegiel et al., 2009) and as a kinase (Lerner-Marmarosh et al., 2008; 2005). 
These alternative functions lead to elevated AKT and MAPK signaling (Hinds et 
al., 2016; Lerner-Marmarosh et al., 2008; Wegiel et al., 2009), both of which 
promote cell survival during oxidative stress. However, we observe no difference 
in the expression, phosphorylation, or nuclear translocation of AKT or ERK1/2 
between WT and BVR-/- MEFs (Fig. 18a-b), leading us to focus on BVR’s 




Figure 16. Reintroducing BLVRA back into the genome of BVR-/- MEFs mitigates their 
sensitivity to pyrogallol.  
Viability of WT MEFs, BVR-/- MEFs, or BVR-/- MEFs expressing virally-reintroduced BLVRA after 
8 h exposure to varying concentrations of pyrogallol. Mean ± SEM depicted. n = 2 in triplicate. 
 
BVR-/- cells are markedly more sensitive to the three different O2•− cyclers 
over other oxidants and electrophiles (Fig. 15a), suggesting that bilirubin may 
physiologically interact with O2•−. Regulating O2•− is critical, because it is the 
immediate product of reduced O2 and is the precursor to several other ROS. 
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Despite its name, O2•− is not particularly “super” in its reactivity, because its 
doublet electronic configuration results in a kinetic spin barrier, while its anionic 
character limits reactivity with other electron-rich centers (Bielski and Richter, 
1977; Bielski et al., 1985; FEE, 1982; Sawyer and Valentine, 2002). Accordingly, 
O2•− is not readily scavenged by the major endogenous small molecule 
antioxidants in humans (such as glutathione, cysteine, uric acid, melatonin, and 
lipoic acid) at physiologically-relevant rates (Jones et al., 2002; Kuzkaya et al., 
2005; Winterbourn and Metodiewa, 1999). Superoxide dismutase enzymes 
(SODs) scavenge O2•− (MCCORD and I, 1969), but are restricted to soluble 
cellular compartments. However, O2•− is often produced within aprotic 
intramembranous compartments, which are more accessible to lipophilic 
molecules like bilirubin than to SODs. SODs are also imperfect antioxidants 





Figure 17. Excess biliverdin does not render MEFs hypersensitive to oxidative stress.  
Viability of WT MEFs treated after 24 h exposure to varying concentrations of pyrogallol. Cells 
were treated with vehicle or 10 µM biliverdin for 1 h just prior to pyrogallol. Mean ± SEM depicted. 
n = 2 in triplicate. 
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We leveraged DHE to measure whether BVR-/- cells accumulate O2•−, as 
DHE reacts with O2•− to form the specific fluorescent product 2-hydroxyethidium 
(2-OH-E+). However, DHE also reacts with other oxidants to form ethidium (E+). 
Both 2-OH-E+ and E+ exhibit similar fluorescence spectra and thus must be 
separated by HPLC in order to specifically quantify intracellular O2•− (Zhao et al., 
2005; 2003). Using the method established by Zhao and colleagues to resolve 2-
OH-E+ and E+ (Fig. 15c), we measured formation of 2-OH-E+ and E+ within WT 
and BVR-/- cells at baseline and after exposure to menadione (Fig. 15d-f and Fig. 
19a-c). BVR-/- cells produce slightly more 2-OH-E+ at baseline than WT cells, 
although the difference is statistically insignificant. As expected, treating both 
WT and BVR-/- cells with menadione results in more 2-OH-E+. However, BVR-/- 
extracts have almost two-fold more 2-OH-E+ than WT extracts, suggesting that 
removing endogenous bilirubin leads to an accumulation of O2•−. Conversely, 
loading WT and BVR-/- cells with extracellular bilirubin reduces 2-OH-E+ 
formation by approximately one-third. To confirm that extracellular bilirubin can 
enter cells, we applied bilirubin to cells expressing UnaG and measured changes 
in intracellular fluorescence. Because BVR-/- neurons do not exhibit basal 
fluorescence when transfected with UnaG (Fig. 11m), we expressed UnaG in 
BVR-/- neurons in order to directly correlate changes in UnaG fluorescence with 
extracellular bilirubin entering the cell. UnaG fluorescence increases within 
seconds of applying bilirubin (Fig. 20a-b), evidence that extracellular bilirubin 
can enter cells.  
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O2•− is generated by various processes in vivo, but most commonly forms 
in mitochondria when electrons leak from Complexes I – III of the electron 
transport chain to O2  (Miwa et al., 2003; Murphy, 2009). O2•− is often retained 
in the matrix or intramembranous spaces because its negative charge prevents 
passive diffusion outward. We examined whether bilirubin localizes to 
mitochondria by heterologously expressing mitochondrial-targeted UnaG 
(mitoUnaG) (Kumagai et al., 2013; Park et al., 2016). MitoUnaG fluoresces and 
localizes with mitochondrial-targeted blue fluorescent protein (mitoBFP) (Fig. 
21a), indicating that endogenous bilirubin localizes to mitochondria. To 
determine if bilirubin must be produced within mitochondria or if 
extracellular/cytoplasmic bilirubin can diffuse in, we applied exogenous 
bilirubin and monitored mitoUnaG fluorescence as performed previously (Park 
et al., 2016). MitoUnaG fluorescence increases within seconds (Fig. 21a), 






Figure 18. BVR-/- cells do not exhibit loss of AKT or MAPK signaling under oxidative stress.  
a, Representative western blots for phosphoserine-473 AKT, total AKT, GAPDH, and Histone 2B 
of subcellular compartments of WT and BVR-/- MEFs treated with 200 µM H2O2 for 4 h. b, 
Representative western blots for phosphothreonine-202/phosphotyrosine-204 ERK1/2, total 
ERK1/2, GAPDH, and Histone 2B of subcellular compartments of WT and BVR-/- MEFs treated 
with 200 µM H2O2 for 4 h. 
 
Although pyrogallol, menadione, and paraquat auto-oxidize to produce 
O2•−, they are only crude stereotypes of pathologic or physiologic O2•−. To 
determine if bilirubin scavenges O2•− in vivo, we treated WT and BVR-/- MEFs 
with rotenone and measured O2•− with the mitochondrial O2•− probe MitoSOX 
Red. Rotenone inhibits Complex I of the electron transport chain, thereby driving 




Figure 19. Superimposed time-adjusted DHE HPLC chromatograms from WT and BVR-/- 
MEFs. 
a-c, Superimposed HPLC chromatograms of organic extracts from WT and BVR-/- MEFs loaded 
with DHE (a) at baseline or after treatment with (b-c) 25 µM menadione for 1 h. Cells treated with 
bilirubin in (c) were pre-treated with 500 nM bilirubin for 30 min just prior to menadione. 
Because elution times shifted over the time, samples traces were adjusted with respect to time 
in order to standardize elution of E+ and 2-OH-E+ between samples. 
 
BVR-/- MEFs exhibit more than double the MitoSOX Red fluorescence of WT 
MEFs after exposure to rotenone (Fig. 15g-h) despite expressing similar levels of 
Sod1, Sod2, Sod3 and respiratory chain complex proteins (Fig. 22a-c). These 
findings suggest that even if SODs are sufficient for scavenging basal O2•−, 
bilirubin may be necessary during heavy mitochondrial activity or stress. Pre-
treating both WT and BVR-/- MEFs with bilirubin reduces MitoSOX Red 
fluorescence (Fig. 15g-h), suggesting that even exogenous bilirubin can reach 
mitochondria to scavenge ROS. In the brain, mitochondrial O2•− is a major driver 
of neuronal death in instances like ischemic stroke (Chouchani et al., 2014; 
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Kontos et al., 1992). To determine whether bilirubin prevents mitochondrial 
stress and neuronal death in the brain, we stereotactically injected rotenone into 
the cerebellum of WT and BVR-/- mice. We injected vehicle into the contralateral 
hemisphere to control for surgical injury. BVR-/- mice exhibit substantially larger 
lesions after exposure to rotenone, suggesting that bilirubin may protect against 
mitochondrial oxidative stress in the brain (Fig. 21b-d). 
 
 
Figure 20. Treating cells with bilirubin extracellularly increases intracellular bilirubin.  
a, Live-cell images of BVR-/- neurons co-expressing UnaG. left, baseline fluorescence of UnaG. 
right, UnaG fluorescence 5 min after application of 1 µM bilirubin. Scale bar = 50 µm. b, Average 
normalized UnaG fluorescence from individual DIV 14-18 primary cortical neurons over 5 min 
after treatment with extracellular bilirubin. After establishing baseline fluorescence for 10 s, 
neurons were treated with 1 µM bilirubin. n = 6 neurons. 
 
Bilirubin scavenges O2•− 
To determine whether bilirubin directly scavenges O2•−, we added one 
equivalent of bilirubin to O2•− in an aprotic solvent and monitored the 
spectroscopic signal of the unpaired electron on O2•− by electron paramagnetic 
resonance (EPR). At 100 K, O2•− alone exhibits its characteristic anisotropic EPR 
spectrum (Bagchi et al., 1989). Adding bilirubin immediately results in loss of 
EPR signal (Fig. 23a), suggesting that bilirubin scavenges the unpaired electron 
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on O2•−. We assessed whether other endogenous heme metabolites, biliverdin 
and conjugated bilirubin (ditaurated bilirubin), can scavenge O2•−. Using the spin 
trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO) at 298 K, we observe that 
ditaurated bilirubin is almost as effective as bilirubin in scavenging O2•− (Fig. 
23b). Biliverdin also scavenges O2•−, but more slowly than bilirubin. In contrast, 
glutathione exhibits no effect even at 100-fold excess. 
 
Figure 21. Bilirubin localizes to mitochondria and prevents mitochondrial stress.  
a, Live-cell images of MEFs co-expressing mitochondrial-targeted UnaG (mitoUnaG) and 
mitochondrial-targeted blue fluorescent protein (mitoBFP). left, baseline fluorescence of 
mitoUnaG and mitoBFP. right, fluorescence 1 min after application of 1 µM bilirubin. Scale bar 
= 10 µm. b, Schematic illustrating localized in vivo rotenone cerebellar microinjections. c, Nissl 
stains of cerebellar sections from WT and BVR-/- mice 48 h after stereotactic injection of vehicle 
or 1 µg of rotenone. Lesions are outlined in orange. Scale bar = 2 mm. d, Lesion volumes in WT 
and BVR-/- mice from rotenone microinjections. Points represent individual mice. Mean ± SEM 
depicted. ** = P < 0.01 by two-tailed unpaired Student’s t-test. 
 
Mitochondrial Complexes II and III produce O2•− at membranous sites (Guo 
and Lemire, 2003; Husen and Solov’yov, 2016), compartments more accessible 
to bilirubin than SODs. Bilirubin’s reactivity towards O2•− in aprotic solvents 
suggests that it may function as an important membranous O2•− scavenger. To 
test whether bilirubin can scavenge O2•− in cytosolic compartments as well, we 
assessed whether bilirubin can scavenge O2•− produced by xanthine oxidase in 
aqueous buffer. Bilirubin rapidly degrades when incubated with xanthine 
oxidase (Fig. 23c), but may be reacting with either O2•− or H2O2 since O2•− rapidly 
disproportionates to H2O2 in aqueous solvents. However, adding catalase to 
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remove H2O2 does not prevent bilirubin from degrading (Fig. 23c). Unlike 
catalase, excess SOD (which coverts O2•− into H2O2) prevents bilirubin from 
degrading, suggesting that bilirubin is not reacting secondarily with H2O2 but 
instead with O2•− directly. Similarly, incubating UnaG-bilirubin complexes with 
pyrogallol quenches UnaG fluorescence, whereas H2O2 has no effect (Fig. 23d). 
This again suggests that bilirubin reacts with O2•− but is inert towards H2O2, 




Figure 22. WT and BVR-/- mice exhibit similar expression of Sod enzymes and respiratory 
chain complex proteins. 
a, Quantitative PCR analysis of Sod1, Sod2, and Sod3 mRNA from WT and BVR-/- brains, 
normalized to β-actin. Points represent individual mice. Mean ± SEM depicted. ns = P > 0.05 by 
two-tailed unpaired Student’s t-test. b, western blots for components of Complexes I-V of the 
mitochondrial electron transport chain and β-actin from WT and BVR-/- brains. c, Relative 
quantification of Complex I-V proteins in WT and BVR-/- brains. Points represent individual mice. 
Mean ± SEM depicted. ns = P > 0.05 by two-tailed unpaired Student’s t-test. 
 
To more fully understand how bilirubin reacts with O2•−, we sought to 
better characterize the product and mechanism of the reaction. We find that the 
product elutes earlier than bilirubin on a reverse-phase column, indicating that 
it is likely more polar than bilirubin (Fig. 23e). The product also exhibits a red-
shifted UV-visible spectrum with a local λmax at 545 nm (Fig. 23f), which 
suggests expansion of bilirubin’s conjugate π network. Formation of a red-shifted 
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electronic network could proceed through several mechanisms, the simplest 
being a single electron transfer (SET) from O2•− to bilirubin. SET reactions 
between O2•− and heterocyclic compounds, such as lucigenin (Legg and Hercules, 
1969) and N-methylacridone (Rosenthal and Bercovici, 1973), often result in 
weak chemiluminescence. As with these heterocyclics, incubating O2•− with 
bilirubin results in chemiluminescence (Fig. 23g), suggesting that the two may 
react via a SET. However, the exact molecular identity of the product remains 
unclear and would require additional electrochemical and spectroscopic data. 
While bilirubin appears to scavenge O2•−, we wondered whether the 
reaction is rapid enough to be physiologically relevant. To determine the rate of 
the reaction, we employed a steady-state competitive kinetic analysis against p-
nitro blue tetrazolium (Fig. 23h), an established O2•− scavenger (Bielski and 
Richter, 1977). We determined that bilirubin scavenges O2•− with a second-order 
rate constant of (4.6 ± 0.8) x 105 M-1 s-1, a rate similar to other physiologic rate 
constants like those of urease (4.0 x 105 M-1 s-1) and chymotrypsin (2.9 x 105 M-
1 s-1) (Voet et al., 2016). Two abundant antioxidants in humans, glutathione and 
cysteine, exhibit little to no reactivity towards O2•− (Table 1). Bilirubin scavenges 
O2•− faster than biliverdin, highlighting an important evolutionary and functional 
distinction between the two metabolites (Fig. 23h). Although the second-order 
rate constant for the reaction between bilirubin and O2•− is larger than the other 
antioxidants we evaluated, O2•− also reacts with nitric oxide and tyrosine radicals 
at near-diffusion controlled rates (k > 109 M-1 s-1) (d’Alessandro et al., 2000; Huie 




Figure 23. Bilirubin selectively scavenges O2•− at physiologically-relevant rates.  
a, EPR spectrum of radicals generated by dissolution of KO2 without (blue) and with (green) 
equimolar bilirubin in 0.2 M 18-crown-6 in DMSO at 100 K. b, EPR spectra of DMPO-spin 
adducts of radicals from solutions of KO2 with or without 1 equivalent of bilirubin, bilirubin 
ditaurate, or biliverdin or 100 equivalents of glutathione at 298 K. c, Rate of change in bilirubin 
absorbance with xanthine/xanthine oxidase (XO) with or without excess 100 nM MnSOD or 1 
µM catalase. Mean ± SEM depicted. n = 2 in triplicate. ** = P < 0.01 and ns = P > 0.05 by two-
way ANOVA followed by a post hoc Tukey test. d, Normalized change in UnaG fluorescence from 
1 µM bilirubin and 1 µM apoUnaG with either 1 mM H2O2 (red), 100 µM pyrogallol (green), or 
100 µM pyrogallol and 100 nM MnSOD (orange). e, Representative HPLC chromatograms of 
bilirubin or bilirubin + KO2 with the detector set to (left) 440 nm or (right) 320 nm. f, UV-visible 
difference spectrum of bilirubin subtracted from bilirubin + KO2. g, Average fold change in 
chemiluminescence upon mixing 5 µM bilirubin with varying equivalents of KO2. h, Average 
competitive kinetic inhibition curves for bilirubin, glutathione, cysteine, and ascorbic acid 
against p-nitro blue tetrazolium (NBT) and xanthine/xanthine oxidase-derived O2•−. i, LUMO 
densities (|LUMO|) and change in Gibbs free energy (ΔG) for reducing cysteine, glutathione, uric 
acid, melatonin, ascorbic acid, biliverdin, and bilirubin, as calculated by the B3LYP functional 




peroxynitrite and tyrosine hydroperoxides, respectively, both of which contribute 
to O2•− toxicity (Nagy et al., 2009; Winterbourn et al., 2004). It is unlikely that 
bilirubin outcompetes nitric oxide or tyrosine radicals for O2•−, which suggests 
that bilirubin instead prevents other modes of O2•− toxicity. 
 
 
Table 1. Second order rate constants between O2•− and various small molecules. 
Experimental and literature rate constants for the reaction between O2•− and bilirubin, 
glutathione, cysteine, and ascorbate. n.d. = not determined. a Jones, C. M., et al. Free Radic. Biol. 
Med 32, 982–990 (2002); b Bielski, B. H. & Shiue, G. G. Ciba Found. Symp. 43–56 (1978); c Sawyer, 
D. T., et al. J. Am. Chem. Soc. 104, 6273–6278 (1982) 
 
To identify kinetic and thermodynamic factors that influence bilirubin 
reactivity towards O2•−, we calculated and compared the electronic structures of 
bilirubin, biliverdin, cysteine, glutathione, uric acid, melatonin, and ascorbic 
acid by density functional theory (DFT) (Becke, 1993; Hohenberg and Kohn, 1964; 
Kohn and Sham, 1965; Stephens et al., 1994). DFT calculations predict that 






bilirubin (4.6  ±  0.84) · 105 
cysteine n.d. 15 ± 2.0 b
ascorbate (8.2 ± 0.15) · 104 (2.8 ± 0.3) · 104 d
glutathione 15.0 ± 0.14 220 ± 10 a
biliverdin (2.0 ±  0.47) · 104 
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several bonds across the metabolite, which may impart unusual electron-
accepting properties and kinetic reactivity towards O2•− (Fig. 23i). Biliverdin also 
exhibits a delocalized LUMO similar to bilirubin, but one that is more densely 
concentrated at a single carbon (the α-meso carbon bridge). A more localized 
electron density could slow SET reactions, and may explain the different 
reactivities of biliverdin and bilirubin to towards O2•−. In contrast to the heme 
metabolites, cysteine, glutathione, uric acid, melatonin, and ascorbic acid 
exhibit much more densely localized LUMOs, rendering them less effective 
electron-acceptors. DFT calculations also predict that reducing bilirubin and 
biliverdin is exergonic. In clear contrast, the Gibbs free energy requirements for 
reducing cysteine, glutathione, uric acid, and melatonin are thermodynamically 
unfavorable. Reducing ascorbic acid is approximately 32 kcal/mol less 
thermodynamically favorable than reducing bilirubin.  
 
NMDA receptors signal via O2•−, and bilirubin prevents NMDA excitotoxicity by 
scavenging O2•− 
Although bilirubin is neurotoxic at high micromolar concentrations, BVR 
is highly expressed in the brain compared to other tissues (Fig. 14a-b) and 
bilirubin is enriched in neurons (Fig. 11m-n). As with MEFs, loss of endogenous 
bilirubin renders neurons vulnerable to oxidative death. BVR-/- neurons are also 
hypersensitive to O2•− over H2O2 (Fig. 24a). Ex vivo, DHE fluorescence suggests 
that BVR-/- neurons similarly cannot clear ROS as efficiently as WT when 





Figure 24. BVR-/- neurons are hypersensitive to oxidative stress.  
a, WT and BVR-/- neuronal viability after 8 h exposure to varying concentrations of (above) 
pyrogallol and (below) H2O2. Mean ± SEM depicted. n = 2 (pyrogallol) and n = 4 (H2O2) in triplicate. 
b, Confocal images of WT and BVR-/- brains that were treated ex vivo with 100 µM pyrogallol for 
30 min, after which total ROS was visualized by loading cells with 10 µM dihydroethidium (DHE) 
for 45 min. Scale bar = 200 µm. c-d, Quantification and histograms of DHE pixel intensity from 
WT and BVR-/- ex vivo brain slices treated with pyrogallol. Points represent independent 
cerebellar slices. Mean ± SEM depicted. ** = P < 0.01 by two-way ANOVA followed by a post hoc 
Tukey test. 
In the brain, O2•− is an important neuromodulator. Activated glutamatergic 
NMDA receptors (NMDARs) stimulate NADPH oxidase to generate O2•− (Brennan 
et al., 2009; Lafon-Cazal et al., 1993), which functions as a second messenger in 
long-term potentiation and neuronal redox processes (Gao et al., 2007; Heusler 
and Boehmer, 2004; Klann, 1998; Wang et al., 1996). BVR-/- mice exhibit 
exaggerated locomotor activity when injected with NMDA or MK-801 (an NMDAR 
agonist and antagonist, respectively) (Fig. 25a-c), indicating that BVR-/- mice 
exhibit aberrant NMDAR function. Accordingly, we explored whether bilirubin 
influences NMDAR redox signaling. 
Gauged by real-time DHE fluorescence, we observe that treating neurons 
with NMDA stimulates O2•− signaling, consistent with previous reports (Fig. 25d) 
(Bindokas et al., 1996; Brennan et al., 2009; Lafon-Cazal et al., 1993). Notably, 
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activating glutamatergic AMPA or kainate receptors does not lead to O2•− 
signaling in the presence of excess Mg2+ or APV, both of which inhibit NMDARs. 
To determine whether endogenous bilirubin scavenges NMDAR-associated O2•−, 
we treated WT neurons expressing UnaG with NMDA and monitored changes in 
UnaG fluorescence. As with pyrogallol in vitro (Fig. 23e), neuronal UnaG 
fluorescence decays after treatment with NMDA on the same time scale that DHE 
fluorescence increases (Fig. 25e-f). Applying the spin trap DMPO to the bath 
beforehand preserves UnaG fluorescence, suggesting that changes in UnaG are 
due to NMDAR-evoked O2•−. Treating neurons with (S)-AMPA or kainate with 
excess Mg2+ or APV also does not alter UnaG fluorescence, presumably because 
AMPA and kainate receptors do not trigger O2•− production.  
Previous studies of whether NMDARs initiate O2•− signaling relied on 
experiments that measured DHE fluorescence rather than formation of 2-OH-E+ 
(Bindokas et al., 1996; Brennan et al., 2009; Reyes et al., 2012), but DHE can 
non-specifically react with diverse oxidants to form different products with 
similar fluorescence spectra (Zhao et al., 2003; 2005). To establish whether 
NMDARs drive O2•− signaling, we measured neural 2-OH-E+ by HPLC before and 
after treating brain slices ex vivo with NMDA. Treating WT slices with NMDA 
leads to significant 2-OH-E+ formation, indicating that NMDARs indeed signal in 
part through O2•− (Fig. 25g-i). By contrast, BVR-/- slices accumulate almost two 
times more 2-OH-E+ than WT slices, suggesting that neural bilirubin scavenges 





Figure 25. NMDA receptors signal via O2•−, and bilirubin prevents NMDA excitotoxicity by 
scavenging O2•−.  
a-c, WT and BVR-/- male mouse open field locomotor activity over time at (a) baseline or after 
treatment with either (b) NMDA (100 mg/kg, i.p.) at 0 min or (c) MK-801 (0.3 mg/kg, i.p.). at 10 
min (arrow). Mean ± SEM depicted. n = 5 WT and 6 BVR-/- mice (baseline and NMDA) and 9 WT 
and 5 BVR-/- mice (MK-801). ** = P < 0.01 and ns = P > 0.05 by two-tailed unpaired Student’s t-
test. d, Normalized DHE fluorescence from individual DIV 14-18 primary cortical neurons over 
time. Neurons were treated (arrow) with 100 µM NMDA + 10 µM glycine, 100 µM (S)-AMPA, or 
100 µM kainate. Neurons treated with (S)-AMPA or kainate were pre-equilibrated with 2 mM 
MgCl2 or 50 µM APV. Points are means ± SEM of n = 6 neurons. Mean ± SEM depicted. ** = P < 
0.01 by one-way ANOVA followed by a post hoc Tukey test. e-f, Live images (e) and traces (f) of 
DIV 14-18 primary cortical neurons expressing UnaG over 15 min after treatment with 100 µM 
NMDA + 10 µM glycine, 50 µM (S)-AMPA, or 50 µM kainate. Scale bar = 25 µm. Neurons treated 
with (S)-AMPA or kainate were pre-equilibrated with 2 mM MgCl2 or 50 µM APV. Neurons treated 
with DMPO were pre-equilibrated with 10 mM DMPO 15 min prior to imaging. Points are means 
± SEM of n = 5 (NMDA), 3 (S-AMPA), and 3 (kainate) neurons. ** = P < 0.01 by one-way ANOVA 
59 
followed by a post hoc Tukey test. g, Representative normalized HPLC chromatograms of organic 
extracts from WT and BVR-/- ex vivo brain slices loaded with DHE at baseline or after treatment 
with 100 µM NMDA + 10 µM glycine for 30 min. h-i, Relative quantification of E+ and 2-OH-E+ 
extracted from WT and BVR-/- brain slices by HPLC at baseline or after treatment with 
NMDA/glycine. Points represent average of slices from individual mice. Mean ± SEM depicted. * 
= P < 0.05 and ** = P < 0.01 by two-way ANOVA followed by a post hoc Tukey test. j, Average 
thiobarbituric acid-reactive substances (TBARS) in WT and BVR-/- neurons 24 h after treatment 
with vehicle or 100 µM NMDA + 10 µM glycine for 20 min. Neurons treated with bilirubin were 
pre-treated with 50 nM bilirubin for 1 h prior to glycine/NMDA. Points represent independent 
data points. Mean ± SEM depicted. * = P < 0.05 and ** = P < 0.01 by two-way ANOVA followed by 
a post hoc Tukey test. k, Schematic illustrating localized in vivo NMDA cortical microinjections. 
l, Nissl stains of coronal sections from WT and BVR-/- mice 48 h after stereotactic injection of 
vehicle or 20 nmoles of NMDA. Scale bar = 2 mm. m, Lesion volumes in WT and BVR-/- mice from 
NMDA microinjections. Points represent individual mice. Mean ± SEM depicted. ** = P < 0.01 by 
two-tailed unpaired Student’s t-test. 
Because NMDARs signal in part through O2•−, pathologic NMDAR activity 
can also lead to uncontrolled lipid peroxidation and neuronal death (Reyes et al., 
2012). Persistent NMDAR activity, or excitotoxicity, is thought to mediate several 
neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and 
Huntington’s diseases (DEXTER et al., 1994; Ferrante et al., 1997; Kellogg and 
Fridovich, 1975; Subbarao et al., 1990). As expected, treating WT and BVR-/- 
neurons with high concentrations of NMDA results in accumulation of 
malondialdehyde, indicative of lipid peroxidation (Fig. 25j). However, BVR-/- 
neurons exhibit greater lipid peroxidation than WT neurons, suggesting that 
endogenous bilirubin protects neurons from excitotoxic death. Pre-treating both 
WT and BVR-/- neurons with bilirubin reduces peroxidation (Fig. 25j). To 
establish whether bilirubin prevents NMDA-driven excitotoxicity in the brain, we 
stereotactically injected NMDA into the cortex of WT and BVR-/- mice. As with 
rotenone, we injected saline into the contralateral hemisphere to control for 
surgical injury (Fig. 25k). BVR-/- mice exhibit substantially larger lesions after 
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exposure to NMDA, suggesting that endogenous bilirubin exerts neuroprotection 
in part by preventing excitotoxicity (Fig. 25l-m). 
 
Discussion 
O2•− is a key messenger in mammals, but its redox activity involves 
chemical specificity. The present study establishes a prominent role for 
endogenous bilirubin as a physiologic O2•− scavenger and establishes an activity 
specific to bilirubin over other major antioxidants. We also find that bilirubin is 
substantially more reactive towards O2•− than biliverdin. Bilirubin’s unique 
antioxidant profile may also explain why it is a major physiologic antioxidant 
despite being 10,000-fold lower in concentration than other antioxidants. 
Intriguingly, bilirubin levels inversely correlate with disease severity in several 
disorders in which O2•− scavenging is compromised, including Parkinson’s 
(Hatano et al., 2016; Moccia et al., 2015; Scigliano et al., 1997) and coronary 
artery diseases (BREIMER et al., 1995; Levinson, 1997).  
Bilirubin’s distinct redox activity may mediate unique redox signaling that 
underlies larger cellular processes. BVR appears to influence innate immunity 
and liver physiology (Bisht et al., 2019; Hinds et al., 2016). By selectively ablating 
Blvra in myeloid cells, Bisht and colleagues recently discovered that BVR 
modulates C5aR1 expression, thereby regulating macrophage chemotaxis. Just 
prior, Hinds and colleagues reported that eliminating BVR in hepatocytes leads 
to hepatic steatosis. Bilirubin could signal in both processes by scavenging O2•−, 
which regulates both macrophage chemotaxis and hepatic steatosis (Browning 
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and Horton, 2004; PETRONE et al., 1980). Recently, Chen and colleagues 
independently generated a mouse that also globally lacks BVR (Chen et al., 2018). 
By rigorously examining plasma lipids and peroxiredoxin-2, Chen et al. observed 
that deleting BVR leads to endogenous oxidative stress even in naïve mice. Both 
of our studies conclude that bilirubin physiologically exerts potent redox activity 
despite being significantly less abundant than other antioxidants. Together with 
the redox mechanisms identified in the present study, these studies may inform 
future work that discovers redox mechanisms specific to bilirubin. 
Previous studies that explored a physiologic connection between bilirubin 
and O2•− proposed that bilirubin and related tetrapyrroles attenuate O2•− 
signaling, but act indirectly by inhibiting NADPH oxidase (IWANAGA et al., 1987; 
Kwak et al., 1991; NAKAMURA et al., 1987). Other studies have observed that 
moderately hyperbilirubinemic mice exhibit less nitrositive/oxidative stress, 
suggesting that bilirubin acts by inhibiting NADPH oxidase (Stec et al., 2013; 
Vera et al., 2009). These studies support our findings that bilirubin is a 
physiologic antioxidant, but also provide intriguing evidence that bilirubin 
functions indirectly. However, these studies monitored the effect of bilirubin on 
NADPH oxidase activity by measuring O2•− and therefore do not disambiguate 
whether bilirubin acts by inhibiting NADPH oxidase, directly scavenging O2•− as 
identified here, or a mix of both.  
Our findings also suggest that diverse metabolic pathways are linked to 
neural activity. Although neural activity triggers changes in oxidative metabolism 
and glycolysis to adapt to energy demands, less is known about the influence of 
62 
neural activity on metabolic processes outside of cellular respiration. We propose 
that heme metabolism influences NMDAR redox signaling, and speculate that 
other metabolites may also shape neural function in yet unidentified ways. 
 
Materials and methods 
Experimental Model and Subject Details 
Mice 
Animal care and use 
All experiments were performed in accordance with protocols approved by the 
Animal Care and Use Committee at the Johns Hopkins University School of 
Medicine. 
 
Generation of BVR knock-out (BVR-/-) mice 
BVR-/- mice were generated at Ozgene (Australia) on a C57BL/6J background. 
To ensure loss of bilirubin biosynthesis, exon 3 of Blvra was flanked by two LoxP 
sequences for deletion via the Cre recombinase. BVR-/- mice were then 
backcrossed to wild-type C57BL/6J mice for four or more generations before 
these studies. Age-matched wild-type C57BL/6J mice were used as controls. 
 
Cell culture  
MEFs 
To isolate WT and BVR-/- MEFs, embryonic day 14.5 (E14.5) embryos were 
obtained from timed BVR+/− matings. The pups were decapitated and eviscerated, 
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after which the remaining portion was trypsinized and sheared. Isolated MEFs 
were plated in 2 wells of a 6-well plate and cultured overnight in DMEM (Gibco) 
supplemented with 10% FBS, 100 U/mL penicillin and streptomycin, and 2 mM 
glutamine at 37°C with 5% CO2. MEFs were then expanded to 6-well plates and 
transiently transfected with SV40T antigen (Addgene) and maintained until 
stably proliferative. DNA was isolated from the heads of the pups and genotyped 
to confirm the genotype of the corresponding MEF cell line. Data for WT and 
BVR-/- cells were drawn from experiments on at least two independent cell lines 
of each genotype.  
 
Primary neurons 
To isolate WT and BVR-/- neurons, cortices of embryonic day 14.5 (E14.5) 
embryos were isolated and washed with HBSS. Tissue was then incubated with 
0.25% trypsin in HBSS for 18 min at 37°C in a conical tube, after which trypsin 
was inactivated with the addition of FBS. Tissue were then pelleted at 2000g for 
5 min at 25°C, after which the supernatant trypsin/FBS was aspirated off. 
Tissue were then rinsed twice with HBSS, resuspended in HBSS, and then gently 
triturated through a fire-polished glass pipette to promote additional dissociation. 
Tissue was then filtered through a 70 µm nylon cell strainer to remove debris. 
The dissociated cells were pelleted at 2000g for 5 min at 25°C and then 
resuspended in neuronal culture media (composed of Neurobasal (Gibco) 
supplemented with 2% B-27 supplement and 2 mM glutamine). Cells were 
filtered once more through a 70 µm nylon cell strainer. Dissociated cells were 
64 
then plated onto rinsed, poly-D-lysine-coated dishes. Four days later, the 
conditioned media was supplemented with fresh neuronal culture media. The 
day before dissections, plates were prepared and coated in 0.25 mg/mL poly-D-
lysine overnight at 37°C. Just prior to plating, plates were rinsed three times 
with sterile water and once with neuronal culture media. 
 
Method Details 
Materials and preparation  
Solvents and compounds were obtained as follows:  
potassium superoxide (KO2) (Sigma), dimethyl sulfoxide (DMSO) (Sigma), 18-
crown-6 (Sigma), bilirubin IXα (Frontier Scientific), biliverdin IXα (Sigma), 
bilirubin ditaurate (Lee Biosciences), hemin (Frontier Scientific), pyrogallol 
(Sigma), paraquat (Santa Cruz Biotech), menadione (Sigma), hydrogen peroxide 
(H2O2) (Sigma), 4-hydroxynonenal (4-HNE) (Cayman Chemical), 
methylthiazoletetrazolium (MTT) (Sigma), rotenone (Sigma), dihydroethidium 
(DHE) (Thermo Fisher Scientific), MitoSOX Red (Thermo Fisher Scientific), 
Hoechst 33258 (Abcam), p-nitro blue tetrazolium (Sigma), 5,5-dimethyl-1-
pyrroline N-oxide (DMPO) (Cayman Chemical), L-glutathione (Sigma), L-cysteine 
(Sigma), L-ascorbate (Sigma), (S)-α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (S-AMPA) (Tocris Bioscience), kainic acid (Tocris 





Bilirubin is highly susceptible to oxidation and photolysis. Accordingly, bilirubin 
was freshly prepared in DMSO immediately prior to each experiment and then 
maintained in the dark. O2•− was freshly prepared by dissolving finely ground 
KO2 in new 0.2 M 18-crown-6 in DMSO. KO2 was prepared and maintained in a 
glove-bag under N2. Glutathione, cysteine, and ascorbate were all prepared 
freshly before experimentation. Both bilirubin and KO2 stock solutions were 
calibrated by UV-light spectroscopy. All other compounds were prepared as 100 
µl – 1,000 µl aliquots and stored at -20°C before thawing at 4°C. Freeze/thaw 
cycles were avoided whenever possible. 
 
Plasmids/cDNA, cloning, and lentivirus 
Plasmids/cDNA 
cDNA encoding UnaG was a gift from Atsushi Miyawaki, PhD (RIKEN, Japan). 
cDNA encoding mitochondrial-targeted UnaG was a gift from Jong-Seok Park, 
PhD and Hyun-Woo Rhee, PhD (Ulsan National Institute of Science and 
Technology, South Korea). cDNA encoding IRFP was a gift from Vladislav 
Verkhusha (Addgene plasmid #31857). psPAX2 and pMD2.G were gifts from 
Didier Trono (Addgene plasmids #12260 and #12259, respectively). 
 
Lentivirus 
Lentiviruses were generated as previously described with a few modifications 
(Jenkins et al., 2013). Briefly, cDNA encoding BVR and GFP separated by a self-
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cleaving 2A peptide was cloned into pLenti6 and transfected HEK293 cells with 
psPAX2 and pMD2.G. Virus was harvested from the media and collected by 
centrifugation at 100,000g for 2 h. BVR-/- MEFs were infected with lentivirus in 
the presence of 8 µg/ml Polybrene overnight. After 48 h, cells were sorted by 
GFP fluorescence using fluorescence-activated cell sorting (FACS). 
 
Spectroscopic analyses 
Electron paramagnetic resonance (EPR) spectroscopy 
EPR spectra were recorded with a Bruker EMXmicro spectrometer equipped with 
a ER4119HS resonator, and ER4141VT temperature control unit (Bruker 
Biospin, Billerica, MA). For analysis of naked radicals, the spectrophotometer 
was set at the following parameters unless otherwise stated: temperature, 100 
K; sweep width, 300 G; modulation amplitude, 1 G; modulation frequency, 100 
KHz; microwave power, 10 mW. For analysis of spin-trapped radicals (100 µM 
DMPO), the spectrophotometer was set at the following parameters unless 
otherwise stated: temperature, 298 K; sweep width, 150 G; modulation 
amplitude, 1 G; modulation frequency, 100 KHz; microwave power, 10 mW. 
 
UV-visible spectroscopy 
UV-visible spectra were recorded from 300 to 750 nm in quartz cuvettes with a 




Chemiluminescence measurements were obtained with a Turner Designs 20/20 
luminometer without filters. Reactions were initiated by adding various 
equivalents of KO2 to a fixed quantity of bilirubin. Chemiluminescence was 
quantified by integrating total counts over 10 seconds. Any chemiluminescence 
from dilution of KO2 or bilirubin was subtracted as background. 
 
Kinetic analyses 
To determine second order rate constants of reactions with O2•−, each reactant 
was individually mixed with 50 µM p-nitro blue tetrazolium (NBT), an established 
O2•− scavenger with a second order rate constant of kNBT = (5.94 ± 0.5) x 104 M-1 
s-1 (Bielski and Richter, 1977). The reactions were initiated by adding 
xanthine/xanthine oxidase as a source of O2•−. The ultimate reactions conditions 
were as follows: 0.1 M Na4P2O7, 100 nM deferoxamine (Sigma), 100 µM xanthine 
(Sigma), 10 mU xanthine oxidase (Sigma) at pH 8.3. The reaction between O2•− 
and NBT was monitored spectrophotometrically at 560 nm. The second order 
rate constants of each reactant was determined as a steady-state approximation 
by evaluating the reaction when rNBT = rreactant ≡ kNBT[NBT][O2•−]  = 
kreacant[reactant][O2•−]. Therefore, kreacant = kNBT[NBT]/[reactant]. 
 
Xanthine/xanthine oxidase-derived O2•− 
To determine rate at which bilirubin reacts with xanthine/xanthine oxidase-
derived O2•−, 5 µM bilirubin was incubated with 100 µM xanthine and 100 nM 
desferrioxamine and various amounts of xanthine oxidase in 0.1 M sodium 
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pyrophosphate at pH 8.5 at 25°C. Reactions were sometimes incubated with 100 
nM MnSOD, 100 nM boiled MnSOD, or 1 µM catalase. Reaction was monitored 
and measured as a change in absorbance at 442 nm. 
 
Quantum mechanical calculations 
Density Field Theory calculations were performed and modeled with Spartan 16 
(Wavefunction). Full geometry optimizations and frequency calculations were 
carried out with DFT-Hartree Fock hybrid B3LYP theory with the 6-31+G* basis 
set. Energies were calculated at ground state in the gas phase at 298 K. 
 
Western blotting 
For western blot analysis, tissues were dounce homogenized at 4°C in lysis buffer 
(pH 7.4 solution of 50 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 0.5% sodium 
deoxycholate, and 1% Triton X-100) supplemented with protease inhibitors 
(Sigma). Lysates were then pulse sonicated and centrifuged at 16,000g for 15 
min at 4°C. Fifteen micrograms of cleared lysate were run on a 4-12% 
polyacrylamide Bis-Tris gradient gel in running buffer (pH 7.3 solution of 50 mM 
MES, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA) and then transferred to a PVDF 
membrane. Membranes were blocked with 5% milk in TBS-T (pH 7.6 solution of 
16 mM Tris-HCl, 140 mM NaCl, 0.1% Tween-20) and incubated with primary 
antibodies in 3% bovine serum albumin (BSA) (w/v) overnight at 4°C. The 
following day, membranes were washed with TBS-T, and then incubated with 
secondary antibodies in 3% BSA for 1 h at 25°C. The following primary antibodies 
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were used: rabbit anti-BVR (Abcam ab180208; 1:1,000), rabbit anti-HO-2 
(generated as previously described (Zakhary et al., 1996); 1:1,000), mouse anti-
total OXPHOS cocktail (Abcam ab110413; 1:5,000), mouse anti-pS473 AKT (Cell 
Signaling 587F11; 1:1000), rabbit anti-AKT (Cell Signaling 11E7; 1:1000), rabbit 
anti-pERK (Cell Signaling 9101; 1:1000), rabbit anti-tERK (Cell Signaling 9102; 
1:1000), and mouse anti-β-actin (Santa Cruz Biotech sc-47778 HRP; 1:10,000). 
The following secondary antibodies were used: sheep anti-mouse IgG (GE 
Healthcare NA931; 1:10,000), and donkey anti-rabbit IgG (GE Healthcare NA934; 
1:10,000) 
 
RNA isolation, reverse transcriptase PCR (RT-PCR), and quantitative-PCR (q-PCR) 
RNA isolation and qPCR were performed as previously described (Paul et al., 
2014). In brief, total cellular or tissue RNA was extracted using the RNeasy Plus 
Universal Kit (Qiagen) per the manufacturer’s instructions. RT-PCR was 
performed with the SuperScript III One-Step RT-PCR System (Invitrogen), 
whereas q-PCR was performed with the TaqMan RNA-to-Ct 1-Step Kit (Life 
Technologies). 
 
Brain slice preparations 
Ex vivo slices were prepared as described (Wang and Kass, 1997). In brief, brains 
from WT and BVR-/- mice were sectioned in 300 µm intervals with a vibratome 
in the sagittal plane. Slices were cut in ice-cold sectioning artificial cerebrospinal 
fluid (S-aCSF) (pH 7.4 solution of 126 mM NaCl, 3 mM KCl, 1.4 mM NaH2PO4, 
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10 mM MgSO4, 0.5 mM CaCl2, 26 mM NaHCO3 and 10 mM glucose), equilibrated 
with 95% O2 and 5% CO2. Sections were equilibrated in room temperature 
experimental aCSF (E-aCSF) (pH 7.4 solution of 126 mM NaCl, 3 mM KCl, 1.4 
mM NaH2PO4, 0 mM MgSO4, 1.4 mM CaCl2, 26 mM NaHCO3 and 4 mM glucose) 
for 1 h before assaying. 
 
High pressure liquid chromatography (HPLC) 
Bile and plasma heme metabolites 
Bile and plasma bilirubin, biliverdin, and heme were separated by HPLC with an 
analytical LC-18 column, 250 × 4.6 mm (Xterra, Waters Corporation) with the 
following mobile phases: 0.1 M ammonium acetate in 60% methanol / 40% water 
(v/v) (pH 5.2) (Solvent A) and 100% methanol (Solvent B) at 1 mL/min.  
Metabolites were eluted as follows: 0 to 14 min: linear gradient from 100% A to 
100% B; 14 to 19 min: linear gradient from 100% A to 100% B; 19-24 min: 
isocratic elution at 100% A. The metabolites were detected by measuring 
absorbance at 405 nm. The bilirubin standard exhibited a retention time of 
approximately 14-15 min, whereas biliverdin and heme standards exhibited 
retention times of 10-11 and 17-18 min, respectively. 
 
DHE, E+, and 2-OH-E+ 
DHE, E+, and 2-OH-E+ were extracted and analyzed by HPLC as previously 
established with a few modifications (Zhao et al., 2003; 2005). To extract 
intracellular DHE, E+, and 2-OH-E+, cells were lysed in lysis buffer (pH 7.4 
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solution of 50 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 
and 1% Triton X-100) supplemented with protease inhibitors (Sigma), mixed with 
1 equivalent of 1-butanol, vortexed for 1 min, and then centrifuged at 16,000g 
for 15 min at 4°C. The organic phase was separated and dried under nitrogen 
gas. Treatments and extractions were performed under dim light to minimize 
photooxidation of DHE (Zielonka et al., 2006). DHE, E+, and 2-OH-E+ were 
separated by HPLC with an analytical LC-18 column, 150 × 3.9 mm (Xterra, 
Waters Corporation) with the following mobile phases: 10% acetonitrile in in 0.1% 
trifluoroacetic acid (Solvent A) and 70% acetonitrile in in 0.1% trifluoroacetic 
acid (Solvent B) at 1 mL/min. The samples were eluted with a linear gradient 
from 100% A / 0% B to 80% A / 20% B from 0 to 40 min. DHE, E+, and 2-OH-
E+ were detected with a fluorescence detector with excitation and emission at 
510 and 595 nm, respectively.  
a. MEFs: MEFs were treated with 25 µM menadione for 1 h, washed with 
HBSS, loaded with 25 µM dihydroethidium (DHE) for 45 min, and then 
rinsed twice more in HBSS before lysis.  
b. Brain slices: Slices were loaded with 25 µM dihydroethidium (DHE) for 
30 min, washed twice with E-aCSF, and then treated in separate 
chambers with vehicle or 100 µM NMDA + 10 µM glycine for 30 min. 
Brain slices were assayed at room temperature in E-aCSF continuously 
bubbled with 95% O2 and 5% CO2. 
 
Cell viability assays 
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Clonogenic assays  
Clonogenic assays were performed as previously described (Weyemi et al., 2015). 
In brief, equivalent numbers of WT and BVR-/- MEFs were plated on 35 mm 
dishes. The cells were treated the following day with an oxidant and then fed 
fresh media the subsequent day. Six days later, the cells were fixed with 100% 
methanol for 10 min, stained with 1% methylene blue, and then destained for 5 
min with a solution of 40% methanol / 10% acetic acid / 50% water (v/v/v). 
Colonies were quantified under a dissection microscope.  
 
Methylthiazoletetrazolium (MTT) assays 
MTT assays were performed as previously described (Baranano et al., 2002). In 
brief, MEFs were plated at a density of 75,000 cells/well into a 24-well plate. The 
following day, the culture media was supplemented with pyrogallol, paraquat, 
menadione, H2O2, or 4-HNE for 8 h, after which the media was replaced with 
fresh media containing 0.5 mg/mL MTT for 1 h. The media was then removed 
before dissolving the reduced cellular MTT in DMSO. Cell viability was 
determined by measuring the absorbance at 570 nm and normalizing 
absorbances to the vehicle condition. 
 
BVR enzymatic activity assays 
BVR activity was assayed at pH 8.5 at 37°C. Tissues were dounce homogenized 
at 4°C in lysis buffer (pH 7.4 solution of 50 mM Tris-HCl, 150 mM NaCl, 1% 
Triton X-100, and 5% glycerol) supplemented with protease inhibitors (Sigma). 
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Lysates were centrifuged at 16,000g for 15 min at 4°C. 50 micrograms of clarified 
lysate was incubated for 5 min at room temperature in a pH 8.5 solution of 50 
mM Tris, NADP+, glucose-6-phosphate, and glucose-6-phosphate 
dehydrogenase (NADPH Regeneration System, Promega). The samples were then 
placed at 37°C and spiked with 10 µM biliverdin IXα. Reaction rates were 
determined by monitoring the change in absorbance at 442 nm over time. 
 
Live-cell imaging and analysis 
DHE ROS imaging 
MEFs: To compare the ROS scavenging capacities of WT and BVR-/- MEFs, cells 
were treated with 25 µM menadione for 1 h. MEFs were then loaded with 25 µM 
dihydroethidium (DHE) for 45 min, after which they were washed and 
maintained in HBSS for imaging. Cells were immediately photographed with a 
confocal microscope.  
Brain slices: To assess ROS levels ex vivo, cerebellar slices were treated with 100 
µM pyrogallol for 30 min in E-aCSF. After washing with E-aCSF, slices were 
loaded with 10 µM DHE in aCSF for 45 min. After washing with E-aCSF, slices 
were immediately photographed with a fluorescent confocal microscope. Sections 
were assayed at room temperature in E-aCSF continuously bubbled with 95% 
O2 and 5% CO2. 
 
MitoSOX Red ROS imaging 
74 
MEFs: To specifically quantify mitochondrial ROS, MEFs were plated at a density 
of 10,000 cells/well in a 96 well plate. The following day, the cells were treated 
with 25 µM rotenone (Sigma) for 4 h in fresh media. Cells treated with bilirubin 
were pre-treated with 500 nM bilirubin for 30 min just prior to rotenone. The 
MEFs were then loaded with 5 µM MitoSOX Red in HBSS for 15 min, after which 
they were washed and maintained in HBSS for imaging. Cells were immediately 
photographed with a fluorescent confocal microscope. 
 
Mitochondrial bilirubin imaging 
To observe mitochondrial bilirubin, MEFs were plated at a density of 60,000 
cells/well in a 35 mm glass-bottom plate (MatTEK). The following day, MEFs 
were transfected with mitochondria-targeted UnaG (mitoUnaG, Dr. Park Lab) 
and mitochondria-targeted BFP (mitoBFP, Addgene) using Lipofectamine 3000 
(Invitrogen) per the manufacturer’s instructions. Two days later, the media was 
replaced with media lacking phenol red and imaged with a fluorescent confocal 
microscope. To assess bilirubin trafficking to the mitochondria, exogenous 
bilirubin was added to the dish to a final concentration of 1 µM. UnaG 
fluorescence was imaged at several time points. 
 
Neuronal DHE and UnaG imaging 
To observe neuronal DHE or UnaG fluorescence, mouse primary cortical neurons 
were isolated from E15.5-E17.5 mice and plated at a density of 1 million 
cells/well in a 35 mm glass-bottom plate (MatTEK). Neurons were maintained in 
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Neurobasal medium for at least 14 days in vitro (DIV) before imaging. Neurons 
were imaged at 25°C in neuronal extracellular solution (NES) (pH 7.3 solution of 
5 mM HEPES, 125 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, and 33 mM glucose). 
After establishing baseline fluorescence over 2 min, neurons were treated with 
either 100 µM NMDA + 10 µM glycine, 50 µM (S)-AMPA, or 50 µM kainate. 
Neurons treated with (S)-AMPA or kainate were pre-equilibrated with NES 
supplemented with 2 mM MgCl2 and/or 50 µM APV. 
a. DHE fluorescence imaging: Neurons were loaded with 5 µM DHE in NES 
for 15 min at 25°C, after which neurons were washed twice in NES. 
b. UnaG fluorescence imaging: Neurons were transfected with UnaG cDNA at 
two days before imaging, typically DIV12. 
 
Image analysis 
Digitized images were quantified with FIJI (ImageJ). The mean fluorescence 
signal intensity was measured as the mean of the frequency distribution of all 
collected pixels. When imaging MEFs, frequency distributions were pooled from 
3-4 replicates per sample condition. When imaging tissues ex vivo, frequency 
distributions were pooled from 2 sections per brain for each 'n'. 
 
UnaG purification 
UnaG was expressed in pMAL-6P2-6xHIS in BL21(DE3) cells. Starter cultures 
were grown to saturation overnight in Luria Broth (LB) at 37°C and then diluted 
10-fold in LB and grown to an OD600 of 0.3 at 37°C, after which cultures were 
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moved to 18°C. At OD600 of 0.6, UnaG expression was induced by the addition of 
400 µM isopropyl β-D-1-thiogalactopyranoside for 16 h at 18°C. Cells were 
harvested by centrifugation, resuspended in 15 ml of resuspension buffer (50 
mM HEPES, 300 mM NaCl, 0.5 mM TCEP, 10% glycerol, 1 mM PMSF, 2.34 µM 
leupeptin, 1.45 µM pepstatin at pH 7.4) per liter of culture, and flash frozen in 
liquid nitrogen. Pellets were thawed on ice and sonicated to lyse. Lysate was 
clarified by centrifugation at 26,000g at 4°C for 30 min and subsequently loaded 
onto an amylose column. Protein was eluted with 20 mM maltose in protease 
buffer (50 mM Tris, 150 mM NaCl, 0.5 mM TCEP, 10% glycerol, 0.01% TritonX-
100 at pH 7.4), after which the MBP was were removed by the addition of 
Prescission Protease (GE Healthcare) for 16 h at 4°C. UnaG was further purified 
via a nickel column to remove the cleaved tag and Prescission Protease. Protein 
was further purified on a gel-filtration column (S-200, GE Healthcare) in 50 mM 
HEPES, 300 mM NaCl, 0.5 mM TCEP, 10% glycerol at pH 7.4, concentrated, and 
flash frozen in gel filtration buffer at 30% glycerol for storage at −80 °C. 
 
Bilirubin immunostaining 
8-12 weeks old mice were anesthetized with 50 mg/kg pentobarbital and 
transcardially-perfused with 20 mL cold 0.1 M heparin/PBS (pH 7.4), followed 
by 25 mL of cold fixative (4% formaldehyde (v/v)). Tissues were post-fixed in 4% 
paraformaldehyde overnight at 4°C and then cryoprotected through a series of 
10%, 20%, and 30% sucrose (w/v) gradients for 48 h at 4°C. Tissues were then 
embedded in Optimal Cutting Temperature compound (OCT) and sectioned in 
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30 µm intervals with a cryostat, after which the sections were dried on slides for 
at least 1 h at 25°C. Sections were fixed with 4% paraformaldehyde for 15 min 
at 25°C and then permeabilized with 100% methanol for 7 min at -20°C. The 
slides were then pre-incubated in blocking solution (50% Seablock 
(ThermoFisher Scientific) (v/v) in TBS-T, pH 7.4) for 30 min at 25°C. Sections 
were incubated overnight at 4°C with a rabbit polyclonal anti-bilirubin antibody 
(1:100) in blocking solution. Sections were washed and incubated with goat anti-
rabbit secondary antibody (Alexa 488, A32723 Invitrogen) diluted 1:250 in 
blocking solution for 1 h at 25°C. Tissues were then mounted with ProLong Gold 
Antifade Mountant with DAPI (Invitrogen). Primary bilirubin antibody was 
generated as previously described (Doré et al., 1999). 
 
Lipid peroxidation quantification 
DIV10-14 primary WT and BVR-/- cortical neurons were exposed to vehicle or 10 
µM glycine/100 µM NMDA for 20 min in control salt solution (CSS) (pH 7.4 
solution of 120 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 25 mM Tris HCl, 15 mM 
glucose). Neurons were washed twice in CSS and then re-fed conditioned media 
for another 24 h, after which thiobarbituric acid-reactive substances (TBARS) 
were measured. TBARS were quantified using the OxiSelect TBARS Assay Kit 
(Cell Biolabs) per the manufactures instructions. Neurons treated with bilirubin 




Adult male mice (2-3 month old) were anesthetized with ketamine (80-100 mg/kg) 
and xylazine (5-10 mg/kg) and subsequently immobilized to a stereotaxic frame 
(Stoelting Digital Mouse Stereotaxic Instrument) with ear bars. Mice were 
maintained at 37°C with a heating pad during surgery. The needle was inserted 
at a rate of 0.1 mm/s and extracted at a rate of 0.5 mm/min, with a 5 min needle 
dwell time before extraction. 
NMDA 
Mice treated with NMDA received unilateral intracortical microinjections of 20 
nmoles NMDA with a contralateral microinjection of PBS as a control. NMDA was 
delivered in a final volume of 0.2 µL over 2 min. NMDA was injected at the 
following coordinates: AP = 0.5, ML = -2.5, DV = -0.5. 
Rotenone 
Mice treated with rotenone received unilateral intracerebellar microinjections of 
2.5 nmoles rotenone with a contralateral microinjection of DMSO as a control. 
Rotenone was delivered in a final volume of 1 µL at a rate of 0.2 µL/min. 
Rotenone was injected at the following coordinates: AP = -6.5, ML = -2.5, DV = -
2.0. 
 
Histology and lesion quantification 
Histology and quantification were performed as previously described (Paul et al., 
2014). In brief, mice were euthanized 2 days post-injection, after which brains 
were fixed, cryopreserved, and sectioned in the same manner as with bilirubin 
immunostaining. Dry sections were then stained with Nissl stain. Lesional 
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volumes were calculated blinded to both genotype and treatment as a sum of 10 
sections for NMDA-induced lesions and 6 sections for rotenone-induced lesions, 
using Cavalieri’s principle (Cyr et al., 2005) (V = s1d1 + s2d2 + … + sndn, where s is 
surface area and d is the distance between two sections). 
 
Behavioral tests 
Behavioral tests were performed on 2-4 months old WT and BVR-/- littermate 
male mice. Baseline, NMDA- and MK-801-induced activity in the open field was 
assessed using activity chambers equipped with infrared beams (Photobeam 
Activity System; San Diego Instruments, San Diego, CA, USA). Behavioral assays 
were initiated by placing mice were placed in the center of an enclosed acrylic 
chamber. Mice were initially habituated to the chambers for 30 min followed by 
a single injection of either NMDA (100 mg/kg, i.p.) or MK-801 (0.3 mg/kg, i.p.). 
Total locomotor activity was automatically recorded and analyzed via 
photobeams in the x and y directions. 
 
Quantification and Statistical Analysis  
Group data were expressed as mean ± SEM unless otherwise noted. Statistical 
comparisons were performed using two-tailed unpaired Student’s t-tests and 
ANOVA analyses, as noted. Differences were considered significant at P < 0.05. 
All ex vivo or in vivo experiments were performed concomitantly or in a blocked 
manner with consideration for both genotype and treatment. 
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Identification of a bilirubin receptor that may mediate a 




Various pathologic conditions result in jaundice, a yellowing of the skin due to 
a buildup of bilirubin. Patients with jaundice commonly report experiencing an 
intense non-histaminergic itch. Despite this association, the pruritogenic 
capacity of bilirubin itself has not been explored, and no bilirubin receptor has 
been identified. Here, we demonstrate that pathophysiologic levels of bilirubin 
excite peripheral itch sensory neurons and elicit pruritus through Mrgprs, a 
family of G-protein coupled receptors expressed in primary sensory neurons. 
Bilirubin binds and activates two Mrgprs, mouse MRGPRA1 and human 
MRGPRX4. In two mouse models of pathologic hyperbilirubinemia, we show 
that genetic deletion of either Mrgpra1 or Blvra, the bilirubin-producing 
enzyme, attenuates itch. Similarly, plasma isolated from hyperbilirubinemic 
patients evoked itch in wild-type animals but not Mrgpra1-/- animals. 
Removing bilirubin decreased the pruritogenic capacity of patient plasma. 
Based on these data, targeting MRGPRs is a promising strategy for alleviating 
jaundice-associated itch.  
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Introduction 
Chronic pruritus, or itch, is a complex and often debilitating symptom that 
accompanies a range of cutaneous and non-cutaneous diseases (Ständer et al., 
2007; Yosipovitch and Bernhard, 2013),(Yamamoto et al., 2009; Yosipovitch et 
al., 2000). The most widely known pruritogen is histamine, which is secreted by 
mast cells in the skin and activates histamine receptors on nearby sensory 
neurons (Bautista et al., 2014; Ikoma et al., 2006; LaMotte et al., 2014; 
Yosipovitch and Bernhard, 2013). While viable treatments exist for histamine-
mediated itch, most non-histaminergic conditions are more difficult to treat 
because the mediators are often unknown (Kremer et al., 2011).  
Jaundice, or yellowing of the skin, sclera, and mucosa due to abnormal 
accumulation of the yellow heme metabolite bilirubin, is often associated with 
chronic non-histaminergic pruritus. Jaundice often presents in patients with 
hepatobiliary disorders such as cholestasis, characterized by impaired bile flow. 
Physiologically, bilirubin is typically bound to albumin in serum and 
concentrates in the liver, where it is conjugated to glucuronic acid and 
subsequently excreted in bile. At physiologic and mildly elevated concentrations 
(0.2-2.7 mg/dL, 3.4 - 46.2 µM), bilirubin is benign. At highly elevated levels 
however, such as in cutaneous jaundice (> 5 mg/dL, > 85.5 µM bilirubin), it is 
associated with pruritus, a correlation first noted by physicians as early as the 




Bilirubin elicits non-histaminergic, Mrgpr-dependent pruritus 
Despite the long-standing association between jaundice and pruritus 
(Talwalkar et al., 2003), bilirubin itself has not been tested as a pruritogen. To 
determine whether bilirubin directly elicits pruritus, we subcutaneously injected 
bilirubin into the napes of mice. Pathophysiologic concentrations of bilirubin 
stimulated scratching in a dose-dependent manner at the site of injection (Fig. 
26a). Pre-incubating bilirubin with excess human serum albumin, which binds 
bilirubin with high affinity (Breaven et al., 1973; Griffiths et al., 1975; Jacobsen 
and Broderson, 1983), elicited fewer scratches (Fig. 26a). The behavioral profile 
of bilirubin-induced scratching mirrored that of two well-characterized 
pruritogens, histamine and chloroquine (Fig. 26b). Notably, histamine and 
chloroquine only elicit itch when injected into mice at millimolar concentrations 
despite having nanomolar affinity towards their receptors. In comparison, 
bilirubin elicited a similar degree of itch even when injected at lower 
concentrations than histamine or chloroquine (Fig. 26b). Since mice 
indiscriminately scratch if injected at the nape with substances that trigger 
either itch or pain, we also injected mice at the cheek. Unlike at the nape, painful 
sensations at the cheek evoke a distinct wiping behavior instead of scratching, 
whereas itchy sensations still elicit scratching (Shimada and LaMotte, 2008). 
Injecting bilirubin in the cheek prompted dose-dependent scratching just as it 
did at the nape (Fig. 27a). Bilirubin elicited neither wiping nor licking, indicating 





Figure 26. Bilirubin elicits non-histaminergic, Mrgpr-dependent pruritus. 
a, Scratching bouts associated with injection of bilirubin. The indicated amount of bilirubin was 
injected into the nape of mice. The blue bar (+HSA) represents animals injected with 60 µg 
bilirubin pre-incubated with 1% human serum albumin. Veh n = 8; 6 µg n = 5, 18 µg n = 11, 30 
µg n = 12, 60 µg n = 7,+HSA n = 12. b, Time course of itch behavior associated with bilirubin, 
histamine, or chloroquine. Scratching bouts were binned according to 5 min intervals. Bilirubin 
n = 16, Histamine n = 13, Chloroquine n = 11. c, 60 µg bilirubin was injected into the nape of 
WT and Mrgpr-cluster KO littermates. WT n = 8, Mrgpr-cluster KO n = 13. d, 60 µg of the 
indicated metabolite was injected into WT and Mrgpr-cluster KO littermates. Hemin (WT n = 10, 
Mrgpr-cluster KO n = 6), Biliverdin (WT n = 7, Mrgpr-cluster KO n = 7), Urobilinogen (WT n = 15, 
Mrgpr-cluster KO n = 8), Stercobilin (WT n = 7, Mrgpr-cluster KO n = 5). e, The pathway of heme 
degradation. The skeletal formula of each metabolite is depicted above its optimal 3D geometry, 
as calculated by a B3LYP functional and 6-31G(d) basis set. Blue and orange represent orbital 
parity of each metabolite’s HOMO obtained from DFT calculations. (a, c, and d) Mean ±s.e.m. 
depicted. Each open circle represents an individual mouse. *, p < 0.05; **, p < 0.01; ***, 
p < 0.001; two-tailed unpaired Student’s t-test. 
We injected mice with similarly structured metabolites to determine the 
specificity of bilirubin’s pruritic activity (Fig. 26e). The two metabolites directly 
epistatic to bilirubin, hemin and biliverdin, did not induce scratching despite 
also being tetrapyrroles (Fig. 26d). While hemin, biliverdin, and bilirubin display 
only minor atomic and electronic differences between them, they vary 
substantially in their physiochemical properties and structures (Fig. 26e). To 
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better understand these differences, we performed density functional theory 
(DFT) calculations (Becke, 1993; Hohenberg and Kohn, 1964; Kohn and Sham, 
1965; Stephens et al., 1994) followed by single point energy calculations to 
determine the optimal geometry of each metabolite. Unlike in heme and 
biliverdin, bilirubin’s four pyrroles are extended and do not lie in the same plane 
(Fig. 26e). DFT calculations revealed that urobilinogen and stercobilin, two 
bacterial metabolites derived from bilirubin, adopt a similar extended 
conformation. Both urobilinogen and stercobilin were able to stimulate 
scratching behavior (Fig. 26d), indicating that bilirubin’s non-polar pyrroles may 
be important for its pruritic activity. 
Patients with jaundice-associated pruritus receive little benefit from 
antihistamines (Carstens et al., 2014). Consistent with these clinical findings, 
the histamine receptor 1 blocker cetirizine (30 mg/kg, i.p.) failed to alleviate 
scratching behavior in mice injected with bilirubin (Fig. 27d). Furthermore, 
bilirubin did not elicit a calcium response or induce appreciable histamine 
release from peritoneal mast cells (Fig. 27e-f). 
The Mas-related G-protein coupled receptor (Mrgpr) family of receptors is 
a major mediator of non-histaminergic pruritus (Han et al., 2012; Liu et al., 2012; 
2009; Sikand et al., 2011). To test whether Mrgprs mediate bilirubin-induced 
pruritus, we injected mice lacking a cluster of 12 Mrgpr genes (Mrgpr-clusterΔ−/−) 
with bilirubin (Liu et al., 2009). Mrgpr-clusterΔ−/− animals scratched 
approximately 75% less than wild type (WT) mice, indicating that one or more of 





Figure 27. Bilirubin elicits non-histaminergic pruritus and not pain. 
a, Scratching bouts associated with cheek injection of bilirubin. The indicated amount of 
bilirubin was injected in a 10 µl volume and the number of scratching bouts was assessed for 30 
min. Vehicle n = 6, 1.8 µg n = 5, 3 µg n = 4, 6 µg n = 5, 6 µg (Mrgpr-clusterΔ−/−) n = 6. b, Wiping 
associated with injection of 6 µg bilirubin into the cheek. Wipes were assessed for 10 min post-
injection, vehicle n = 5, bilirubin n = 7. c, Lick time associated with injection of 6 µg bilirubin 
into the paw. Licking was assessed for 10 min post-injection. n = 3 per condition. d, H1 blocker 
does not inhibit bilirubin-induced pruritus. Either vehicle or 30 mg/kg Cetirizine was 
given i.p. 30 min prior to injection of bilirubin at the nape of the neck. Scratching bouts were 
assessed for 30 min post-injection. Vehicle n = 10, Cetirizine n = 5. e, Mast cell histamine release 
in response to 100 µM bilirubin. Vehicle for Compound 48/80 n = 4, Compound 48/80 (10 
µg/mL) n = 4, Vehicle n = 6, Bilirubin n = 8. f, Ca2+ imaging of murine peritoneal mast cells. 
After a 10 s baseline, 100 µM bilirubin was added. 15 s later, a 1 min wash was applied before 
addition of 10 µg/mL compound 48/80. Drugs were applied when indicated by the black bars. 
Mean ±95% CI depicted. n = 26. (a-e) Mean plus s.e.m. depicted. Open circles represent 
independent data points. *, p < 0.05; **, p < 0.01; ***, p < 0.001; two-tailed unpaired Student’s t-
test. n.s., not significant. 
 
Bilirubin activates murine MRGPRA1 and human MRGPRX4 
To identify which Mrgpr is sensitive to bilirubin, we individually expressed 
each of the 12 Mrgprs deleted in the Mrgpr-clusterΔ−/− mouse in human 
embryonic kidney (HEK) 293 cells and monitored changes in intracellular 
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calcium upon applying bilirubin. To ensure we would observe a calcium response 
following a true ligand-receptor interaction, we expressed the receptors in 
HEK293 cells stably expressing the G-protein alpha-subunit Gα15, a Gα protein 




Figure 28. Bilirubin activates murine MRGPRA1 and human MRGPRX4. 
Ca2+ imaging and transformed binding isotherms of HEK293 cells stably expressing MRGPRA1 
(a-e) or MRGPRX4 (f-j). a-c and f-h, 50 µM bilirubin was added where indicated by black bars. 
After 15 s, a 1 min wash was applied. Mean ±95% confidence interval (CI) depicted. n = 10. In (a) 
30 µM FMRF was added after washing as indicated by the black bar. In (b-c) and (g-h), cells were 
pre-incubated with either 10 µM of the PLC inhibitor U73122 or 10 µM of the Gαq inhibitor 
YM254890 for 30 min prior to imaging. Concentration–Ca2+ response curves of bilirubin, 
conjugated bilirubin, and hemin towards (d) MRGPRA1, (i) MRGPRX4, and (n) MRGPRC11 and 
BAM8-22 towards MRGPRC11, an established peptide ligand. Data are a representative 
experiment of three independent replicates performed in triplicate, depicted as mean ±s.e.m. 
Transformed binding isotherms for bilirubin, conjugated bilirubin, and hemin to (e) MRGPRA1, 
(j) MRGPRX4, and (o) MRGPRC11 and BAM8-22 to MRGPRC11. Data are an average of three 
independent experiments, depicted as mean ±s.e.m. k, Bilirubin-stimulated G-protein activity of 
partially-purified MRGPRA1, MRGPRX4, and MRGPRC11 membrane complexes. [35S]GTPγS 
binding was measured in the presence of 0.5% DMSO or 50 µM bilirubin. Mean ±s.e.m. depicted. 
**, p < 0.01; two-tailed unpaired Student’s t-test. l, Scratching bouts from injection of 60 µg of 
bilirubin in WT and A1 KO animals. WT n = 10, A1 KO n = 12. m, Scratching bouts from injection 
of 60 µg of FMRF in WT and A1 KO animals. WT n = 8, A1 KO n = 7. (l-m) Mean ±s.e.m. depicted. 
Open circles represent individual mice. *, p< 0.05 by two-tailed unpaired Student’s t-test. 
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Among the twelve cell lines expressing an Mrgpr, only MRGPRA1-
expressing cells exhibited a calcium response to bilirubin (EC50 of 145.9 µM [96, 
220]) (Fig. 28a and 28d). The same cells that responded to bilirubin also 
responded to FMRF, an MRGPRA1 agonist (Dong et al., 2001). To ensure that 
bilirubin initiated signaling at MRGPRA1 and not downstream, we pre-treated 
MRGPRA1-expressing cells with inhibitors of GPCR signaling: the PLC inhibitor 
U73122 or the Gaq inhibitor YM-254890. Both compounds abolished bilirubin-
induced calcium responses (Fig. 26b-c).  
In addition to bilirubin, glucuronidated bilirubin is often upregulated in 
jaundice-associated itch. We assessed whether ditaurate bilirubin, a distinct but 
similar bilirubin derivative, could activate MRGPRA1. Indeed, ditaurate bilirubin 
activated MRGPRA1-expressing cells (Fig. 28d). Hemin failed to activate 
MRGPRA1 (Fig. 28d), consistent with our earlier behavioral findings in which 
hemin did not evoke scratching. No other Mrgpr among the 12 that we screened 
responded to bilirubin (Fig. 28n and Fig. 29).  
 
 
Figure 29. Bilirubin does not activate other itch-associated Mrgprs. 
a-e, Ca2+ imaging of HEK293 cells transiently expressing (a) MRGPRA3, (b) MRGPRC11, (c) 
MRGPRD, (d) MRGPRX1, or (e) MRGPRX2. 50 µM bilirubin was added where indicated by black 
bars. After fifteen seconds, a one-minute wash was applied. After washing, either (a) 1 mM 
chloroquine, (b) 3 µM BAM8-22, (c) 1 mM β-alanine, (d) 3 µM BAM8-22, or (e) 10 µg/mL 
compound 48/80 was added as indicated by black bars. Mean ±95% CI depicted. n = 10. 
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The human MRGPRX family of receptors has functional similarities 
between species but have no obvious structural homologs in rodents (Solinski et 
al., 2014; Zylka et al., 2003). The mouse Mrgpra family is closest in sequence 
homology to the human MRGPRX family (Dong et al., 2001; Lembo et al., 2002; 
Zhang et al., 2005). Of the four human MRGPRX receptors, only MRGPRX4-
expressing cells responded to bilirubin (EC50 of 61.9 µM [44, 87]) (Fig. 28f and 
28i). U73122 and YM-254890 inhibited bilirubin-induced calcium responses in 
MRGPRX4-expressing cells just as with MRGPRA1 (Fig. 28g-h). Conjugated 
bilirubin also activated MRGPRX4, whereas hemin had no effect (Fig. 28i). 
To confirm that bilirubin directly binds the identified receptors, we assayed 
thermophoresis of each receptor in the presence and absence of bilirubin. 
Thermophoresis of a molecule is affected by physical parameters such as size, 
charge, and solvation. By extension, the thermophoresis of one molecule is 
altered when it interacts with another, and can therefore be used to measure 
interactions between molecules (Duhr and Braun, 2006). Using this approach, 
we determined that bilirubin bound MRGPRA1 with a KD of 92.9 ± 15 µM and 
MRGPRX4 with a KD of 54.4 ± 13 µM (Fig. 28e and 28j). Bilirubin exhibited little 
to no affinity for the closely related BAM8-22 receptor MRGPRC11 (Fig. 28o). 
Hemin, which did not activate MRGPRA1 or MRGPRX4 by calcium imaging (Fig. 
28d and 28i), also did not bind MRGPRA1 or MRGPRX4 (Fig. 28e and 28j). 
Conjugated bilirubin bound both MRGPRA1 and MRGPRX4, although with a 
lower affinity than unconjugated bilirubin (Fig. 28e and 28j). To make certain 
that bilirubin activates MRGPRA1 and MRGPRX4 upon binding, we measured 
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exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP), one 
of the first events in GPCR signaling. Bilirubin increased GTP binding to 
MRGPRA1 and MRGPRX4 membrane complexes, but not to MRGPRC11 (Fig. 
28k). To confirm that bilirubin activates MRGPRA1 in vivo to trigger itch, we 
generated an Mrgpra1 (A1-/-) knockout mouse line using CRISPR-Cas9 (Jinek 
et al., 2012) (Fig. 30). A1-/- animals scratched significantly less than WT mice 
after exposure to either bilirubin or the established agonist FMRF, 
demonstrating that Mrgpra1 is functional in adult mice (Fig. 28l-m). The KD of 
bilirubin towards MRGPRA1 and MRGPRX4 suggests that bilirubin likely does 
not interact with these receptors in healthy individuals. Additional ligands with 
nanomolar affinities towards MRGPRA1 or MRGPRX4 may exist that modulate 





Figure 30. CRISPR deletion of MRGPRA1. 
a, Comparison of WT and A1 KO genomic sequences. Location of 2 base pair (bp) deletion shown 
by dashes. Numbers correspond to MRGPRA1 open reading frame. b, Sequencing data depicting 
the 2 bp deletion. c, A translation of the open reading frame of MRGPRA1 KO beginning with the 
start codon. The 2 bp deletion creates a frameshift which results in early termination, marked 
by a red asterisk. 
Bilirubin activates sensory neurons in an MRGPR-dependent manner 
We reasoned that if bilirubin triggers itch through MRGPRA1 and 
MRGPRX4, bilirubin should activate these receptors in sensory itch neurons. 
Previous studies have demonstrated that both Mrgpra1 and MRGPRX4 are 
expressed in sensory neurons within the dorsal root ganglia (DRG) (Dong et al., 
2001; Flegel et al., 2015; Lembo et al., 2002). Mrgpra1 is expressed in a subset 
of adult DRG and trigeminal ganglia (TG) sensory neurons that innervate the 
skin and ramify in lamina I and II of the spinal cord (Fig. 31a-d). Bilirubin 
elicited robust action potentials in small-diameter (< 30 µm) WT DRG sensory 
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neurons at a proportion consistent with the percentage of sensory neurons that 
encode itch (5 of 50). Bilirubin failed to elicit action potentials in A1 -/- neurons 
(0 of 60), suggesting bilirubin activates sensory neurons through MRGPRA1 (Fig. 
31e). Bilirubin-sensitive neurons had an average somal diameter of 20.4 ± 1.3 
µm, a diameter characteristic of itch sensory neurons (Fig. 31f). Applying 
bilirubin to neurons elicited calcium transients in approximately 5% of WT DRG 
neurons (Fig. 31g), whereas significantly fewer sensory neurons from either 
Mrgpr-clusterΔ−/− or A1-/- mice responded (Fig. 31h). We sought to determine 
whether expression of either MRGPRA1 or MRGPRX4 was sufficient to render 
neurons sensitive to bilirubin. To address this question, we infected Mrgpr-
clusterΔ−/− DRGs with lentivirus carrying either Mrgpra1, MRGPRX4, or 
MRGPRX3. Bilirubin activated 14% of Mrgpra1-and 32% of MRGPRX4-
transduced Mrgpr-clusterΔ−/− DRGs (Fig. 31i-j). Mrgpr-clusterΔ−/− DRGs infected 





Figure 31. Bilirubin activates sensory neurons in an Mrgpr-dependent manner. 
a-d, Confocal microscopy immunofluorescence images of adult mouse tissue sections from 
Mrgpra1GFP animals with GFP expression under the control of the endogenous Mrgpra1 locus. a, 
Mrgpra1 expression in dorsal root ganglia. Green depicts Mrgpra1GFP. Red depicts anti-PLAP 
antibody staining where PLAP expression is controlled by the endogenous Mrgprd locus 
(MrgprdPLAP). Blue depicts antibody staining against calcitonin gene-related peptide (CGRP). Scale 
bar is 50 µM. b, Trigeminal ganglia (TG) stained with Mrgpra1GFP (green) and anti-Substance P 
antibody (red). Scale bar is 50 µm. c, Back skin stained with anti-GFP antibody (green) to 
visualize Mrgpra1GFP nerve fibers in the dermis. Blue represents DAPI counterstain. Scale bar is 
50 µm. d, Spinal cord (SC) (lamina 1 and 2) stained with anti-GFP and IB4-564. 
Mrgpra1GFP (green) staining was found in lamina two along with IB4 (red) positive terminals. 
Scale bar is 100 µm. e, Representative whole-cell current-clamp recording of either WT or A1 KO 
DRG neurons. In WT DRG, bilirubin elicited action potentials in 5 out of 50 small-diameter 
neurons. In A1 KO DRG, bilirubin elicited action potentials in 0 out of 60 small-diameter neurons. 
Fisher’s exact test p < 0.05. f, Histogram of bilirubin-activated neuronal soma diameter. g, 
Ca2+ imaging of WT DRG neurons. Mean ±95% CI depicted. Compounds applied where indicated 
by black bars. After a 10 s baseline, 50 µM bilirubin was added. 50 mM KCl was added at the 
end of each trial. n = 20 neurons. h, Percent activation of WT, A1 KO, and Mrgpr-cluster KO DRG 
by vehicle and 50 µM bilirubin. *, P < 0.05; **, p < 0.01; ***, p < 0.001; Chi-squared test. A 
neuron was considered to be activated if ∆F > 0.2 for at a least 30 s. i, Ca2+ imaging of Mrgpr-
cluster KO DRG neurons 48 hr after either mock infection with lentivirus (n = 10) or infected 
with lentivirus encoding Mrgpra1 (n = 6), MRGPRX4 (n = 10), or MRGPRX3 (n = 20). 50 µM 
bilirubin was added when indicated by the black bar. After 20 s, a 1 min wash was applied before 
addition of 50 mM KCl. Compounds applied where indicated by black bars. Mean ±95% CI 
depicted. n = 10 neurons. j, Percent activation of uninfected, Mrgpra1-infected, MRGPRX4-
infected, and MRGPRX3-infected Cluster -/- neurons by bilirubin. ***, p < 0.001. Chi-squared 
test. 
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Bilirubin-responsive neurons partially overlapped with neurons that 
responded to 1mM chloroquine, a ligand for MRGPRA3 that typifies itch sensory 
neurons (Han et al., 2012) (Fig. 32a-c). To validate that bilirubin activates 
MRGPRA3-positive itch neurons, we performed calcium imaging on DRG 
neurons isolated from Tg(Mrgpra3-Cre);lsl-tdTomato mice, which express the 
fluorescent protein tdTomato in Mrgpra3-expressing neurons. Bilirubin activated 
a substantial percentage of tdTomato-positive neurons (Fig. 32d). To confirm 
that bilirubin activates sensory neurons in vivo, we injected 5µL of vehicle or 
bilirubin into paws of Tg(Pirt-Cre);lsl-GCaMP6s mice, which express the 
fluorescent calcium reporter GCaMP6s in DRG sensory neurons (Kim et al., 
2014). Bilirubin, but not vehicle, activated numerous DRG sensory neurons in 
the paws of GCaMP6s mice (Fig. 32e). Inhibiting transient receptor potential 
(TRP) and other Ca2+ channels with ruthenium red prevented bilirubin from 
activating sensory neurons (Fig. 32f-g) (Imamachi et al., 2009; Liu et al., 2009; 





Figure 32. Bilirubin activates a population of small-diameter, chloroquine-sensitive 
sensory neurons in a TRP channel dependent mechanism. 
a, A representative whole-cell current-clamp recording of a WT DRG neuron responsive to 
addition of both 50 µM bilirubin and 1 mM chloroquine (CQ). b, Ca2+ imaging of WT DRG neurons. 
Mean ±95% CI depicted. Compounds applied where indicated by black bars. After a 10 s baseline, 
50 µM bilirubin was added. After 20 s, a 3 min wash was applied before 1 mM chloroquine was 
added. After 15 s, 50 mM KCl was added. n = 10 neurons. c, Venn diagram of total neurons 
activated by either bilirubin and/or chloroquine (Bilirubin alone = 7, Chloroquine = 40, 
Overlap = 13). d, Percent activation of Tg(Mrgpra3-Cre);lsl-tdTomato neurons as assessed by 
calcium imaging with vehicle, 1 mM Chloroquine, or 50 µM bilirubin. e, In vivo Ca2+ imaging of 
Pirt-Cre; lsl-GCaMP6s animals. Briefly, a surgery was performed to expose L4 DRG. Baseline 
measurements were taken before a vehicle injection in ipsilateral paw and subsequent injection 
of 5 µL of 100 µM bilirubin. Depicted is a representative Ca2+ imaging trace of bilirubin-activated 
neurons, n = 20, identified by post hoc imaging analysis. The black trace is the mean Ft/F0 and 
red dotted lines represent 95% confidence intervals. f, Neurons were incubated with 10 µM 
ruthenium red for 10 min before application of 50 µM bilirubin. g, Percent activation of WT 
neurons, incubated with either vehicle or 10 µM ruthenium red, by 50 µM bilirubin. 
MrgprA1 KO, Mrgpr-cluster KO, and BVR KO animals exhibit decreased 
cholestatic pruritus 
We wondered whether chronic elevation of bilirubin in vivo, like in 
cholestasis, stimulates Mrgpr-dependent itch. Bile is the primary means by 
which bilirubin is excreted, and patients with cholestasis exhibit elevated levels 
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of bilirubin and other pruritogenic substances in their blood (Alemi et al., 2013). 
To induce hyperbilirubinemia and model intrahepatic cholestasis, we 
administered a-napthyl isothiocyanate (ANIT) to mice (Eliakim et al., 1959).  We 
treated WT, Mrgpr-clusterΔ−/−, and A1-/- animals with 25 mg/kg ANIT for five 
days before assessing spontaneous itch (Fig. 33a). WT, Mrgpr-clusterΔ−/−, and 
A1-/- animals exhibited equivalently severe hepatocellular injury judged by 
increases in plasma bilirubin, bile acids, alkaline phosphatase (ALP), aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl 





Figure 33. MrgprA1 KO, Mrgpr-cluster KO−, and BVR KO animals exhibit decreased 
cholestatic pruritus. 
a, Experimental flowchart for ANIT model of cholestasis. b, Scratching bouts for vehicle and 
ANIT-treated mice among WT, Mrgpr-cluster KO, and A1 KO groups. Bouts were assessed in a 
30 min period. For the vehicle cohort: WT n = 15, Mrgpr-cluster KO n = 6, A1 KO n = 6. For ANIT 
cohort: WT n = 20, Mrgpr-cluster KO n = 14, A1 KO n = 14. c, Scratching bouts for vehicle and 
ANIT-treated animals among WT and BVR KO groups. Bouts were assessed in a 30 min period. 
For the vehicle cohort: WT n = 5 and BVR KO n = 8. For ANIT cohort: WT n = 21 and BVR KO 
n = 20. d, Plasma bilirubin levels (mg/dL) from WT and Mrgpr-cluster KO ANIT-treated and 
vehicle-treated animals. For the vehicle cohort: WT n = 14, Mrgpr-cluster KO n = 6. For the ANIT 
cohort: WT n = 21, Mrgpr-cluster KO n = 17. e, Plasma bile acid levels (µM) from ANIT-treated 
and vehicle-treated animals. For the vehicle cohort: WT n = 4, Mrgpr-cluster KO n = 5, BVR KO 
n = 5. For the ANIT cohort: WT n = 10, Mrgpr-cluster KO n = 7, BVR KO n = 14. f, Experimental 
flowchart for Cyclosporin A model of cholestasis. g, Scratching bouts for vehicle and Cyclosporin 
A-treated WT and A1 KO animals. For the vehicle cohort: n = 5 for all. For Cyclosporin A cohort: 
WT n = 10 and A1 KO n = 8. h, Scratching bouts from vehicle and Cyclosporin A treated WT and 
BVR KO animals. For the vehicle cohort: n = 5. For Cyclosporin A cohort: WT n = 11 and BVR 
KO n = 7. i, Correlation of serum bilirubin levels from cholestatic animals and scratching bouts. 
Line of best fit: Y = 0.23 (X) + 28.78. j, Correlation of skin bilirubin levels from cholestatic 
animals and scratching bouts. Line of best fit: Y = 12.34 (X) + 16.7. k, Correlation of skin and 
serum bilirubin levels from cholestatic animals. Line of best fit: Y = 7.015(X) – 14.52. (a-h) 
Mean ±s.e.m. depicted. Open circles represent individual data points. *, p < 0.05; **, p < 0.01; 
***, p < 0.001 by unpaired two-tailed Student’s t-test. 
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As expected, ANIT treatment significantly increased pruritus in all animals 
(Fig. 33b). However, Mrgpr-clusterΔ−/− and A1-/- mice scratched markedly less 
than WT mice (Fig. 33b), suggesting that MRGPRA1 mediates a component of 
hepatobiliary pruritus. In humans, bile acids, endogenous opioids, and LPA are 
often increased in cholestatic sera and have been shown to mediate pruritus 
(Alemi et al., 2013; Bergasa et al., 1998; 1992; Kremer et al., 2010). The serum 
of ANIT-treated animals exhibited elevated bilirubin and bile acids (Fig. 33d-e), 
whereas neither the endogenous opioid peptide met-enkephalin (Thornton and 
Losowsky, 1989a; 1989b) nor the LPA-producing enzyme autotaxin were elevated 
(Fig. 34e-f). To assess whether other cholestatic pruritogens act at MRGPRs in 
mice, we injected WT and Mrgpr-clusterΔ−/− with deoxycholic acid (a bile acid), 
opiates, and LPA. These other cholestatic pruritogens elicited equivalent degrees 
of scratching in WT and Mrgpr-clusterΔ−/− animals (Fig. 35a-d). Mrgprs are 
promiscuous receptors. It should be noted that there remain multiple bile acids, 
LPA molecules, and opiates which remain untested and could be agonists against 
Mrgprs. However, based on this data, we speculated that Mrgpr-clusterΔ−/− and 






Figure 34. Plasma levels of pathological markers of liver injury are similar between WT, 
Mrgpr-clusterΔ−/−, A1 KO, and BVR KO animals. 
a, Plasma alkaline phosphatase (ALP) levels among vehicle and ANIT-treated animals. For vehicle 
cohort: WT n = 10, Mrgpr-cluster KO n = 4, A1 KO n = 4, BVR KO n = 6. For ANIT cohort: WT 
n = 17, Mrgpr-cluster KO n = 6, A1 KO n = 5, BVR KO n = 15. b, Plasma aspartate 
aminotransferase (AST) levels among vehicle and ANIT-treated animals. For vehicle cohort: WT 
n = 10, Mrgpr-cluster KO n = 4, A1 KO n = 4, BVR KO n = 9. For ANIT cohort: WT n = 12, Mrgpr-
cluster KO n = 6, A1 KO n = 5, BVR KO n = 17. c, Alanine aminotransferase (ALT) levels among 
vehicle and ANIT-treated animals. For vehicle cohort: WT n = 10, Mrgpr-cluster KO n = 4, A1 KO 
n = 4, BVR KO n = 6. For ANIT cohort: WT n = 15, Mrgpr-cluster KO n = 6, A1 KO n = 5, BVR 
KO n = 17. d, Gamma-glutamyl transferase (GGT) levels among vehicle and ANIT-treated animals. 
For vehicle cohort: WT n = 10, Mrgpr-cluster KO n = 4, BVR KO n = 6. For ANIT cohort: WT 
n = 17, Mrgpr-cluster KO n = 6, BVR KO n = 15. e, Met-enkephalin levels among plasma from 
vehicle and ANIT-treated animals. For vehicle cohort: WT n = 4, Mrgpr-cluster KO and BVR KO 
n = 5. For ANIT cohort: WT n = 19, Mrgpr-cluster KO n = 10, BVR KO n = 11. f, Autotaxin activity 
among plasma from vehicle and ANIT-treated animals. For vehicle cohort: WT and BVR KO n = 4, 
Mrgpr-cluster KO n = 5. For ANIT cohort: WT n = 12, Mrgpr-cluster KO n = 8, BVR KO n = 10. 
(a-f) Mean ±s.e.m. depicted. Open circles represent independent data points. *, p < 0.05; **, 
p < 0.01, ***, p < 0.001; two-tailed unpaired Student’s t-test. n.s., not significant. 
To determine whether bilirubin is activating MRGPRA1 to stimulate itch 
in cholestasis, we induced cholestasis in a mouse that lacks the biosynthetic 
enzyme for bilirubin, biliverdin reductase (BVR-/-) (Kutty and Maines, 1981) (Fig. 
26e and Fig. 36a). Mice lacking BVR do not have detectable levels of bilirubin 
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in plasma (Fig. 36b-d). When treated with ANIT, BVR-/- mice scratched 
significantly less than WT mice (Fig. 33c). Plasma levels of bile acids, ALP, AST, 
ALT, GGT, met-enkephaline, and autotaxin were indistinguishable between 
treated BVR-/- animals and WT controls (Fig. 34a-d). The diminished response 
to ANIT is not due to aberrant itch circuits, as BVR-/- mice scratched normally 
when injected with either chloroquine or exogenous bilirubin (Fig. 36e-f). 
 
 
Figure 35. Mrgpr-cluster KO animals have intact itch to other cholestatic pruritogens and 
bilirubin synergism with chloroquine itch. 
a, Scratching bouts to 1.3 mM deoxycholic acid (DCA) injected into cheek. WT n = 9, Mrgpr-
cluster KO n = 9. b, Scratching bouts to 4 mM lysophosphatidic acid (LPA) injected into cheek. 
WT n = 6, Mrgpr-clusterΔ−/−n = 6. c, Scratching bouts to 25 µg of morphine injected into back. 
WT n = 7, Mrgpr-clusterΔ−/−n = 8. d, Scratching bouts to 25 µg of DAMGO injected into back. WT 
n = 5, Mrgpr-cluster KO n = 5. e, Synergism of bilirubin with chloroquine pruritus. Scratching 
bouts to 1 mM chloroquine plus either vehicle or 500 µM bilirubin injected into back. For 1 mM 
chloroquine plus vehicle: WT n = 9, A1 KO n = 5. For 1 mM chloroquine plus 500 µM bilirubin: 
WT n = 11, A1 KO n = 5. (a-e) Mean ±s.e.m. depicted. Open circles represent independent data 
points. **, p < 0.01, ***, p < 0.001; two-tailed unpaired Student’s t-test. n.s., not significant.  
 
To confirm that the observed differences in cholestatic pruritus were not 
just specific to ANIT, we administered the hepatotoxin cyclosporin A to WT, A1-
/-, and BVR -/- mice (Laupacis et al., 1981). We treated mice with either 50 
mg/kg cyclosporin A or vehicle for eight days before assessing spontaneous itch 
(Fig. 33f). Cyclosporin A induced spontaneous itch in WT animals, whereas A1-
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Figure 36. BVR KO and A1 KO animals have intact itch circuits. 
a, Quantitative PCR analysis of BLVRA transcript from whole brain of WT and BVR KO mice. b, 
Representative chromatogram of HPLC analysis of plasma from WT and BVR KO mice separated 
via a C18 column and analysed by absorbance at 450 nm. c, HPLC chromatogram of plasma 
from a WT mouse spiked with excess bilirubin. d, Total bilirubin levels from plasma of WT and 
BVR KO animals. WT n = 7, BVR KO n = 6. e, Scratching bouts to 150 µg (50 µL of 10 mM) of 
chloroquine. After chloroquine injection, scratching bouts were assessed in a 30 min period. WT 
n = 9, BVR KO n = 5, A1 KO n = 6. f, Scratching bouts to 60 µg (100 µL of 1 mM) of bilirubin. 
After bilirubin injection, scratching bouts were assessed in a 30 min period. WT n = 8, BVR KO 
n = 9. (d-f) Mean plus S.E.M. depicted. Open circles represent independent data points. **, 
p < 0.01 by student’s t-test. n.s., not significant. 
 
Notably, we found that plasma bilirubin correlates poorly with cholestatic 
itch in patients and in cholestatic animals (Fig. 33i). We hypothesized that the 
levels of bilirubin in the skin would correlate better with itch than serum 
bilirubin largely because bilirubin likely binds and activates the sensory neurons 
in the skin. Unlike with serum, skin bilirubin appears to be a much stronger 
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predictor of itch severity in mice (Fig. 33j). This is consistent with how the 
anatomical distribution of itch sensory neurons and may explain why studies 
aimed at identifying plasma pruritogens that correlate with itch severity may 
have missed bilirubin. Secondarily, we find that plasma bilirubin does not 
correlate well with skin bilirubin, further suggesting that plasma bilirubin may 
be a poor predictor of itch severity and may not necessarily serve as a proxy for  
 
 
Figure 37. QWF treatment blocks bilirubin activation of Mrgpra1 and cholestatic pruritus. 
a, Concentration-response curve for bilirubin induced Ca2+ signal in MRGPRA1-expressing HEK 
cells. 200 µM bilirubin was maintained in competition with indicated doses of QWF. Mean ±s.e.m. 
depicted. n = 3 replicates in duplicate. b-c, Scratching bouts from (b) 60 µg (100 mL of 1 mM) 
bilirubin or (c) 150 µg chloroquine co-injected with either vehicle or 1 mg/kg QWF. After injection, 
the number of scratching bouts in 30 min was assessed. For bilirubin: Vehicle n = 7, QWF n = 8. 
For chloroquine: Vehicle n = 4, QWF n = 7. d, Scratching bouts from WT ANIT-treated animals. 
Either vehicle or 1 mg/kg QWF was delivered i.p. Vehicle n = 8, QWF n = 9. e-h, Plasma (e) 
bilirubin, (f) AST, (g) ALT, and (h) ALP levels from of vehicle and QWF-dosed WT animals that 
have undergone ANIT liver injury. (b–h) Mean ±s.e.m. depicted. Open circles represent 
independent data points. n.s., not significant; *, p < 0.05 by two-tailed unpaired Student’s t-test. 
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skin bilirubin (Fig. 33k). The amount of bilirubin in the skin is likely affected by 
several factors and equilibria, such as serum albumin. 
We assessed whether pharmacologically antagonizing MRGPRs could 
alleviate cholestatic itch. Recently, a 3-amino acid peptide, QWF, was identified 
as an MRGPRA1 antagonist (Azimi et al., 2016). QWF abolished bilirubin-
associated calcium signaling in MRGPRA1-expressing cells with an IC50 of 2.9 
µM [1, 5] (Fig. 37a). Mirroring its pharmacology in vitro, co-injecting 0.25 mg/kg 
QWF with bilirubin significantly alleviated pruritus associated with bilirubin (Fig. 
37b). QWF specifically antagonized bilirubin, as it did not attenuate chloroquine-
MRGPRA3 associated itch (Fig. 37c). Lastly, we evaluated whether the 
MRGPRA1 antagonist QWF could alleviate cholestatic pruritus. We dosed WT 
animals with ANIT as previously described, but intraperitoneally injected mice 
with either vehicle or 1 mg/kg QWF thirty minutes prior to behavioral analysis. 
Mice treated with QWF scratched significantly less than vehicle-treated animals 
(Fig. 37d). QWF treatment did not change plasma levels of total bilirubin, AST, 
ALT, or ALP, suggesting that QWF treatment did not alter the underlying liver 
pathology (Fig. 37e-h). 
 
Bilirubin from mouse and human cholestatic plasma contributes to pruritus in a 
Mrgpra1-dependent manner 
Nasobiliary drainage is the most effective treatment for cholestatic pruritus 
(Hegade et al., 2016). Based on this clinical observation, we predicted that 
plasma isolated from cholestatic animals would elicit pruritus (Fig. 38a). Indeed, 
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plasma from WT animals with cholestasis elicited itch when injected into naïve 
WT animals (Fig. 38b). Cholestatic plasma isolated from BVR -/- mice, which 
lacks bilirubin (Fig. 36b-d), elicited significantly fewer scratches than WT 
cholestatic plasma (Fig. 38b). The levels of ALP, AST, and ALT were 
indistinguishable between WT and BVR -/- cholestatic plasma (Fig. 34a-d), 
presumably because ANIT induced similar hepatotoxicity in WT and BVR -/- 
mice. Instead, BVR -/- plasma likely results in less pruritus because it lacks 
bilirubin. 
We also isolated plasma from six patients suffering from various conditions 
that result in hyperbilirubinemia and six age- and sex-matched control patients 
(Fig. 38c-g). All six cholestatic patients’ plasma evoked itch in WT animals (Fig. 
38d). When injected into A1 -/- animals, each patient’s plasma elicited less itch 
(Fig. 38d). Compared to plasma from itchy patients, plasma from healthy donors 
(six tested) which have low level of bilirubin elicited less itch in WT animals (Fig. 
38c). When injected into A1 -/- animals, we observed no differences in scratching 
behavior (Fig. 38c). To assess whether removing bilirubin from cholestatic 
plasma may be therapeutic, we depleted bilirubin both by selective oxidation 
with FeCl3 or an anti-bilirubin antibody before evaluating its pruritic capacity. 
We verified depletion of bilirubin by HPLC (Fig. 39a-b). Injecting WT mice with 
plasma (cholestatic patients 1 and 4) treated with FeCl3 or an anti-bilirubin 
antibody evoked less pruritus compared to untreated or control IgG-treated 





Figure 38. Bilirubin from mouse and human cholestatic plasma contributes to pruritus in 
an Mrgpra1-dependent manner. 
a, Experimental flowchart of plasma injection assay. b, Scratching bouts from WT mice injected 
with either vehicle- or ANIT-treated plasma from WT and BVR KO animals. For the vehicle plasma 
cohort: n = 7. For cholestatic ANIT-treated plasma: WT n = 10 and BVR KO n = 8. c, Scratching 
bouts from either WT or A1 KO mice injected with control donor plasma. Ctrl 1, WT n = 5, A1 KO 
n = 5. Ctrl 2, WT n = 5, A1 KO n = 5. Ctrl 3, WT n = 5, A1 KO n = 4. Ctrl 4, WT n = 4, A1 KO 
n = 5. Ctrl 5, WT n = 4, A1 KO n = 4. Ctrl 6, WT n = 4, A1 KO n = 4. d, Scratching bouts from 
either WT or A1 KO mice injected with either cholestatic patient plasma. Patient 1, WT n = 7, A1 
KO n = 9. Patient 2, WT n = 8, A1 KO n = 5. Patient 3, WT n = 7, A1 KO n = 8. Patient 4, WT 
n = 6, A1 KO n = 8. Patient 5, WT n = 5, A1 KO n = 6. Patient 6, WT n = 7, A1 KO n = 5. e, 
Scratching bouts from either WT or A1 KO mice injected with plasma collected from all tested 
control donor samples and all tested cholestatic patient samples. For Control: WT n = 27, A1 KO 
n = 27. For cholestatic patient: WT n = 41, A1 KO n = 41. f–g, Biochemical characteristics of 
patient and control plasma. f, Age, sex, and bilirubin levels of control plasma collected. All control 
plasma donors did not suffer from any chronic itch condition. g, 5D itch questionnaire was 
administered at time of plasma collection. Asterisk denotes patients taking anti-pruritic 
medication at time of plasma collection and questionnaire administration. Patient one was taking 
sertraline (100 mg QD) and Patient four was taking Gabapentin (800 mg TID). A score of 25 
represents the maximum level of itchiness. h, Scratching bouts from mice injected with either 
untreated (NT) control human plasma, FeCl3-treated control human plasma, NT cholestatic 
patient 1 and 4 plasma (same data from Patient WT data in (d), or FeCl3-treated patient plasma. 
For control plasma, NT n = 6 and FeCl3n = 5. For Patient one plasma, NT n = 7 and FeCl3n = 7. 
For Patient four plasma, NT n = 7 and FeCl3n = 6. i, Scratching bouts from mice injected with 
either normal rabbit IgG –treated patient plasma or anti-bilirubin IgG – treated patient plasma. 
For Patient 1, Normal IgG n = 5, Anti-bilirubin n = 7. For Patient 4, Normal IgG n = 5, Anti-
bilirubin n = 6. (b–i) Mean ±s.e.m. depicted. Open circles represent independent data points. n.s., 





Figure 39. FeCl3 and anti-bilirubin antibody depletion of plasma bilirubin. 
a, Representative HPLC chromatogram of 100 µM biliverdin +100 µM bilirubin standards and 
treated plasma samples. Absorbance was measured at 405 nm. b, Quantification of plasma 
bilirubin in untreated, FeCl3, normal rabbit IgG, and bilirubin antibody-treated samples. Points 
represent technical replicates. Mean ±s.e.m. depicted **, p<0.01; n.s., not significant by two-way 
ANOVA followed by post-hoc Tukey test. 
 
Discussion 
To date, bilirubin has either been considered a neonatal neurotoxin or an 
inert biomarker in disease. Our results reveal that bilirubin itself is a pruritogen 
that evokes itch by binding and activating MRGPRs on sensory neurons and may 
be an overlooked source of some patients’ unrelenting itch. The KD of bilirubin 
towards MRGPRA1 and MRGPRX4 suggests that bilirubin likely only interacts 
and activates these receptors in individuals with markedly elevated bilirubin and 
not in healthy people. More narrowly in hepatobiliary diseases such as 
cholestasis, our data supports a model in which bilirubin is one of several 
pruritogens that contributes to itch. Specifically, we find that genetically 
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removing either MRPGRA1 (A1-/-) or bilirubin (BVR-/-) both strongly attenuated 
itch. However, these mutant mice still exhibit greater itch compared to untreated 
mice. This suggests that other pruritogens contribute to itch alongside bilirubin 
in hepatobiliary disease, consistent with the diverse and complex presentations 
of patients suffering from conditions such as chronic pruritus. Other responsible 
pruritogens could include bile acids, endogenous opioids, and LPA. While 
depleting bilirubin in jaundiced patients like in mice may be effective in reducing 
itch, not every patient who suffers from hepatobiliary pruritus is jaundiced. 
Accordingly, identifying and depleting other pruritogens may similarly reduce 
itch.  
Although our findings directly illustrate that bilirubin is pruritic, it is also 
clear that not every patient with jaundice experiences itch. For example, patients 
with genetic hyperbilirubinemias such as Dubin-Johnson syndrome, a disorder 
involving mutations in the bilirubin transporter ABCC2, or Crigler-Najjar Type 1, 
a disorder involving mutations in the bilirubin glucuronosyltransferase UGT1A1, 
rarely complain of pruritus (Levitt and Levitt, 2014; Van Der Veere et al., 1996). 
Moreover, neonates can have high levels of bilirubin in their skin but not itch. 
Bilirubin thus appears to exert selective pruritic activity in certain contexts, 
which we hypothesize may derive from its dynamic biophysical behavior and 
complex network of interactions. 
In isolated genetic hyperbilirubinemias, few – if any – other organic 
metabolites are elevated. In contrast, several other metabolites are elevated in 
addition to bilirubin in cholestasis, many of which may alter the equilibrium 
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between bilirubin and albumin (Alemi et al., 2013; Jacobsen and Broderson, 
1983; Kalir et al., 1990; Kozaki et al., 1998). Moreover, bilirubin’s affinity for 
albumin and other lipoproteins is disrupted by numerous agents in bile that are 
upregulated specifically in cholestasis. Bilirubin also exhibits distinct chemical 
behavior in cholestatic serum, and several groups have suggested that bile acids 
affect bilirubin’s solubility and conformation (Ostrow and Celic, 1984; Rege et 
al., 1988). Accordingly, it is reasonable to speculate that bilirubin is more likely 
bound to albumin in isolated hyperbilirubinemias than in cholestasis, and is 
therefore less likely to enter the skin in conditions like Dubin-Johnson. Notably, 
a predictive metrics for cholestatic pruritus is the Mayo risk score, which 
considers both serum bilirubin and albumin levels (Talwalkar et al., 2003). The 
Mayo risk score predicts that itch burden increases with increasing bilirubin and 
decreasing albumin levels; in such circumstances, bilirubin is less likely bound 
to albumin and is free to enter other tissues such as the skin. Crigler-Najjar 
patients may be even less likely to complain of itch than Dubin-Johnson patients 
because the standard treatments for Crigler-Najjar (phenobarbital and light 
therapy) may directly interfere with bilirubin’s pruritic activity. Specifically, light 
therapy induces photoisomerization and/or photolysis of bilirubin, which alter 
its structure and activity. Phenobarbital itself acts by broadly decreasing neural 
excitability, and may dampen itch circuitry alongside other central nervous 
system circuits. Notwithstanding these questions, our results suggest that 
blocking MRGPRX4 may offer relief to those suffering from jaundice and/or 
cholestatic-associated pruritus. 
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Materials and methods 
Experimental Model and Subject Details 
Mice 
Animal care and use 
All experiments were performed in accordance with protocols approved by the 
Animal Care and Use Committee at the Johns Hopkins University School of 
Medicine. 
 
Generation of knock-in and knock-out mice 
Mrgpr-clusterΔ-/- mice, Mrgpra1GFP mice, and MrgprdPLAP were generated as 
previously described (Dong et al., 2001; Liu et al., 2009; 2007). Tg(Mrgpra3-Cre) 
mice were generated as previously described (Han et al., 2012). Tg(Pirt-Cre) mice 
were generated as previously described via homologous recombination (Kim et 
al., 2014).   
 
Rosa26-LoxP-STOP-LoxP (lsl)-GCaMP6s mice were purchased from Jackson 
Labs. Lsl-tdTomato mice (Ai9, 007909) were purchased from Jackson Labs.  
 
Mrgpra1-/- mice were generated using CRISPR-Cas9 on the C57BL/6 background 
using the following guide RNA sequence: TTCCCAGCAGCACCTGTGCAGGG. 
Blvra -/- mice were generated at Ozgene (Australia) on a C57BL/6J background.  
 




Plasma from patients suffering from hyperbilirubinemia, specifically cholestasis, 
was isolated under a protocol approved by the Institutional Review Board at the 
Johns Hopkins University School of Medicine (Study number: IRB00154650). 
Control plasma was isolated from donors who did not exhibit kidney or liver 
disease, had no complaints of itch, and were free from any detectable viral 
infection (HCV, HBV, HIV). Both cholestatic and control plasma were isolated 
under protocols approved by the Institutional Review Board at the Johns 
Hopkins University School of Medicine (Cholestasis Study number: 
IRB00154650; Control study number: NA_00013177, the Johns Hopkins 
Department of Dermatology Patient Database and Tissue Bank). Whole blood 
was collected into PAXgene tubes (PreAnalytiX 761115) and centrifuged for 5 
minutes at 300g. Plasma was then collected, aliquoted, and stored at -20°C until 
experimentation. At time of plasma collection, a 5D itch questionnaire was 
administered. 
 
Cell culture  
DRGs 
DRG neurons from all spinal levels were collected in cold DH10 media (90% 
Dulbecco’s modified Eagle’s medium (DMEM)/F-12, 10% FBS, penicillin (100 
U/mL), and streptomycin (100 µg/mL)). DRGs were digested with a dispase (5 
mg/ml)/collagenase type I (1 mg/ml) enzyme mixture at 37°C for 45 minutes. 
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After trituration, cells were spun at 300g and re-suspended in DH10 before being 
plated on glass coverslips coated with poly-D-lysine (0.5 mg/ml) and laminin (10 
µg/ml, Invitrogen). DRGs were cultured with DH10 supplemented with 50 
ng/mL NGF at 37°C.  
 
HEK293 
Human embryonic kidney 293 (HEK293) cells were cultured in DMEM (Gibco) 
supplemented with 10% FBS, 100 U/mL penicillin and streptomycin, and 2 mM 
glutamine at 37°C with 5% CO2. 
 
Method Details 
Materials and preparation  
Solvents and compounds were obtained as follows:  
The following molecules were used: bilirubin IXα (Frontier Scientific). a-naphthyl 
isothiocyanate (ANIT, Sigma), biliverdin (Sigma), chloroquine (Sigma), compound 
48/80 (Sigma), cyclosporin A (Sigma), hemin (Sigma), human serum albumin 
(HSA, Sigma), BAM8-22 (Sigma), BOC-GLN-D-(FORMYL)TRP-PHE-
BENZYLESTER (QWF, Sigma), bilirubin ditaurate (Lee Biosciences). cetirizine 
(Tocris Biosciences), stercobilin (Santa Cruz Biotechnology), urobilinogen (Santa 
Cruz Biotechnology), FMRF peptide (Sigma), cholera toxin (Santa Cruz 
Biotechnology), U73122 (Santa Cruz Biotechnology), YM-254890 (Wako 
Chemicals), pertussis toxin (Fisher Scientific), fibronectin (Sigma), ruthenium 




Bilirubin is highly susceptible to oxidation and photolysis. Accordingly, bilirubin 
was freshly prepared just prior to each experiment in either DMSO or 0.1 M 
NaOH and then maintained in the dark. For calcium imaging analyses, bilirubin 
was diluted into calcium imaging buffer a few seconds before use. Final 
concentration of DMSO in all applicable tested solutions was < 0.5%. ANIT and 
cyclosporin A were dissolved in olive oil and prepared freshly as needed. 
Urobilinogen and stercobilin were dissolved in phosphate buffered saline and 
adjusted to a pH of 7.4 before being stored at -20°C in 100 µl aliquots until 
needed. To maintain the integrity of bilirubin in human plasma samples, 
samples were stored at -80°C until use. Plasma stocks were maintained in the 
dark to minimize photolysis during injection or experimental manipulation. 
Plasma bilirubin was evaluated by HPLC as described above. All other drugs were 
prepared as 100 µl – 1,000 µl aliquots and stored at -20°C before thawing at 4°C. 
Freeze/thaw cycles were avoided whenever possible. To remove microprecipitates, 
we centrifuged our bilirubin solutions at 21,000g for 20 min to ensure that 
bilirubin was in solution. Whenever physiologically and experimentally 
reasonable, we excluded divalent cations in our in vitro biophysical experiments. 
 
Behavioral studies 
All applicable behavioral tests were performed and analysed with the 
experimenter blind to genotype. All mice used were 8-12 week old males and 
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females (20 to 30 g) that had either been generated on a C57BL/6J background 
or backcrossed to C57BL/6J mice for at least 10 generations. There were no 
significant differences in itch between male and female mice. All itch behavior 
experiments were performed between 8 a.m. and 12 p.m. On the day before the 
experiment, animals were placed in the test chamber for 30 minutes before being 
subjected to a series of three mock injections with 5-minute break periods in 
between. On the day of the experiment, animals were first allowed to acclimatize 
to the test chamber for 10 minutes before injection. Pruritic compounds were 
subcutaneously injected into the nape of the neck (50µL volume) or cheek (10µL 
volume), and scratching behavior was observed for 30 minutes. A bout of 
scratching was defined as a continuous scratching movement with either 
hindpaw directed at the area of the injection site. In the cheek injection model, 
a wipe was defined as a single forepaw stroking the site of the injection. Use of 
both forepaws on the face or cheek was considered as grooming behavior. 
Scratching behavior was quantified by counting the number of scratching bouts 
at 5 min intervals over the 30-min observation period. Wiping was quantified at 
2 min intervals over a ten-minute observation period. For H1R block, 30 mg/kg 
of cetirizine HCl (pH 7.4) was given intraperitoneally thirty minutes prior to 
injection of bilirubin. Licking behavior was quantified in seconds and identified 
as the licking of the toes or footpad of the hind paw site of injection that was 
neither preceded nor followed by licking of any other portion of the body.  For 
QWF co-injection experiments, either 100 µM (for bilirubin) or 500 µM (for 
chloroquine) QWF was injected in the same volume as solubilized pruritogen. 
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Quantum mechanical calculations 
DFT calculations were performed with Spartan 16 and modelled with 
wxMacMolPlt. Geometry optimizations and single point energy calculations were 
carried out with DFT-Hartree Fock hybrid B3LYP theory with the 6-31G(d) basis 
set. Energies were calculated at ground state in the gas phase 298 K. 
 
Calcium imaging and analysis 
Cells were imaged in calcium imaging buffer (CIB; 10 mM HEPES, 1.2 mM 
NaHCO3, 130 mM NaCl, 3 mM KCl, 2.5 mM CaCl2, 0.6 mM MgCl2, 20 mM glucose, 
and 20 mM sucrose at pH 7.4 and 290-300 mOsm). To monitor changes in 
intracellular [Ca2+] ([Ca2+]i), cells were loaded with either Fura 2-AM (HEK293 
cells) or Fluo 4-AM (DRG neurons and mast cells) for 30 min in the dark at 37°C 
in CIB just prior to imaging. With Fura 2-AM, emission at 510 nm was monitored 
from excitation at both 340 nm and 380 nm. With Fluo 4-AM, emission at 520 
nm was monitored from excitation at 488 nm. Cells were identified as responding 
if the intracellular [Ca2+] rose by either 50% compared to baseline or 50% 
compared to the [Ca2+]i change assayed during addition of 50 mM KCl (neurons 
only). Damaged, detached, high-baseline, and motion-activated cells were 
excluded from analysis.  
 
HEK293 cells  
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In initial screens, HEK293 cells stably expressing the murine G-protein alpha-
subunit Gα15, a unique Gα protein that non-selectively couples a large variety of 
GPCRs to phospholipase C 30, were plated on poly-D-lysine-coated coverslips and 
transiently transfected with constructs encoding the MRGRPR of interest. 12-24 
h later, cells were loaded with the Fura 2-AM. Unless otherwise specified, 
compounds were perfused into the imaging chamber for approximately thirty 
seconds after a baseline period was established. Response was then monitored 
at 5 s intervals for an additional 60 s.  
 
DRG neurons 
DRGs were incubated with Fluo-4 AM 24 hour after dissociation (native genotype) 
or 48 hour after dissociation (virally transduced). Unless otherwise noted, cells 
were imaged for 20 sseconds to establish a baseline before compounds were 
added. After 30 s, a 2 min wash was applied before addition of another 
substances. At the end of every imaging trial, 50 mM KCl was added as a positive 
control. Cells included in calculating percentages all displayed at least a 50% 
increase in [Ca2+]i compared to baseline upon addition of KCl. For ruthenium red 
inhibitor experiments, neurons were incubated with 10 µM ruthenium red for 5 
minutes prior to imaging. Percentage activated was determined as earlier 
described. 
 
Mast cells  
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Mast cells were purified as described and plated onto glass coverslips coated with 
30 mg/mL fibronectin and allowed to recover for 2 h at 37°C. Cells were then 
loaded with Fluo-4 AM. 
 
EC50 and IC50 determinations 
HEK293 cells stably expressing either MRGPRA1, MRGPRX4, and MRGRPC11 
were seeded in poly-D-lysine-coated 96-well plates at 10,000 cells/well. Cells 
were loaded with Fura 2–AM, washed twice, and maintained in CIB. Haem 
metabolites were freshly dissolved in DMSO in dim light and then diluted into a 
buffer comprised of 20 mM Tris and 150 mM NaCl at pH 8.8. Potential changes 
in pH were evaluated prior to each experiment. EC50 values were determined 
from dose-responses performed in triplicate, repeated 2-4 times. To determine 
potential antagonism by QWF against bilirubin, cells were treated with varying 
doses of QWF for 1 min in CIB prior to application of agonist. 
 
Murine peritoneal mast cell purification and calcium imaging.  
Adult male mice 8–12 weeks of age were sacrificed through CO2 inhalation. A 
total of 25 mL of mast cell dissociation media (MCDM; HBSS with 3% fetal bovine 
serum and 10 mM HEPES, pH 7.2) was chilled on ice before being used to make 
two sequential peritoneal lavages. Lavages were combined and spun at 200g. The 
pellet was re-suspended in 2 mL MCDM, layered over 4 ml of an isotonic 70% 
Percoll suspension (2.8 ml Percoll, 320 ml 10% HBSS, 40 ml 1 M HEPES, 830 
ml MCDM), and spun for 20 min at 500g at 4°C. Mast cells were recovered in the 
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pellet. Mast cells were re-suspended in DMEM with 10% fetal bovine serum (FBS) 
and 25 ng/mL recombinant mouse stem cell factor (Sigma).  
 
Mouse peritoneal mast cell histamine release assay 
Mast cells were purified as described and allowed to recover for 2 h at 37°C. Cells 
were then seeded in 96-well plates coated with 20 mg/mL fibronectin at 300 
cells/well. Plates were incubated at 37°C for 45 min before assay. For the assay, 
all compounds tested were diluted in CIB. Five minutes after compound addition, 
supernatant was aspirated and frozen at -80°C until histamine levels were 
determined with an HTRF histamine assay kit (Cisbio Assays) according to the 
manufacturer’s instructions. 
 
Generation of cells stably expressing GFP-tagged MRGPRs 
HEK293 stable cell lines expressing GFP-tagged MRGPRA3, MRGPRC11, 
MRGPRD, MRGPRX1, and MRGPRX2 were generated in previously described 
reports (Liu et al., 2009; 2012; McNeil et al., 2015). Briefly, plasmids containing 
the receptor of interest were transfected into HEK cells using Lipofectamine 3000. 
After 3 days, cells were then selected using 0.5 mg/mL G418. After 3 weeks, 
monoclonal colonies were established and each the highest expressing clones 
were identified. For this study, Mrgpra1 and MRGPRX4 were inserted into 
pEGFP-N1 and transfected into HEK293 cells. MRGPR-positive cells were 
selected using 0.5 mg/mL G418 for three weeks, after which GFP-positive cells 
were sorted by FACS and monoclonally expanded. Two lines expressing similar 
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levels of MRGPRA1 and MRGPRX4, as measured by GFP fluorescence, were 
selected for study. 
 
Microscale thermophoresis binding  
Binding isotherms for MRGPRA1, MRGPRX4, and MRGRPC11 towards various 
ligands were determined by microscale thermophoresis with the NanoTemper 
monolith NT.115 instrument (Duhr and Braun, 2006). Ligands were pre-
incubated with 10 µM of the GFP-tagged receptor of interest for 5 minutes at 
room temperature in binding buffer (20 mM Tris and 150 mM NaCl at pH 8.8). 
Receptors were crudely purified as a membrane fraction from cells stably 
expressing the receptor (Vasavda et al., 2017). Haem metabolites were freshly 
dissolved in 0.1 M NaOH in dim light and then diluted into assay buffer. 
Lyophilized BAM8-22 was dissolved in binding buffer. The pH of each ligand was 
evaluated prior to incubation with a receptor. Samples were loaded into NT.115 
Hydrophobic-Treated Capillaries from NanoTemper. Microscale thermophoretic 
experiments were executed using 20% LED power and 15% MST power. KDs were 
calculated using the law of mass action with data from three independent 
experiments. Binding between bilirubin and receptors was evaluated purely 
thermophoretically, whereas binding between BAM8-22 and MRGPRC11 was 
evaluated by T-Jump. Samples with dramatic deviations in initial fluorescence 
were excluded. 
 
[35S]GTPγS binding  
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MRGPR activation was determined by measuring binding of a radiolabelled and 
non-hydrolyzable form of GTP, [35S]guanosine-5’-(γ-thio)triphosphate 
([35S]GTPγS) as previously described (Vasavda et al., 2017). Briefly, 10 µg of crude 
membrane fractions were diluted into 175 µL assay buffer (50 mM HEPES, 5 mM 
MgCl2, 100 mM NaCl, 1 mM EDTA, 0.1% Triton 80) supplemented with 10 µM 
GDP and incubated at room temperature for 5 min. Membranes were then 
incubated an additional 1 min in a final volume of 199 µL assay buffer 
supplemented with 50 µM bilirubin. Samples were then brought to 200 µL with 
the addition of 10 nM [35S]GTPγS. Samples were incubated for 2 h at 4°C with 
gentle agitation. The experiment was terminated by rapid filtration onto GF/B 
filters and washed three times with wash buffer (50 mM Tris-HCl, 5 mM MgCl2, 
and 50 mM NaCl at pH 7.4). Filters were then immersed in scintillation cocktail 
and counted. Nonspecific binding was determined by competition with 10 µM 
unlabelled GTPγS. GTPγS binding assays were performed as two independent 
experiments, in triplicate. 
 
DRG dissociation and culture  
DRG neurons from all spinal levels were collected in cold DH10 media (90% 
Dulbecco’s modified Eagle’s medium (DMEM)/F-12, 10% FBS, penicillin (100 
U/mL), and streptomycin (100 µg/mL)). DRGs were digested with a dispase (5 
mg/ml)/collagenase type I (1 mg/ml) enzyme mixture at 37°C for 45 minutes. 
After trituration, cells were spun at 300g and re-suspended in DH10 before being 
plated on glass coverslips coated with poly-D-lysine (0.5 mg/ml) and laminin (10 
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µg/ml, Invitrogen). DRGs were cultured with DH10 supplemented with 50 
ng/mL NGF at 37°C.  
 
DRG viral transduction  
Lentiviruses encoding various cDNA for MRGPRs were generated using psPAX2 
and pMD2.G. Virus was pelleted by centrifugation at 100,000g for 4 h, gently 
washed with twice with DH10 media, and suspended in DH10. One day after 
DRG isolation and culture, DRGs were infected with lentivirus 24 h overnight. 
The following morning, media was completely replaced with fresh DH10 




DRG neurons from 3-5 week old mice were collected as described. After culture 
for 1-3 days, DRG neurons were transferred into a chamber with extracellular 
solution containing (in mM) 144 NaCl, 2.5 KCl, 2 CaCl2, 0.5 MgCl2, 5 HEPES, 
and 10 glucose, adjusted to pH 7.4 with NaOH. Whole-cell current-clamp 
recordings were performed at ~23°C using borosilicate capillary glass electrodes 
(Sutter Instrument) with a tip resistance of 3-5 MΩ. Internal solution contained 
(in mM) 80 K-acetate, 30 KCl, 40 HEPES, and 1 CaCl2, adjusted to pH 7.4 with 
potassium hydroxide (KOH). Small-diameter neurons with diameter 15-25µm 
were chosen for patch-clamp. Data were acquired using an Axopatch 700B 
Amplifier and Digidata 1322A Digitizer with pClamp9.2 software package (Axon 
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Instrument). Chloroquine (CQ) in 1mM was added by perfusion for 20 seconds, 
and bilirubin freshly made in 50µM was added by pipette. Solutions containing 
50mM KCl were applied at the end of each cellular recording. Only neurons that 
could fire action potentials after adding KCl were regarded as healthy and 
appropriate for inclusion in data analysis.  
 
Immunohistochemistry 
Adult mice (5-6 weeks old) were anesthetized by i.p. injection of chloral hydrate 
(20 µl /gram of 25mg/ml solution) and perfused with 30 ml 0.1 M phosphate 
buffered saline (PBS) (pH 7.4, 4 °C) followed with 30 ml of fixative (4% 
paraformaldehyde (vol/vol), 4 °C). Skin, trigeminal ganglia, dorsal root ganglia, 
and spinal cord were dissected from the perfused mice. Tissues were post-fixed 
in fixative at 4° for 2 h. Tissues were cryoprotected in 20% sucrose (wt/vol) for 
up to 8 h followed by 30% sucrose for 24 h and then sectioned (25 µm width) 
with a cryostat. The sections were dried at 37°C on slides for 1 h and fixed with 
4% paraformaldehyde at 21–23 °C for 10 min. The slides were pre-incubated in 
blocking solution (10% normal goat serum (v/v), 0.2% Triton X-100 (v/v) in PBS, 
pH 7.4) for 1 h at 21–23 °C, then incubated overnight at 4 °C with primary 
antibodies. Secondary antibody incubation was performed at 21–23 °C for 2 h. 
For primary antibodies, we used rabbit antibody to CGRP (T-4239, Peninsula, 
1:1,000), rabbit antibody to GFP (A-11122, Molecular Probes, 1:1,000), and 
Substance P (rat monoclonal from Abcam, 1:250 dilution, M09205). For 
secondary antibodies, we used goat antibody to rabbit (A11011, Alexa 568 
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conjugated; A11008, Alexa 488 conjugated; Molecular Probes) and Invitrogen 
547 (A-21247) for Substance P, all diluted 1:500 in blocking solution. To detect 
IB4 binding, sections were incubated with Griffonia simplicifolia isolectin GS-
IB4 Alexa 568 from Invitrogen at 1:500 dilution (I-21412). Sections were washed 
three times with PBS and Fluoromount (Southern Biotech) was applied before 
cover slips were placed over section.  
 
In vivo DRG calcium imaging  
Adult mice expressing Pirt-Cre and lox-stop-lox GCaMP6s were anesthetized by 
i.p. injection of chloral hydrate (20 µl /gram of 25 mg/ml solution). The back 
was shaved and disinfected with alcohol before application of ophthalmic 
ointment (Lacrilube; Allergen Pharmaceuticals). A dorsal laminectomy was 
performed below the lumbar enlargement (L5) targeting S1. During the procedure, 
care was taken to keep dura intact. A 2 cm incision was made at the lumbar 
enlargement. 0.1 mL of 1% lidocaine was injected into paravertebral muscles 
before dissection to expose L3–L5 vertebrae. Using rongeurs, the surface aspect 
of the L4 DRG transverse process was removed and the underlying DRG exposed. 
Mice were laid abdomen-down on a custom-designed microscope stage and the 
spinal column was secured at two sites using clamps. Images were acquired 
using a laser-scanning confocal microscope (Leica LSI microscope) equipped with 
a 53 0.5 NA macro dry objective and fast EM-CCD camera. Live images were 
acquired at 8 to 10 frames in frame-scan mode per 7–8 s, at depths of 0 to 70 
mm below the dura with the DRG in the focal plane. Images were taken 30 min 
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after peripheral stimulation of DRG via injection of vehicle or bilirubin by 
Hamilton syringe (5 µl) Throughout imaging, body temperature was maintained 
at 37°C ± 0.5°C with a heating pad and rectal temperature monitoring. 
Anesthesia was maintained with 2% isoflourane and pure oxygen delivered 
through nosecone.  
 
Raw image stacks were collected, deconvoluted, and imported into ImageJ (NIH). 
Optical planes from sequential time points were re-aligned and motion-corrected 
using the stackreg rigid-body cross-correlation-based image alignment plugin in 
ImageJ. Calcium signaling amplitudes were expressed as Ft /F0 as a function of 
time. F0 was defined as the average pixel intensity during the first two to six 
frames of each imaging experiment. All neurons that displayed a > 0.25 F0 
change from baseline were selected for further analysis. In subsequent analysis, 
neurons that displayed a > 0.25 F0 change during either the baseline or the saline 
imaging periods were excluded from analysis.  
 
Mouse models of cholestasis and sample collection 
1-naphthyl isothiocyanate (ANIT; Sigma) was solubilized in olive oil (Sigma). 
Animals were dosed with 25 mg/kg ANIT per os daily for five days. On day five, 
animals were acclimatized for itch behavior. On day six, animals were placed in 
test chambers and videotaped for one hour. The number of scratching bouts, 
defined as a continuous scratching movement with either hindpaw, was counted 
and binned in five minute intervals during the one hour period. After itch 
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behavior was assessed, animals were administered pentobarbital (50 mg/kg, i.p.). 
Blood was collected by cardiac puncture and placed into heparinized tubes (BD 
Biosciences). After centrifugation, plasma was collected, aliquoted, and stored at 
-20°C until analysis. Bile acid levels were assessed by a fluorometric kit from 
Cell Biolabs. When applicable, mice were then proceeded for histology. For QWF 
antagonism of cholestatic itch, Day 5 ANIT-treated animals were dosed with 
either 1mg/kg QWF dissolved in PBS or PBS vehicle i.v. via tail vein injection 
approximately 10 minutes before behavioral assessment of spontaneous itch.  
The dose was chosen based on previous studies (Azimi et al., 2017) as well as 
published pK data indicating stability in plasma (t1/2 = 70 min). 
 
Skin bilirubin extraction 
 The skin of mice were exposed by applying a hair removal cream for 5 min, 
after which the skin was excised from the back and nape of mice and frozen at -
80°C until processing. To extract skin bilirubin, skin was finely minced with a 
blade and then dounce homogenized at 4°C in 99% chloroform/1% glacial acetic 
acid (v/v). The organic layer was separated from any remaining tissue by 
centrifugation at 4°C at 16,000g for 10 min. The organic layer was subsequently 
washed in 1% glacial acetic acid, then 0.2 M NaHCO3, and then H2O. The organic 
layer was evaporated with a speedvac until the pellet was dry, after which the 
pellet was resolubilized in buffer (50 mM Tris,150 mM NaCl, 1% TritonX-100, 5% 
glycerol at pH 7.4). The final pellet was resuspended as thoroughly as possible, 
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but was unfortunately relatively insoluble. The calculated yield was 1.83 ± 
0.2463 (SD) % and accordingly factored in to normalize skin bilirubin.  
 
UnaG purification 
 UnaG was expressed in pMAL-6P2-6xHIS in BL21(DE3) cells. Starter 
cultures were grown to saturation overnight in Luria Broth (LB) at 37°C. Starter 
cultures were then diluted 10-fold in LB and grown to an OD600 of 0.3 at 37°C, 
after which cultures were moved to 18°C. At OD600 of 0.6, protein expression was 
induced by the addition of 400 µM isopropyl β-D-1-thiogalactopyranoside for 16 
h at 18°C. Cells were harvested by centrifugation, resuspended in 15 ml of 
resuspension buffer (50 mM HEPES, 300 mM NaCl, 0.5 mM TCEP, 10% glycerol, 
1 mM PMSF, 2.34 µM leupeptin, 1.45 µM pepstatin at pH 7.4) per liter of culture, 
and flash frozen in liquid nitrogen for storage at −80 °C. 
For purification, pellets were thawed on ice and sonicated to lyse. Lysate was 
clarified by centrifugation at 26,000g at 4°C for 30 min and subsequently loaded 
onto an amylose column. Protein was eluted with 20 mM maltose in protease 
buffer (50 mM Tris, 150 mM NaCl, 0.5 mM TCEP, 10% glycerol, 0.01% TritonX-
100 at pH 7.4), after which the MBP was were removed by the addition of 
Prescission Protease (GE Healthcare) for 16 h at 4°C. UnaG was further purified 
by a second nickel-affinity step to remove the cleaved tag and Prescission 
Protease. Protein was further purified on a gel-filtration column (S-200, GE 
Healthcare) in 50 mM HEPES, 300 mM NaCl, 0.5 mM TCEP, 10% glycerol at pH 
7.4. The purity of peak fractions was assessed by SDS-PAGE. The purified 
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protein was concentrated using a 10-kDa MWCO filter (Amicon) and flash frozen 
in gel filtration buffer supplemented with 30% glycerol for storage at −80 °C. 
 
Patient plasma and skin bilirubin quantification 
To measure plasma bilirubin, patient plasma was diluted 1:20 in HBSS 
containing purified UnaG. To measure skin bilirubin, UnaG was added directly 
After a 10 min incubation at 25°C, bilirubin was quantified by interpolating from 
a standard curve. Samples with blood and hemolysis were excluded from 
analysis. Skin bilirubin was ormalized to the dry weight of the skin.  
 
Plasma bilirubin depletion 
Plasma bilirubin was depleted either by selective oxidation by FeCl3 to biliverdin 
IXα/biliverdin XIIIα or by immunoprecipitation. FeCl3 was prepared as solution 
of 20% FeCl3 in 0.1N HCl/methanol. FeCl3 was fluxed with plasma at a final 
concentration of 1.5% FeCl3 at 37°C for 10 min. FeCl3 is a mild oxidant but 
exhibits a redox potential that the oxidation of bilirubin to biliverdin (Dolphin, 
1978). Bilirubin was also immunopreciptated by incubating plasma with 5 µg of 
either normal rabbit IgG or anti-bilirubin antibody (generated as previously 
described (Doré et al., 1999)) coupled to protein A/G beads for 1 h at 25°C. To 
quantify bilirubin depletion, bilirubin was extracted from samples with 100% 
methanol and subjected to HPLC and UV-visible spectroscopic analysis. 
Absorbance was adjusted to a baseline of 0 OD, and bilirubin was quantified by 
integrating the area under the chromatographic peak. 
126 
 
High pressure liquid chromatography (HPLC) 
Plasma bilirubin was detected by HPLC using an analytical LC-18 column, 25 
cm × 4.6 mm (Xterra, Waters Corporation). Bilirubin was eluted with gradients 
of mobile phases: 0.1 M ammonium acetate in 60% methanol/40% water (v/v) 
(pH 5.2) (Solvent A) and 100% methanol (Solvent B).  Bilirubin was eluted as 
follows: 0 to 14 min: linear gradient from 100% A to 100% B; 14 to 19 min: linear 
gradient from 100% A to 100% B; 19-24 min: isocratic elution at 100% A. 
Bilirubin exhibited a retention time of approximately 14-15 min and was 
detected by measuring absorbance at 450 nm. The peak corresponding to 
plasma bilirubin was confirmed with the addition of 10 µM bilirubin to the 
sample as an internal standard. 
 
Quantification and Statistical Analysis  
Group data were expressed as mean ± SEM unless otherwise noted. Two-tailed 
unpaired Student’s t-tests, Fisher’s exact test, and Chi-squared tests were used 
to determine significance in statistical comparisons, and differences were 
considered significant at P < 0.05. Statistical power analysis was used to justify 
sample size, and variance was determined to be similar among all treatment 
groups as determined by F test. No samples or animals subjected to successful 
procedures and/or treatments were excluded from analysis. All behavior 
experiments were designed in a blocked manner with consideration for both 
genotype and treatment.  
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G-protein-coupled receptors (GPCR) are a large family of transmembrane 
receptors that play critical roles in normal cellular physiology and constitute a 
major pharmacological target for multiple indications, including analgesia, blood 
pressure regulation, and the treatment of psychiatric disease. Upon ligand 
binding, GPCRs catalyze the activation of intracellular G-proteins by stimulating 
the incorporation of guanosine triphosphate (GTP). Activated G-proteins then 
stimulate signaling pathways that elicit cellular responses. GPCR signaling can 
be monitored by measuring the incorporation of a radiolabeled and non-
hydrolyzable form of GTP, [35S]guanosine-5’-O-(3-thio)triphosphate ([35S]GTPγS), 
into G-proteins. Unlike other methods that assess more downstream signaling 
processes, [35S]GTPγS binding measures a proximal event in GPCR signaling and, 
importantly, can distinguish agonists, antagonists, and inverse agonists. The 
present protocol outlines a sensitive and specific method for studying GPCR 
signaling using crude membrane preparations of an archetypal GPCR, the µ-
opioid receptor (MOR1). Although alternative approaches to fractionate cells and 
tissues exist, many are cost-prohibitive, tedious, and/or require non-standard 
laboratory equipment. The present method provides a simple procedure that 
enriches functional crude membranes. After isolating MOR1, various 
128 
pharmacological properties of its agonist, [D-Ala, N-MePhe, Gly-ol]-enkephalin 




G-protein-coupled receptors (GPCRs) are a large family of cell-surface 
receptors responsible for a remarkable array of physiological processes, 
including analgesia, olfaction, and behavior(Kobilka, 2007). GPCRs act by 
sensing specific external signals and subsequently stimulating intracellular 
signaling. They therefore mark a key junction between the external and internal 
environments of a cell. Due to the critical role GPCRs play in biology, they have 
become major targets for both basic research and drug discovery(Neubig and 
Siderovski, 2002; Overington et al., 2006). 
Unlike other receptor families that bind discrete ligands, GPCRs can bind 
very different types of molecules. While one GPCR may interact with peptides, 
another may sense photons, small molecules, or ions(Buck and Axel, 1991; 
Kobilka, 2007). While their ligands are diverse, GPCRs are unified in their overall 
architecture and function. Individual GPCRs are made up of seven α-helical 
transmembrane proteins with extracellular amino terminals and intracellular 
carboxyl terminals(Kobilka et al., 1987; Stenkamp et al., 2000). GPCRs are 
coupled to intracellular G-proteins—heterotrimeric protein complexes composed 
of α, β, and γ subunits—which mediate diverse signaling pathways(Neer, 1995). 
The Gα subunit is a guanine nucleotide-binding protein that is inactive when 
bound to guanosine diphosphate (GDP) and active when bound to guanosine 
triphosphate (GTP)(LONDOS et al., 1974; Ross and Gilman, 1977). When GPCRs 
bind their ligands, they undergo a conformational change that permits Gα to 
dissociate from Gβγ, thereby allowing Gα to exchange GDP for GTP(Neer, 1995). 
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The receptor itself is phosphorylated at its carboxyl terminal by various 
serine/threonine kinases(STADEL et al., 1983; WILDEN and KUHN, 1982) and 
internalized to attenuate receptor signaling(Lefkowitz, 2004; Leftowitz and 
Shenoy, 2005; Lohse et al., 1990). Meanwhile, the activated Gα monomer and 
Gβγ dimer proceed to activate distinct signaling pathways(Neer, 1995). There are 
several isoforms of each G-protein subunit, and each isoform targets particular 
downstream pathways and secondary messenger systems. The major Gα 
isoforms include Gs, Gq, Gi/o, and G12-13. Typically, individual GPCRs associate 
with a particular Gα isoform, thereby linking an external stimulus to a specific 
cellular response(Kobilka, 2007). 
Characterizing a GPCR-ligand interaction is critical to understanding the 
biology of the receptor. As GDP/GTP exchange is one of the earliest events that 
follows ligand binding, monitoring GTP binding can measure GPCR activation or 
inhibition. Assaying more downstream events in GPCR signaling is often not as 
quantitative or stoichiometric, may not distinguish full agonists from partial ones, 
and can require expensive reagents. Moreover, increased GTP binding to Gα 
proteins is an almost-universal event following GPCR activation, meaning that 
measuring GTP binding is a broadly applicable assay for monitoring the activity 
of most GPCRs. Measuring GTP binding is a simple and rapid approach to 
monitor GPCR signaling in cells overexpressing the receptor of interest or in 
native tissue. The present protocol details a functional GTP-binding assay using 
an archetypal GPCR, the µ-opioid receptor (MOR1), to quantitatively determine 
the activity of an agonist and antagonist on GPCR signaling. 
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This protocol first outlines how to isolate crude membranes from cells 
overexpressing MOR1. Note that this protocol is not limited to overexpression 
systems and can be applied to many sources of membrane, including native 
tissue or preparations expressing multiple receptors and G proteins(Salah-Uddin 
et al., 2008). The protocol then details how to measure the binding of a 
radioactive GTP analog to these membranes in response to varying 
concentrations of [D-Ala, N-MePhe, Gly-ol]-enkephalin (DAMGO) or naloxone, a 
MOR1 agonist and antagonist, respectively. The GTP analog, [35S]guanosine-5’-
O-(3-thio) triphosphate ([35S]GTPγS), is non-hydrolyzable. This property is 
critical because Gα subunits exhibit intrinsic GTPase activity(Neer, 1995) and 
would eliminate the labeled gamma phosphate on a hydrolyzable GTP 
radiochemical. Membranes are then trapped onto glass fiber filters and washed, 
after which the radiolabeled GTP is quantified by liquid scintillation counting. 
Multiple pharmacological parameters can be derived to characterize the receptor-
ligand interaction, including the half-maximal response (EC50) and Hill 
coefficient (nH) for agonists and the half-maximal inhibitory concentration (IC50) 
and equilibrium dissociation constant (Kb) for antagonists(Lazareno and Birdsall, 
1993; MarÉchal, 2011; Yung-Chi and Prusoff, 1973). 
 
Protocol 
1. Expression of recombinant HA-MOR1 in cultured cells 
Note: Follow all cell culture protocols in a sterile laminar flow hood. 
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1.1) Sterilize the cell culture laminar flow hood with 70% ethanol and 
maintain sterile technique throughout the cell culture. 
1.2) Prepare human embryonic kidney cells 293 (HEK293) cell culture 
medium, complete Dulbecco’s Modified Eagle Medium (DMEM): DMEM, 
pH 7.4, supplemented with 2 mM L-glutamine, 1% 
penicillin/streptomycin, and 10% fetal bovine serum. 
1.3) Plate 2.5 x 106 HEK293 cells onto a 10-cm tissue culture plate in 10 mL 
of complete DMEM and incubate at 37 °C and 5% CO2 until 70%-80% 
confluency is reached (overnight).  
Note: To collect enough protein for a complete GTP-binding experiment, 
plate at least three 10-cm plates of cells.  
1.4) Transfect the cells with HA-MOR1 using a transfection reagent of choice 
and by following the manufacturer’s guidelines. Incubate for 36-48 h. 
Note: Human MOR-1 cDNA (NCBI Reference Sequence: NM_000914.4) was 
a generous gift from Gavril Pasternak and was cloned into pCMV-HA. 
2. Cell fractionation and membrane collection 
2.1) Prepare the following lysis buffers: 
2.1.1) Buffer 1: 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), pH 7.4; 1 mM ethylene glycol-bis(β-aminoethyl ether)-
N,N,N',N'-tetraacetic acid (EGTA); 10% sucrose; protease inhibitor 
cocktail; and 1 mM dithiothreitol (DTT). Add the DTT fresh on the day 
of membrane isolation. 
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2.1.2) Buffer 2: 10 mM HEPES, pH 7.4; 1 mM EGTA; 1 mM MgCl2; and 1 
mM DTT. Add the DTT fresh on the day of membrane isolation. 
2.2) Remove the transfected cells from the incubator (step 1.4), aspirate the 
medium, and rinse the cells with 5 mL of ice-cold phosphate-buffered 
saline (PBS). Aspirate the PBS and excess liquid from the plate.  
2.3) Add 600 µL of Buffer 1 to the cells. Using a cell scraper, dislodge the cells 
from the plate surface and pipette the cell suspension into a 1.6-mL 
microcentrifuge tube. 
2.4) Immediately snap-freeze the microcentrifuge tube in liquid nitrogen. 
Once the samples are frozen, thaw the lysates on ice or place them at -
80 °C for long-term storage.  
2.5) Repeat steps 2.3 and 2.4 with all plates of cells. 
2.6) Once the lysates have thawed, use a single-pulse micro-tube 
homogenizer to break open the cells. Pulse the homogenizer 3-5 times for 
10 s, placing the tube back on ice for 30 s between pulses. 
2.6.1) Collect 20 µL as whole cell fraction. 
2.7) Centrifuge the remaining sample for 10 min at 1,000 x g and 4°C. Collect 
the supernatant and place in a new 1.6-mL microcentrifuge tube on ice. 
2.8) Resuspend the pellet in 100 µL of Buffer 1 and re-homogenize with a 
pestle. Pulse the homogenizer 3-5 times for 5 s, placing the tube back on 
ice for 30 s between pulses. 
2.8.1) Centrifuge the sample a second time for 10 min at 1,000 x g and 
4 °C. Combine the supernatant with the supernatant from step 2.7. 
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Note: The remaining pellet contains nuclear and membrane proteins. 
2.9) Centrifuge the combined supernatants for 20 min at 11,000 x g and 4 °C. 
Separate the supernatant (the cytosolic fraction) into a new 1.6-mL 
microcentrifuge tube.  
2.10) Resuspend the pellet in 200 µL of Buffer 2. Homogenize the pellet by 
triturating it 3-5 times. Centrifuge the sample for 20 min at 21,100 x g 
and 4 °C. Aspirate the supernatant. Resuspend the pellet containing the 
crude membrane fraction in 50 µL of Buffer 2.  
2.11) Immediately proceed to the GTPγS binding experiments (section 3) 
or snap-freeze in liquid nitrogen and store at -80 °C. 
3. [35S]GTPγS binding 
Note: Use standard radiochemical safety protocol when handling 
[35S]GTPγS and when conducing [35S]GTPγS binding experiments. Wear 
protective gloves and a lab coat at all times. Check the packaging material for 
leaks or cracks. Dispose of waste and excess reagents according to institutional 
protocols. 
3.1) Prepare incomplete binding buffer (IBB) by mixing 50 mM HEPES, pH 7.4; 
5 mM MgCl2; 100 mM NaCl; and 1 mM ethylenediaminetetraacetic acid 
(EDTA) in distilled water. 
3.2) Dilute stock [35S]GTPγS to 50 nM in 10 mM Tris-HCl, pH 7.6, and 10 mM 
DTT. Make 500-µL aliquots and store them at -80 °C. Use only a freshly 
thawed aliquot immediately before initiating the experiment. Thaw the 
aliquots on ice. 
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3.3) Prepare non-radiolabeled GTPγS by dissolving 1 mg of GTPγS powder in 
177.62 µL of pure water for a stock concentration of 10 mM. Make 10-µL 
aliquots and store them at -20 °C. 
3.4) Prepare complete binding buffer (CBB) by supplementing IBB to include 
a final concentration of 1 mM DTT, 0.1% (wt/vol) bovine serum albumin 
(BSA), 10 µM GDP, and 0.1 nM [35S]GTPγS.  
Note: The CBB now contains radiolabeled GTP. Take appropriate safety 
precautions while working with radioactive solutions. 
3.5) Thaw the membrane fraction from step 2.11 on ice. 
3.6) Quantify the protein concentration of the membrane fraction via a 
Bradford protein assay using a spectrophotometer at 595 nm. 
3.6.1) Prepare a dilution series of BSA protein standards with Buffer 2, at 
final concentrations of 0, 250, 500, 750, 1,500, 2,500, and 5,000 
µg/mL. 
3.6.2) Add 2 µL of each standard or membrane to 1 mL of Bradford reagent 
in a cuvette. Mix thoroughly by vortexing. 
3.6.3) Adjust the spectrophotometer to a wavelength of 595 nm and blank 
using the cuvette with 0 µg/mL protein. 
3.6.4) Wait 5 min and read each of the standards and each of the samples 
at a 595-nm wavelength. 
3.6.5) Plot the absorbance of the standards versus the concentration. 
Using the Beer-Lambert Law (A = εcl, where ε = extinction coefficient, 
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l = length of cuvette, and c = concentration), calculate the 
concentration of the membrane samples. 
3.7) Dilute the membrane fractions to a concentration of 100 µg protein/mL 
in IBB. 
Note: One 10-cm dish of HEK293 cells typically yields between 1 and 3 mg 
protein/mL. 
3.8) Prepare the following experimental conditions in individual 1.6-mL 
microcentrifuge tubes: a ligand dilution series, a basal activity condition 
to measure basal GTP binding, and a non-specific binding condition to 
measure non-specific GTP binding.  
3.8.1) For the ligand dilution series, prepare a dilution series of the ligand 
of interest in a final volume of 100 µL of CBB. Prepare the ligand series 
at 2x the desired final concentrations. Space the ligand concentrations 
to adequately cover a range of responses.  
3.8.1.1) To assay the effect of DAMGO on GTP binding via MOR1, prepare 
DAMGO dilutions of 2 mM, 200 µM, 20 µM, 2 µM, 200 nM, 20 nM, 2 nM, 
200 pM, 20 pM, and 2 pM in CBB (final volume: 100 µL). 
Note: For example, if the ligand of interest has an expected EC50 value of 
10 µM, prepare ligand dilutions of 200 nM, 2 µM, 20 µM, 200 µM, and 2 mM. 
These five conditions cover a wide range of concentrations and are 2x the 
concentration desired for the assay. 
3.8.2) For basal binding, prepare a tube with 100 µL of CBB only. 
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3.8.3) For non-specific binding, prepare a tube with 99 µL of CBB 
supplemented with 1 µL of 2 mM non-radiolabeled GTPγS. 
3.9) Add 100 µL of the diluted membrane solution (step 3.7) to each 
experimental condition. 
3.10) Incubate the membranes with the various experimental conditions 
in 1.6-mL microcentrifuge tubes for 30 min at 25 °C in a thermomixer or 
on an orbital shaker. 
4. Membrane filtration 
4.1) Prepare wash buffer by combining 50 mM Tris-HCl, pH 7.4; 5 mM MgCl2; 
and 50 mM NaCl in distilled water. 
4.2) Presoak the glass fiber filters in water for 10 min. 
Note: Filters have a pore size of 1 µm, a diameter of 2.1 cm, and a thickness 
of 675 µm. 
4.3) Remove the samples from the thermomixer or orbital shaker (step 3.10). 
Briefly pulse-spin the samples for 5 s to collect each sample at the bottom 
of the tube.  
4.4) Remove the lid of the vacuum filtration apparatus. Lay the presoaked 
filters onto the vacuum ports of the apparatus. Re-secure the apparatus 
lid to form a vacuum seal. Turn on the vacuum. 
4.5) Pipette 195 µL of each 200-µL experimental condition onto filters to 
minimize error from adsorption to the walls of the tube and/or from 
pipetting. 
4.6) Wash the filters three times with 1 mL of ice-cold wash buffer.  
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5. Liquid scintillation counting 
5.1) Place 5-mL scintillation counting vials in a counting rack. Add 5 mL of 
scintillation fluid to each vial. 
5.2) Turn off the vacuum (step 4.4). Remove the lid of the vacuum filtration 
apparatus. Using tweezers, pick up the filters from the vacuum ports of 
the filtration apparatus and drop each filter into an individual 5-mL 
scintillation vial. 
5.3) Prepare one vial with 195 µL of CBB to determine the maximal signal. 
5.4) Cap each vial securely. Incubate the vials on an orbital shaker at 25 °C 
for 10 min. 
5.5) Turn on the scintillation counter. Program the scintillation counter to 
measure 35S isotope emission for 5 min per sample using the standard 
associated scintillation program. 
5.6) Press “Start” to take a count.  
5.7) When the counting is done, dispose the counted vials as hazardous waste. 
6. Data analysis 
6.1) Enter the data into statistics and analysis software. 
6.1.1) Subtract the non-specific binding from each of the other 
measurements to determine the specific binding.  
Note: The degree of non-specific binding is determined by the sample 
incubated with non-radiolabeled GTPγS (step 3.8.3). 
6.1.2) Open the statistics and analysis software and select an XY dataset 
entry. 
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6.1.3) Enter the specific binding data from the [35S]GTPγS-binding 
experiments into a data table in the statistics and analysis software. 
Enter the agonist concentrations, as molar concentrations, in the “X” 
column. Enter the associated 35S counts as “Y” values.  
6.2) Transform the data. 
6.2.1) Convert the X values to their respective logarithm by clicking 
“Analyze.” Select “Transform” from the built-in analyses. 
6.2.2) Within the “Transform” dialog box, select “Transform X values using” 
and select the function “X=log(X).” Choose to create a new graph of the 
results. 
6.2.3) Click “OK.” 
6.3) Normalize the Y-values. 
6.3.1) With the transformed results displayed, click “Analyze.” Select 
“Normalize” from the built-in analyses. 
6.3.2) Within the “Normalize” dialog box, select the radio button to define 
0% as the “smallest value in each data set” and 100% as the “largest 
value in each data set.” Select the box to present the results as 
percentages. Select the box to create a new graph of the results. 
6.3.3) Click “OK.” 
6.4) Fit a nonlinear regression curves to the plotted data. Perform a nonlinear 
regression analysis. 
6.4.1) With the normalized results displayed, click “Analyze.” From the 
built-in analyses, select “Nonlinear regression (curve fit).” 
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6.4.2) If investigating an agonist, select “log(agonist) vs. normalized 
response - variable slope” from the dialog box. 
6.4.3) If investigating an antagonist, “select log(antagonist) vs. normalized 
response - variable slope” from the dialog box. 
6.4.4) Click “OK.” 
6.5) Review the graph and results to ensure that the fit and data are in 
reasonable agreement. Ensure that the regression matches the general 
pattern of the plotted data and that the residuals are not so large that 
they render the dose-response curve flat. 
Note: The software will summarize the results of the nonlinear regression 
and detail the half-maximal response (EC50), Hill coefficient (nH), and half-
maximal inhibitory concentration (IC50). 
6.6) Derive agonist/antagonist parameter potency. 
6.6.1) Derive the agonist equilibrium dissociation constants (Kb) from 
either of the following experiments(Lazareno and Birdsall, 1993; 
MarÉchal, 2011; Yung-Chi and Prusoff, 1973): 
6.6.1.1) Assess the shift in the dose-response of an agonist in competition 
with a fixed concentration of antagonist. Here, EC50’ = EC50 (1 + 
[antagonist]/antagonistKb), where EC50’ is the right-shifted EC50. 
6.6.1.2) Assess [35S]GTPγS binding with varying concentrations of antagonist 
in competition with a fixed concentration of agonist. Here, Kb = IC50/ (2 
+([agonist]/agonist EC50)n)1/n – 1, where n is the Hill coefficient of the 
agonist. 
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Depending upon the variability of the data, repeat the experiment (steps 
3.8-5.6) for each ligand approximately 3-5 times and average the results using a 
statistics and analysis software. 
 
Representative Results 
Cell fractionation can be used to isolate and enrich membrane-associated 
proteins from cytosolic and nuclear proteins. Fig. 40 is a Western blot 
demonstrating the contents of the three primary fractions that can be collected 
during the subcellular fractionation process. Specifically, Fig. 40 shows that 
fractionation cleanly separates membrane proteins (i.e., Na+/K+ ATPase, protein 
disulfide isomerase (PDI), and HA-MOR1) from histone H2A and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), nuclear proteins, and cytosolic proteins, 
respectively. Additionally, Fig. 40 demonstrates the enrichment of proteins (lane 
1 compared to lane 4) in their respective subcellular fractions as a result of 
fractionation. A representative Ponceau stain demonstrates equal protein loading 
in each fraction. It is important to note that this fractionation protocol does not 
distinguish between different cellular membranes. PDI is generally localized to 
the endoplasmic reticulum (ER), whereas Na+/K+ATPase is predominantly at the 
plasma membrane. However, both proteins are present in the final crude 
membrane fraction (Fig. 40, lane 4). Additionally, while this protocol robustly 
separates nuclear proteins from the cytosolic and final membrane fraction (Fig. 
40, lanes 2-4), the fraction enriched for nuclear proteins contains some 




Figure 40. Cellular Fractionation Separates Membrane-associated, Nuclear, and Cytosolic 
proteins.  
(Top) Lane 1 represents the protein present in the whole cell. Lane 2 contains nuclear and 
membrane-associated proteins separated during the first centrifugation steps. Lane 3 is the 
cytosolic fraction separated following 20 min of centrifugation at 11,000 x g. Lane 4 contains a 
crude membrane fraction suitable for [35S]GTPγS-binding experiments. (Bottom) Ponceau stain 
of a Western membrane demonstrates protein loading for each cellular fraction. 
Multiple pharmacological parameters can be derived to characterize a 
GPCR-ligand interaction via GTP-binding experiments (Table 2). For example, 
the half-maximal response (EC50) and Hill coefficient (nH) of an agonist can be 
derived by monitoring GTP binding in response to varying doses of the agonist. 
Fig. 41a demonstrates dose-responsive GTP binding to MOR1 after DAMGO 
treatment. When the data is fit to a four-parameter nonlinear regression, the fit 
describes a receptor-ligand interaction with an EC50 of 185 ± 23 nM and a Hill 
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coefficient of 0.46 ± 0.06. The shallow GTP-binding curve observed after DAMGO 
treatment suggests negative cooperativity between DAMGO and MOR1. This 
method can also identify and describe the pharmacology of an antagonist. As Fig. 
41a-b illustrates, naloxone is an MOR1 antagonist. The agonist potency (Kb) of 
naloxone, 97 ± 20 nM, was determined by varying the concentration of naloxone 
in competition with a fixed concentration of DAMGO (Fig. 41a). Naloxone 
exhibited a Hill coefficient of 0.88 ± 0.06, suggesting independent binding 
between naloxone and MOR1. If the action of a ligand is unknown, this assay 
can discriminate between an agonist, antagonist, and inverse agonist. If the 
ligand is an agonist, there would be an increase in GTP binding, as in Fig. 41a, 
following DAMGO application. If the ligand is an inverse agonist, there would be 
diminished binding of GTP relative to basal binding. If the ligand is an antagonist, 
there would be no effect upon treatment with ligand alone. If applied 
concomitantly with an agonist, an antagonist would inhibit the ability of the 
agonist to stimulate GTP binding. Fig. 41a illustrates the antagonist activity of 





Figure 41. Agonism and Antagonism at µ-opioid Receptors Defined by [35S]GTPγS binding.  
a, [35S]GTPγS dose-response curve to DAMGO alone (blue) or naloxone in competition with 2.5 
µM DAMGO (green). [35S]GTPγS binding was normalized to the maximal stimulation in each 
experiment and was expressed as a percentage. The points shown are the mean of triplicate 
determinations and are expressed as the mean ±S.E.M. b, Antagonism of DAMGO-stimulated 
[35S]GTPγS binding by naloxone. [35S]GTPγS binding was quantified after the addition of 
naloxone alone (100 µM), DAMGO alone (10 µM), or DAMGO (10 µM) in competition with naloxone 
(100 µM). The results are expressed as the mean ±S.E.M. of three independent experiments. 
Discussion 
The present protocol describes two separate but complementary methods: 
a simple approach to fractionate cells and tissues into broad but distinct 




Table 2. Pharmacological parameters of DAMGO and naloxone activity at µ-opioid 
receptors.  
The half-maximal response (EC50) and Hill coefficient (nH) for DAMGO were derived from 
[35S]GTPγS binding in response to varying doses of DAMGO. The half-maximal inhibitory 
concentration (IC50) and equilibrium dissociation constant (Kb) for naloxone were determined 
from the effect of competition between naloxone and 2.5 µM DAMGO on [35S]GTPγS binding. The 
results are expressed as the mean ±S.E.M. of three independent experiments. 
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Efficient cellular fractionation has a wide range of applications, ranging 
from the extraction and enrichment of proteins, to the assessment of the 
subcellular localization of proteins, to the study of receptor pharmacology. 
Although alternative approaches to fractionate cells and tissues exist, the 
protocol presented here is comparatively cheaper, faster, and simpler. Unlike 
more established methods, however, this method is unable to cleanly separate 
plasma membrane-associated proteins from other membranous compartments, 
such as endosomes or the ER. It must also be noted that while the above protocol 
uses a transient overexpression system to generate cell membranes containing 
the GPCR of interest, this protocol is compatible with stable overexpression 
systems, as well as with animal or human tissue(Salah-Uddin et al., 2008). 
Sample preparation is critical to maximize fraction yield and purity. It is 
particularly important to ensure complete homogenization and to minimize the 
transition times between centrifugation steps. Using a pellet homogenizer/pestle 
to completely disrupt the cell membrane significantly increases the crude 
membrane yield in the final cell fraction. If the membrane yield is too low, the 
two simplest solutions would be to scale up the initial cell culture and/or to 
homogenize the cell pellet a few more times. If individual fractions show a high 
degree of impurity, reduce the transition times between centrifugation and 
separation. Do not allow the samples to sit following centrifugation, as proteins 
may diffuse into the sample and reduce fraction purity. 
Filtration-based [35S]GTPγS binding is a rapid and quantitative method to 
measure the activation of G-proteins using the associated receptor. Measuring 
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GTP binding allows for a more quantitative measurement of GPCR activity than 
is generally possible when monitoring downstream processes. However, there are 
two critical limitations to the method outlined here. Most importantly, filtration-
based [35S]GTPγS quantitation is not equally feasible with all Gα 
isoforms(Harrison and Traynor, 2003; Milligan, 2003). In general, this method is 
restricted to Gi/o-coupled GPCRs like MOR1(Traynor and Nahorski, 1995). Gs- 
and Gq-coupled receptors tend to be less sensitive. This is likely due to the 
combination of the lower abundance of Gs/Gq and their relatively slower 
nucleotide exchange rate, making it difficult to distinguish real [35S]GTPγS 
binding above background. This limitation has been addressed elsewhere using 
G-protein antibody capture techniques(Milligan, 2003). Some groups have found 
that eliminating GDP from the reaction improves the signal-to-noise ratio for Gs- 
or Gq-coupled receptors(Sittampalam et al., 2004). The second limitation is the 
membrane sensitivity to lipophilic agonists or surfactants. [35S]GTPγS assays 
require functional receptor-G-protein complexes, and the addition of lipophilic 
molecules to the reaction system may disrupt the structure of the membranes 
or these complexes. If this is a potential concern, it may be advantageous to test 
whether the reagent of interest disrupts [35S]GTPγS binding in an already well-
characterized system, such as in DAMGO-mediated MOR1 stimulation. Other 
conditions to consider optimizing include the binding buffer pH, the 
concentrations of Mg2+ and NaCl, the protein concentration, and the incubation 
time(Sittampalam et al., 2004; Strange, 2010). 
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This protocol focused on a well-characterized GPCR, the MOR1, and well-
characterized drugs, DAMGO (agonist) and naloxone (antagonist), that act on 
MOR1. However, one of the advantages of this technique is that it can be used 
to characterize unknown ligands as agonists, antagonists, or inverse agonists, 
depending upon how the ligand modulates GTP binding. When designing 
experiments, it is critical to use a range of concentrations of the ligand of interest 
and to be mindful of the range of outcomes: agonists will cause an increase in 
GTP binding over baseline, inverse agonists will cause a decrease in GTP binding 
compared to baseline, and antagonists will have little to no effect when added in 
isolation on baseline GTP binding. 
In summary, this protocol describes a technique for performing 
subcellular fractionation, collecting crude membrane preparations, and 
investigating GPCR activation by measuring [35S]GTPγS binding. These 
techniques can be readily adapted to a variety of cell culture and tissue models 
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